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1. Equine herpesvirus type 1 
 
1.1. Introduction 
 
Equine herpesvirus type 1 (EHV-1) is a ubiquitous pathogen in horses. The virus is 
responsible for respiratory disorders, abortion, neonatal foal death and neurological 
disorders (Allen & Bryans, 1986). As current vaccines do not provide full protection 
against severe symptoms, EHV-1 is still a major threat for the horse industry, causing 
serious economic losses every year. 
 
1.2. History 
 
In 1933, Dimock and Edwards documented epidemic virus abortion in mares in 
Kentucky (Dimock & Edwards, 1933). The virus was first designated as ‘equine 
abortion virus’ and later renamed equine herpesvirus type 1. EHV-1 was isolated for 
the first time in 1966 from cases of abortion and paralysis (Saxegaard, 1966). Until 
1981, EHV-1 and EHV-4 were considered as two subtypes of the same virus, namely 
EHV-1 (Patel & Heldens, 2005). Only in 1988, the distinction between both viruses 
was recognized by the International Committee for Taxonomy of Viruses (Roizman et 
al., 1992). 
 
1.3. Taxonomy 
 
EHV-1 belongs to the herpesviruses, which represents one of the largest known virus 
groups. The latest taxonomy has incorporated herpesviruses into a new order, 
Herpesvirales, which is divided into three families: Herpesviridae, Alloherpesviridae 
and Malacoherpesviridae (Davison et al., 2009). Herpesviridae incorporates viruses 
of mammals, birds and reptiles and the members of this family share four significant 
biological properties: (i) they encode a variety of enzymes involved in nucleic acid 
metabolism, DNA synthesis and processing of proteins, (ii) synthesis of viral DNA 
and encapsidation occur in the nucleus, (iii) productive infection results in cell 
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destruction and (iv) they are able to remain latent in their hosts (Roizman & Baines, 
1991). 
The family of Herpesviridae is divided into three distinct subfamilies: alpha-, beta- 
and gamma-herpesviruses based on their differences at the level of gene content, host 
range, duration of the reproductive cycle, spread in cell culture, destruction of 
infected cells and capacity to establish latency. The Alphaherpesvirinae have a broad 
host range and a short replication cycle with a rapid destruction of infected cells. They 
spread rapidly in cell culture and establish latency primarily in sensory ganglionic 
neurons. The Betaherpesvirinae are characterized by a narrow host range, a slow 
replication cycle and a frequent enlargement of infected cells (cytomegaly). These 
viruses can establish latency in different tissues including secretory glands, kidneys, 
and lymphoreticular cells. The host-range of Gammaherpesvirinae is restricted and 
viruses remain latent in lymphoid tissues (Roizman, 1996). 
 
In equid populations, nine herpesviruses have been identified so far, of which EHV-1, 
EHV-3, EHV-4, EHV-6 (asinine herpesvirus 1), EHV-8 (asinine herpesvirus 3) and 
EHV-9 (gazelle herpesvirus 1) belong to the genus Varicellovirus of the subfamily 
Alphaherpesvirinae, while EHV-2, EHV-5 and EHV-7 (asinine herpesvirus 2) belong 
to the Gammaherpesvirinae subfamily (Davison et al., 2009; Patel & Heldens, 2005). 
EHV-1 shares its classification with other animal herpesviruses of agricultural 
importance including bovine herpesvirus type 1 (BoHV-1), bovine herpesvirus type 5 
(BoHV-5) and suid herpesvirus 1 (Pseudorabies virus, PrV) (Davison et al., 2009). 
 
Of all equid herpesviruses, EHV-1 and EHV-4 are clinically, economically and 
epidemiologically the most relevant pathogens. Although both viruses show a high 
degree of antigenic and genetic similarity, they are strikingly different in their 
pathogenicity. While EHV-1 infection results in respiratory disease, abortion, fatal 
neonatal illness and/or neurological disorders, EHV-4 infection is limited mainly to 
the upper respiratory tract (Allen & Bryans, 1986; Ostlund, 1993). In contrast, EHV-
2, -3 and -5 are considered of less economic and veterinary importance. EHV-2 is 
widespread throughout the equine population and has been implicated in 
immunosuppression in foals, upper respiratory tract disease, conjunctivitis, general 
malaise and poor performance but its precise role as a pathogen is still unclear 
(Gleeson & Studdert, 1977). EHV-3 causes an acute and self-limiting venereal 
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infection of external genitalia but the prognosis for clinical recovery is generally 
good, although some mares and more rarely stallions can show recurrent coital 
exanthema (Blanchard et al., 1992). EHV-5 infection has an unclear pathogenicity 
and distribution among the horse population. It has been reported that EHV-5 
infections associate with equine multinodular pulmonary fibrosis (EMPF) but the role 
of EHV-5 in EMPF is still unclear (Williams et al., 2007). 
 
1.4. Virion structure 
 
Like most herpesviruses, EHV-1 particles have a size of 200-250 nm and consist of 
four main structural components: genome, capsid, tegument and envelope. The 
general structure of a herpesvirus particle is given in Figure 1. 
1.  
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of an EHV-1 virion. (a) Schematic representation. (b) Transmission electron 
microscopic image of a herpesvirus particle. The bar represents 100 nm. Image courtesy of University 
of Michigan Health System. 
 
 
Genome 
The viral genome consists of a linear double stranded DNA of 150 kbp. The complete 
genome contains at least 76 open reading frames (ORFs). The genome consists of a 
long unique region (UL) flanked by a short inverted repeat (TRL/IRL) linked to a short 
unique region (Us) flanked by an inverted repeat (TRs/IRs) (Roizman et al., 1992; 
Telford et al., 1992). 
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 Capsid 
The genome is enclosed in an icosahedral capsid consisting of 162 capsomers (12 
pentons, 150 hexons) (Perdue et al., 1974). Genome and capsid together form the 
nucleocapsid. 
 
Tegument 
The nucleocapsid is surrounded by the tegument, a proteinaceous matrix that lines the 
space between the nucleocapsid and the envelope. The tegument is encoded by at least 
15 viral genes. 
 
Envelope 
Nucleocapsid and tegument are enclosed by an envelope that forms the outer layer of 
the virus. The envelope consists of an irregularly shaped bilayer of phospholipids that 
is derived from the trans-Golgi network of the host cell and in which different 
glycoproteins are embedded. For EHV-1, 12 glycoproteins have been characterized of 
which 11 have been found to be homologous to other alphaherpesvirus glycoproteins 
(Herpes simplex virus (HSV), PRV or BoHV). Therefore, these 11 glycoproteins have 
been named according to the nomenclature established for HSV (Roizman & Furlong, 
1974). EHV-1 encodes an additional glycoprotein, gp2. An overview of the different 
EHV-1 glycoproteins with their main functions is provided in Table 1. 
 
1.5. Cell infection 
  
EHV-1 has a broad host spectrum in vitro as the virus can replicate in cultured cells of 
various origins, such as equine, human, swine, bovine, canine, feline and rabbit. In 
vivo, EHV-1 occasionally infects domestic cattle, captive cervids, zebras and donkeys  
(Abdelgawad et al., 2014; Chowdhury et al., 1988; Crandell et al., 1988; Pusterla et 
al., 2012; Rebhun et al., 1988). EHV-1 primarily infects epithelial cells, mononuclear 
cells in lymphoid tissue and peripheral blood (PBMC) and endothelial cells of inner 
organs (Osterrieder & Van de Walle, 2010). EHV-1 can infect cells via extracellular 
EHV-1 virions or by direct cell-to-cell spread of EHV-1 from infected cells to 
uninfected cells. In contrast, the natural host range of EHV-4 is restricted to horses 
and replicates poorly in non-equine cells (Azab & Osterrieder, 2012). 
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Table 1. Overview of the EHV-1 glycoproteins and their functions. Red box indicated gp2, a viral 
glycoprotein that is unique to EHV-1/-4. 
  
!
!"#$%&'%()*+,! -.+$(*%+! /)0)')+$),!"#! $%&'()'*+!,&!-..-/01*&.!$233*&.,-)!4(5!',563!7*&*.5-.,(&8!463,(&!75(/*33!$9*))$.($/*))!375*-+!$:&.,"*&,/!75(7*5.,*3!
9-,!!"#$%&'#;<==!>*)),&".(&!!"#$%&'#;<<?@!!A*6@-6*5!!"#$%&'#;<<B!:01*+!!"#$%&'#;<<C!
"9! $%&'()'*+!,&!,&,.,-)!&(&$*33*&.,-)!@,&+,&"!(4!',563!-&+!,&!5*)*-3*!(4!',5,(&3!$#,&+3!D,.0!9C!(4!.0*!/(17)*1*&.!/-3/-+*!$E-*1-"")6.,&-.,(&!-/.,',.F!
G3.*55*,+*5!!"#$%&'#;<<<!!E6*1*5!!"#$%&'#;<<H!!:&+(0!!"#$%&'!IJ;H!"K! $233*&.,-)!4(5!3.-@)*!@,&+,&"!(4!',563!.(!.0*!/*))!-&+!36@3*L6*&.!463,(&!$K*.*51,&*!/*))!.5(7,31!@F!@,&+,&"!.(!/*))6)-5!5*/*7.(53!$9*))$.($/*))!375*-+!
93*))&*5!!"#$%&'#IJJJ!!!:M-@!!"#$%&'#IJ;I!!>*)),&".(&!!"#$%&'#;<<?-!"2! $%&'()'*+!,&!/*))$.($/*))!375*-+!-&+!',563!*"5*33!$N,56)*&.!75(.*,&!$%116&(1(+6)-.(5F!75(7*5.,*3O!"28"%!/(17)*P!-/.3!-3!-!Q/!5*/*7.(5R!
S-.36165-!!"#$%&'#;<<=!T36U,165-,!!"#$%&V!IJJ<!!!
"W! $N,5-)!/0*1(X,&*!@,&+,&"!75(.*,&!!$%&.*54*5*&/*!D,.0!)*6X(/F.*!1,"5-.,(&!,&!.,336*3!
#5F-&.!!"#$%&'#IJJC(#N-&!+*!>-))*!
!"#$%&'#IJJBV!IJJ=@!T0(51-&&!!"#$%&'#IJ;IY!G3.*55*,+*5!Z!N-&!+*!>-))*V!IJ;J!"E! $Q63,(&!5*"6)-.(5F!4-/.(5!$9*))6)-5!0(3.!5-&"*!-&+!,&.*"5,&!@,&+,&"!$9*))$.($/*))!375*-+! :.-&-3,6!!"#$%&'#IJ;JY!90(D+-5F!!"#$%&'#IJ;J!:M-@!!"#$%&'#IJ;C!:M-@!!"#$%&'#IJ;I!!"%! $Q(513!D,.0!"2!-!46&/.,(&-)!*&.,.F! S-.36165-!!"#$%&'#;<<=!"[! $233*&.,-)!4(5!',5-)!*"5*33!-&+!/*))$.($/*))!375*-+!$Q-/,),.-.*!',563!7*&*.5-.,(&!-&+!3F&/F.,61!4(51-.,(&!!
A*6@-6*5!Z!G3.*55*,+*5V!IJJ\!
"]! $Q(513!D,.0!"E!-!46&/.,(&-)!*&.,.F!!$%17(5.-&.!4(5!/(55*/.!4()+,&"!-&+!.5-44,/X,&"!-&+!46&/.,(&!(4!"E!! 2,3*&@*5"!!"#$%&'#IJ;I!!Q-&!!"#$%&'#IJJ<!"S! $N,563!7*&*.5-.,(&!-&+!/*))$.($/*))!375*-+!! G3.*55*,+*5!!"#$%&'!;<<?!!"A! $Q(513!D,.0!"S!-!46&/.,(&-)!*&.,.F!$%116&(1(+6)-.(5F!75(.*,&!^T:_$,&0,@,.,&"!1()*/6)*`! !!N*5D*,U!!"#$%&'#IJ;;!"7I! $a&,L6*!")F/(75(.*,&!4(5!2EN$;!$N,563!-..-/01*&.!-&+!*"5*33!$%116&(1(+6)-.(5F!75(.*,&!)*#+)+,! b6&!!"#$%&V!;<<?!c6+()70!Z!G3.*55*,+*5V!IJJI!b1,.0!!"#$%&'#IJJH!
18   Chapter 1 
___________________________________________________________________ 
 
1.6. Replication cycle 
 
A general overview of the alphaherpesvirus productive replication cycle, valid for 
EHV-1, is depicted in Figure 2. 
 
Viral attachment 
In order to infect a cell, EHV-1 must bind to the cell surface. The initial attachment of 
EHV-1 is mediated by interactions of positively charged residues on EHV-1 gB and 
gC with heparan sulfate proteoglycans present on the cell surface, which are 
negatively charged (Spear & Longnecker, 2003). This interaction is relatively 
unspecific, reversible and serves to concentrate the virus at the cell surface. After 
initial attachment, the interaction with gD and a putative receptor on the cell is 
required to stabilize the binding and promote virus entry (Csellner et al., 2000; 
Frampton et al., 2005). The interaction with an entry receptor is highly specific and 
irreversible and triggers the fusion between the viral envelope and the cellular 
membrane. Currently, the receptor of EHV-1 has still not been clearly identified. 
While some studies have shown that EHV-1 uses the same viral glycoproteins utilized 
by other alphaherpesviruses, such as HSV-1 and PRV, for binding and entry into 
permissive cells, other studies have demonstrated that EHV-1 uses a unique entry 
receptor that is distinct from HSV-1 and PRV receptors. 
To date, three classes of entry receptors for HSV and PRV gD have been identified, 
which include herpesvirus entry mediator (HVEM), a member of the tumor necrosis 
factor receptor family; nectin-1 and nectin-2, two members of the immunoglobulin 
superfamily; and a modified form of heparan sulfate called 3-O-sulfated heparan 
sulfate (Spear et al., 2000). Frampton et al., 2005, demonstrated that EHV-1 could 
still replicate in cells lacking entry receptors HVEM, nectin-1 and nectin-2, ruling out 
that these surfaces molecules are EHV-1 receptors. Other authors have identified the 
Major Histocompatibility Complex Class I (MHC-I) as a functional entry receptor for 
EHV-1 gD in equine dermal and equine brain microvascular endothelial cells (Kurtz 
et al., 2010; Sasaki et al., 2011). However, MHC-I molecules are expressed on the 
cell surface of all nucleated cells (David-Watine et al., 1990), which makes it 
impossible to explain the clear, delineated tissue tropism of EHV-1 in horses. As an 
explanation for this inconsistency, it was suggested that not all equine MHC-I alleles 
serve as functional EHV-1 entry receptors and that host factors other than MHC class 
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I may be involved in the observed EHV-1 tropism (Sasaki et al., 2011). In the 
meantime, a study from Azab et al., 2012 showed that EHV-1 uses different 
receptor(s) than MHC I to infect PBMC, further demonstrating that additional 
research is needed to clearly establish the receptor(s) of EHV-1 on the different 
equine target cells.  
 
Viral entry 
Once attached, EHV-1 penetrates the cells either by direct fusion of the virus 
envelope with the plasma membrane at neutral pH or by non-classical 
endocytosis/phagocytosis pathways. Receptor engagement results in a conformational 
change in gD and leads to the activation of the heterodimeric gH-gL complex, which 
in turn primes gB for fusion (Spear & Longnecker, 2003). EHV-1 can enter cells, 
such as rabbit kidney epithelial cells (RK-13) and equine dermal cells (ED) via direct 
fusion with the plasma membrane (Frampton et al., 2007). In addition, EHV-1 can 
enter via the endocytic/phagocytic pathway into Chinese hamster ovary cells (CHO-
K1) and PBMC and αv integrins are involved in this type of viral entry (Van de Walle 
et al., 2008a). Moreover, EHV-1 can enter equine brain microvascular endothelial 
cells (but not ED cells) via caveolar endocytosis, suggesting that EHV-1 entry 
pathways are cell-type dependent (Hasebe et al., 2009). Glycoprotein gH and cellular 
α4β1 integrins are important determinants in the choice of alphaherpesvirus entry 
pathways (Azab et al., 2013).  
Irrespective of the entry route, naked EHV-1 capsids are released into the cytosol after 
the virus fuses with the plasma membrane/endosomal membrane. Successful infection 
through either mechanism requires the activation of Rho-associated coiled-coil kinase 
1 (ROCK1) (Frampton et al., 2007). 
 
Viral transport to the nucleus 
Consequent to fusion between the two lipid membranes, the capsid is released into the 
cytoplasm of the cell and transported along microtubules to the nucleus. Viral DNA is 
released in the nucleus via the nuclear pore complex (Pasdeloup et al., 2009; Sodeik 
et al., 1997). 
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Gene expression and replication 
Upon delivery of the viral genome in the nucleus, the viral DNA circularizes and 
transcription is initiated. As for all alphaherpesviruses, EHV-1 transcription is tightly 
regulated in a cascade-manner where the immediate-early (IE), early (E) and late (L) 
genes are sequentially transcribed (Gray et al., 1987a; 1987b; Caughman et al., 1985; 
Purewal et al., 1994). The IE protein (IEP) upregulated by a tegument ETIF protein 
(ETIFP) (Elliot and O’Hare, 1995) trans-activates early and some late genes (Kim et 
al., 1997; Smith et al., 1992; 1994), and also downregulates its own promoter (Kim et 
al., 1995). Early genes are expressed before DNA replication and encode enzymes 
that are required for genome replication, DNA repair and nucleotide metabolism and a 
number of other proteins with yet unknown functions. Viral DNA replication occurs 
in the nucleus. Late genes are expressed after DNA replication has initiated and 
typically encode viral structural proteins, such as capsid proteins and envelope 
glycoproteins.   
 
Virion assembly and egress 
EHV-1 nucleocapsids are assembled in the nucleus prior to viral DNA encapsidation. 
The newly produced head-to-tail concatameric genomic DNA is then cleaved and 
packaged as unit-length molecules resulting in mature capsids (Lehman & Boehmer, 
1999). Nucleocapsids leave the nucleus by budding through the inner nuclear 
membrane into the perinuclear space, thus acquiring a primary envelope. This primary 
envelope is then lost by fusion with the outer nuclear membrane, resulting in the 
release of naked nucleocapsids into the cytoplasm (Granzow et al., 2001). The naked 
nucleocapsids acquire their final tegument in the cytoplasm. A second envelopment 
process takes place in the trans-Golgi network, which contains all viral envelope 
proteins. The mature virions are transported to the cell surface within secretory 
vesicles and released via exocytosis in the extracellular space (Mettenleiter, 2002; 
Mettenleiter et al., 2009). The infectious virus can also directly infect other cells via 
cell-to-cell spread. This strategy allows the virus to escape from antibodies, 
complement and phagocytes. EHV-1 glycoproteins gB, gD, gE/gI, gK and gM are 
mainly involved in this process.  
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Figure 2. The replication cycle of the alphaherpesvirus pseudorabies virus (PrV), a close relative of 
EHV-1, associated with electron micrographs. (1) and (2) Attachment and  penetration of PRV into the 
cytoplasm of the host cell. (3) and (4) Nucleocapsids are transported to the nucleus (N) via interaction 
with microtubules (MT). (5) The viral genome is released in the nucleus through the nuclear pore (NP). 
(6) Transcription and viral DNA replication occur in the nucleus. (7) and (8) The genome is cleaved 
and packaged into newly formed capsids, which leave the nucleus by budding into the inner nuclear 
membrane (9). (10) and (11) Nucleocapsids lose the primary envelope when passing through the outer 
nuclear membrane and naked nucleocapsids are released into the cytoplasm. (12) The nucleocapsids 
acquire their secondary envelope via budding into the trans-Golgi network (TGN). (13) The mature 
virions are transported to the cell surface within sorting vesicles and released via exocytosis in the 
extracellular space (14). Rough endoplasmic reticulum (RER); mitochondrion (M); golgi apparatus 
(G); nuclear membrane (NM). Adapted from Mettenleiter et al., 2009. 
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Fig. 1. Virion morphology of herpesviruses.
Extracellular virions of the alphaherpesviruses HSV-1 and PrV, the betaherpesvirus HCMV, the gammaherpesvirus bovine herpesvirus 4 (BHV-4) and the alloherpesvirus koi
herpesvirus (KHV) are shown. Bar =100nm.
the three different herpesvirus families, their common virion
morphology suggests that the underlying mechanisms of virion
formation are comparable (Davison and Davison, 1995; Fig. 1).
However, very little is known about these stages beyond the
Herpesviridae.
Detailed mass spectrometric analyses of purified extracellular
herpes virions identified numerous viral and cellular proteins as
constituents of themature virus particle (reviewed inMaxwell and
Frappier, 2007). For the prototypic alphaherpesvirus herpes sim-
plex virus type 1 (HSV-1), in addition to eight capsid, and intimately
capsid-associated polypeptides, 13 viral glycoproteins, 23 potential
viral tegument proteins and up to 49 distinct host proteins were
identified in the virion (Loret et al., 2008). In the betaherpesvirus
human cytomegalovirus (HCMV), 71 viral and more than 70 host
proteins were detected (Varnum et al., 2004). In the gammaher-
pesviruses 23viral and6 cellular proteinswere found in alcelaphine
herpesvirus 1 (Dry et al., 2008), 35 viral proteins and several cellu-
lar proteins in Epstein-Barr Virus (Johannsen et al., 2004), and 24
viral and 21 cellular proteins in Kaposi’s sarcoma associated her-
pesvirus (KSHV) (Zhu et al., 2005). 33 viral proteins were found
in purified rhesus monkey rhadinovirus of which 17 are supposed
to be tegument proteins and 9 envelope proteins (O’Connor and
Kedes, 2006). Themost frequently found, andmost abundant cellu-
larproteins inherpesvirusparticles areactin, hsp70,hsp90, enolase,
ezrin/moesin,!-tubulin and annexin (Maxwell and Frappier, 2007).
So far, it is unclear whether packaging of these proteins has an
impact on infection. Besides proteins, RNAs of viral and cellular ori-
gin have also been detected in purified herpesvirus preparations
Fig. 2. Replication cycle of the alphaherpesvirus pseudorabies virus (PrV).
A diagram of the replication cycle is shown together with electron micrographs of the respective stages. After attachment (1) and penetration (2), capsids are transported to
the nucleus (N) (3) via interaction with microtubules (MT) (4), docking at the nuclear pore (NP) (5) where the viral genome is released into the nucleus. Here, transcription
of viral genes and genome replication cur (6). Concatemeric replicated viral genomes are cleaved to unit-length during encapsidation (8) into preformed capsids (7),
which then leave the nucleus by budding at t e INM (9) followed by fusion of the envelope of these primary virions located in the perinuclear space (10) with the outer
nuclear membrane (11). Final maturation then occurs in the cytoplasm by secondary envelopment of intracytosolic capsids via budding into vesicles of the trans-Golgi
network TGN (12) containing viral glycoproteins (black spikes), resulting in an enveloped virion within a cellular vesicle. After transport to the cell surface (13), vesicle and
plasma membranes fuse, releasing a mature, enveloped virion from the cell (14). RER, rough endoplasmic reticulum; M, mitochondrion; G, Golgi apparatus (Reprinted from
Mettenleiter, T.C. Pseudorabies virus. Encyclopedia of Virology, 2008 (B.W.J. Mahy and M.H.V. van Regenmortel, Editors), pp. 341–351, Elsevier, Oxford).
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2. Pathogenesis of EHV-1 infection 
 
The pathogenesis of EHV-1 is illustrated in Figure 3. 
 
2.1. Introduction 
 
EHV-1 is a highly contagious pathogen and is usually transmitted via direct contact 
with infectious secretions (saliva, nasal discharge) or via inhalation of infectious 
aerosols (Patel et al., 1982). Fetal or placental tissues that contain large virus loads 
may also serve as a possible source of infection (Reed & Toribio, 2004). 
 
2.2. Primary replication in the upper respiratory tract (URT) 
 
Upon entry into the host, EHV-1 first replicates in a plaquewise manner in the 
epithelial cells lining the URT, including nasal septum, turbinates, nasopharynx, soft 
palate and trachea (Fig 3.1) (Gryspeerdt et al., 2010; van Maanen, 2002). In vivo, 
EHV-1 induced plaques were observed in the epithelium of the nasal mucosa starting 
from 2 till 7 days post-inoculation (dpi) (Gryspeerdt et al., 2010). In ex vivo 
experiments, single infected epithelial cells were visible at 12 hpi and EHV-1 induced 
plaques were observed starting from 24 hpi in the epithelium of equine nasal and 
nasopharyngeal explants (Vandekerckhove et al., 2010). Primary EHV-1 infection of 
several tissues of the URT results in the destruction and erosion of the epithelium and 
in nasal shedding starting from 1 to 10-14 dpi (Edington et al., 1986; Gibson et al.; 
Gryspeerdt et al., 2010).  
Following infection of the respiratory epithelium, EHV-1 crosses the basement 
membrane (BM) by the use of single infected leukocytes (Edington et al., 1986; Kydd 
et al., 1994). These cells were mainly identified as CD172a+, cells originating from 
the myeloid lineage (monocytes, macrophages and dendritic cells) (Gryspeerdt et al., 
2010; Vandekerckhove et al., 2010). This invasion mechanism is distinct from other 
alphaherpesviruses, such as PRV and BoHV-1, which spread in a plaquewise manner 
across the BM. PRV and BoHV-1 can cause severe respiratory symptoms while EHV-
1 causes a self-limited respiratory infection. It was proposed that the different 
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mechanisms of invasion between PRV/ BoHV-1 and EHV-1 might correlate with 
their different clinical outcomes (Glorieux et al., 2009; Steukers et al., 2012).  
Similar to EHV-1 infection, EHV-4 can infect and replicate in the epithelium of the 
URT following direct contact with infectious secretions or via inhalation of infectious 
aerosols. However, EHV-4 infection remains mostly restricted to the URT and does 
not extend beyond the local lymph nodes (Patel et al., 1982). 
 
2.3. Replication in the draining lymph nodes and cell-associated viremia   
 
Upon crossing the BM, EHV-1 can penetrate connective tissues and reach the 
bloodstream and the draining lymph nodes. Within 24-48 hours after infection, 
infectious virus as well as viral antigens have been detected in submandibular, 
retropharyngeal and bronchial lymph nodes. EHV-1 infection is amplified in the 
draining lymph nodes with discharge of infected leukocytes, via the efferent lymph, 
into the blood circulation (Figure 3.2) (Kydd et al., 1994). As a result, EHV-1 initiates 
a cell-associated viremia in PBMC that allows it to disseminate within the host. 
Viremia can be detected starting from 1 dpi and persists for at least 14 days 
(Gryspeerdt et al., 2010). The cell-associated viremia is a prerequisite for the 
dissemination of EHV-1 to target organs such as the pregnant uterus and/or central 
nervous system (CNS).  
During cell-associated viremia, all PBMCs subpopulations have been shown to be 
susceptible to EHV-1 infection both in vivo and in vitro. However, the degree of 
susceptibility to EHV-1 infection between PBMC subpopulations varies between 
studies. An early in vivo study using PBMC collected from EHV-1 infected horses 
identified the T-lymphocyte population as the primary PBMC subpopulation infected 
with EHV-1 during viremia (Scott et al., 1983). A more recent in vivo study using 
neurovirulent and non-neurovirulent EHV-1 strains identified CD172a+ monocytic 
cells and to a lesser extent T-and B-lymphocytes as the main carrier cells of both 
EHV-1 strains in the blood (Gryspeerdt et al., 2010). A possible explanation for this 
discrepancy could be the choice of EHV-1 strain used and/or the method to isolate 
PBMC.  Scott and colleagues used an American strain isolated from an aborted fetus 
and separated the leukocyte population by glass-bead column. Moreover, no direct 
characterization of the leukocyte subpopulations was performed. In contrast, 
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Gryspeerdt and colleagues used two different Belgian strains and isolated PBMC by 
density centrifugation on Ficoll-Paque. Specific markers for monocytic, T- and B- 
cells were used to characterize PBMC subpopulations. In vitro studies showed that all 
PBMC subpopulations are susceptible to EHV-1 infection but that monocytic cells are 
the main target cells infected in resting PBMCs (van der Meulen et al., 2000). 
Dendritic cells (DC) are also susceptible to EHV-1 infection in vitro (Siedek et al., 
1997; Siedek et al., 1999). After mitogen stimulation, T-lymphocytes showed an 
increased susceptibility to EHV-1 infection (van der Meulen et al., 2000). It was 
suggested that blastic transformation of T-lymphocytes, induced in vitro by mitogens, 
may provide a signal for the virus to start its replication, and thus lead to increased 
susceptibility of T-lymphocytes to EHV-1 infection. This is consistent with an early 
in vivo study from McCulloch et al. (1993) demonstrating an increase in the 
percentage of blastic cells in the blood after experimental infection with EHV-1. This 
might explain the earlier results of Scott’s in vivo study that pointed to T-lymphocytes 
as the predominant PBMC subpopulations infected with EHV-1. Another in vitro 
study demonstrated a difference in leukocyte tropism between neuro- and non-
neurovirulent EHV-1 strains (Goodman et al., 2007). This is in striking contrast with 
the in vivo study of Gryspeerdt et al. (2010). This might be due to differences in the 
frequency of infected PBMC between in vitro (10-30%) and in vivo situations (1-10 
positive cells/107 PBMC) (Goodman et al., 2007; van der Meulen et al., 2006). The 
majority of PBMC do not show viral envelope proteins on their surface during 
viremia (Gryspeerdt et al., 2012; van der Meulen et al., 2003). This suggests that 
EHV-1 misuses these cells to spread through the body without being detected by the 
immune system. 
In contrast to EHV-1, cell-associated viremia is extremely rare during EHV-4 
infections. Thus, EHV-4 is only very rarely associated with abortion and neurological 
disorders (Matsumura et al., 1992; Osterrieder & Van de Walle, 2010; Patel & 
Heldens, 2005; Verheyen et al., 1998). 
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Figure 3: Schematic overview of the pathogenesis of EHV-1. (1) EHV-1 first replicates in the epithelial cells of the URT; (a) EHV-1 infection; (b) viral spread and shedding; 
(c) EHV-1 crosses the BM by the use of single immune cells; (d) viral dissemination (2) Upon crossing the BM, EHV-1 penetrates the connective tissues and reaches the 
bloodstream and draining lymph nodes. (3) Via a cell-associated viremia in PBMC, EHV-1 is transported to target organs such as the pregnant uterus (3.a), CNS (3.b) 
and/or eye (3.c) where it initiates a secondary replication in the endothelial cells lining the blood vessels of these organs. Pink = respiratory tract; red = blood circulation; 
orange = lymph nodes; yellow = vertebrae; green = spinal cord; blue = uterus. 
2. Replication in the lymph nodes  
and cell-associated viremia 
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2.4. Secondary replication in the pregnant uterus, CNS and/or eye  
 
Once in the blood circulation, infected leukocytes can adhere and subsequently 
transfer EHV-1 to the endothelial cells (EC) lining the blood vessels of target organs 
such as the pregnant uterus or CNS. The infection of EC located in the vasculature of 
the late-gravid uterus or CNS is mediated by cell-to-cell contacts between infected 
PBMC and EC and was found to occur even in the presence of virus neutralizing 
antibodies (Goehring et al., 2011; Smith et al., 2001). 
 
The migration of leukocytes from the bloodstream into perivascular tissue, so called 
leukocyte extravasation, is a dynamic process, which has been widely studied in 
humans. According to the current paradigm, this interaction involves the sequential 
engagement of leukocyte and endothelial adhesion molecules. First, selectins and 
their carbohydrate counter ligands mediate leukocyte tethering and rolling. Then, 
leukocyte integrins and their ligands, including immunoglobulin-like intercellular 
adhesion molecules, mediate firm leukocyte adhesion. Chemokines play a role in firm 
adhesion by activating integrins on the leukocyte cell surface (Chavakis et al., 2009). 
In the final stage of leukocyte extravasation, leukocytes migrate through the 
endothelium into the tissues. A schematic overview of the distinct steps of the 
leukocyte recruitment to EC is provided in Figure 4. 
 
 
Figure 4: Schematic overview of the multistep process of leukocyte recruitment to the endothelium. 
Adapted from Rivera-Nieves et al., 2008. 
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It is likely that the recruitment of leukocytes to the endothelium of target organs plays 
a crucial role in the pathogenesis of EHV-1. It has been suggested that activation of 
adhesion molecules present on both leukocytes and EC surfaces is a prerequisite for 
the transfer of EHV-1 from leukocytes to the endothelium (Smith et al., 2001). 
However, the exact nature of the adhesion molecules present on the surface of both 
equine leukocytes and EC has not been examined yet; a task hampered by the lack of 
antibodies against specific adhesion molecules that cross-react with equine cells. 
Moreover, it is still unknown whether there are differences in the adhesion molecules 
expressed on EC of target organs compared to other organs or there are variations in 
their expression levels, which could explain why EHV-1 targets specific organs in the 
horse. 
 
Secondary replication in the EC of the pregnant uterus can cause vasculitis and 
multifocal thrombosis that particularly affects small arteriolar branches in the 
glandular layer of the endometrium at the base of the microcotyledons (Fig 3.3a) 
(Edington et al., 1991; Smith et al., 1992; Smith et al., 1993). This leads to avascular 
necrosis and edema of the endometrium. A widespread EC infection may cause 
detachment of the fetal membranes, thus leading to the abortion of a virus-negative 
fetus. Less extensive uterine vascular pathology may allow EHV-1 to invade the fetus 
through the uteroplacental barrier and lead to the abortion of a virus-infected fetus. In 
EHV-1 positive fetuses, infected EC can be detected in blood vessels of the umbilical 
cord and allantochorion (Smith et al., 1997; Smith et al., 1993). The viral aborted 
fetus can show multiple lesions, including multifocal hepatic necrosis, subcutaneous 
edema, pleural fluid accumulation, pulmonary edema and splenic enlargement 
(Corner et al., 1963; Machida et al., 1997). At late stage of gestation, transplacental 
EHV-1 infection could result in the delivery of a live infected foal that may die 
within few days.  
Secondary replication in the EC lining the blood vessels of the CNS can cause 
vasculitis with or without local haemorrhage and thrombo-ischemic necrosis, in the 
brain and spinal cord (Fig 3.3b) (Edington et al., 1986; Wilson, 1997). The lack of 
nutrients and oxygen may cause degeneration of the nervous tissues and lead to the 
development of equine herpes myeloencephalopathy (EHM).  
Secondary replication in the vasculature of the eye can cause multifocal chorioretinal 
lesions in infected horses (Fig 3.3c) (Matthews, 2004; Slater et al., 1992). This type 
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of lesion is typically caused by endothelial damage with subsequent ischemic injury 
to the chorioretina that may result from direct infection of the vascular endothelium 
following viremia. 
 
2.5. Latency and reactivation  
 
Latency by alphaherpesviruses is an important epidemiological strategy that ensures 
survival and spread of the virus within the natural host population (Whitley & Gnann, 
1993). Upon lytic infection in the URT, EHV-1 enters a latent state in lymphoid 
tissues draining the respiratory tract, CD8+ lymphocytes and neurons of the 
trigeminal ganglia (Baxi et al., 1995; Edington et al., 1994; Gibson et al., 1992; 
Slater et al., 1994b; Smith et al., 1998a; Welch et al., 1992). The CD8+ lymphocytes 
are defined as a predominant site of latency and it is estimated that 1/50 000 PBMC 
are latently infected (Chesters et al., 1997). The CD8+ lymphocytes undergo a 
transition from productive to latently infected cells, which usually takes between 2 to 
3 weeks (Slater et al., 1994a). During latency, the transcription of EHV-1 genome is 
restricted. Like for HSV-1, only latency-associated transcripts (LAT) accumulate in 
the latently infected cells and no infectious virus is produced (Roizman et al., 1992). 
EHV-1 can be reactivated from latency upon corticosteroid treatment and natural 
stimuli such as stress, weaning and castration (Burrows & Goodridge, 1984; Edington 
et al., 1985; Slater et al., 1994b). Upon reactivation months or years after primary 
infection, EHV-1 is delivered back to the URT and can start a lytic infection 
depending on the local immune status of the epithelium. This can result in virus 
shedding with the potential to infect other horses. A cell-associated viremia is also 
initiated prior to or following infection of the respiratory epithelium and may result in 
dissemination of EHV-1 to the pregnant uterus or the CNS to cause abortions and/or 
neurological disorders. EHV-1 induced abortions usually occur in single mares within 
a group, suggesting that abortion has resulted from viral reactivation rather than from 
newly acquired respiratory infection (Doll & Bryans, 1963). The majority of horses 
(>60%) are latently infected by EHV-1 (Lunn et al., 2009). Latently infected cells are 
masked from immune surveillance and constitute a permanent reservoir of the virus 
that is difficult to eliminate by conventional antiviral therapies and vaccine strategies.  
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Interestingly, studies have linked chromatin remodeling and histone 
acetylation/deacetylation events to the regulation of promoter activity, the control of 
viral replication and maintenance of viral latency during herpesvirus infections 
(Knipe & Cliffe, 2008; Sinclair et al., 2006; Lu et al., 2003; Danaher et al., 2005). 
Acetylation of histones typically results in open chromatin, which allows cellular and 
viral transcription, while deacetylation generally causes the chromatin to close and 
therefore repress transcription (Figure 5). The acetylation of histones is carried out by 
a group of enzymes known as histone acetyl transferases (HAT) and histone 
deacetylases (HDAC) catalyse the reverse reaction (Berger et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Chromatin remodeling by histone acetylation/ deacetylation events. HAT= histone  
acetyltransferase; HDAC=histone deacetylase; Ac= acetyl group.  
 
 
It has been demonstrated that, during HSV-1 latency, lytic gene expression is 
repressed and the viral genome (with the exception of the LAT gene) associates with 
heterochromatin (Deshmane et al., 1989). In contrast, during lytic infection, HSV-1 
DNA is associated with hyperacetylated histones at promoter regions and the 
chromatin adopts a more disordered state (relaxed chromatin), which directly 
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correlates with the activation of viral transcription (Kent et al., 2004). HDAC 
regulate HSV-1 latency directly by inducing histone deacetylation and reducing 
histone acetylation at HSV-1 promoter sites (Kubat et al., 2004). HDAC inhibitors 
induce global histone acetylation resulting in HSV-1 transcription and reactivation 
from latency (Danaher et al., 2005). So far, the control of EHV-1 replication and 
reactivation from latency by HDACs is largely undefined. 
 
2.6. Factors determining the development of abortion vs EHM 
 
The cell-associated viremia is a prerequisite for the development of severe EHV1 
symptoms. The magnitude and duration of the viremia are important factors 
determining whether a horse will develop abortion or neurological disorders (Allen 
& Breathnach, 2006). However, severe symptoms do not necessarily follow viremia. 
During EHV-1 outbreaks, the incidence of abortions is higher (approx. 50%) than the 
incidence of EHM (10%) (Goehring et al., 2006). A combination of viral, host and 
environmental factors has been proposed to contribute to the development of these 
severe symptoms.  
First of all, it was demonstrated that a single nucleotide polymorphism (SNP) in the 
catalytic subunit of the viral DNA polymerase, causing a substitution of asparagine 
(N) by aspartic acid (D) at amino acid position 752, is significantly associated with 
the neurovirulent potential of naturally occurring strains (Nugent et al., 2006). It was 
shown that more than 95% of non-neuropathogenic outbreaks were caused by virus 
strains encoding DNA pol N752, and more than 86% of neuropathogenic outbreaks 
are caused by strains encoding D752. This finding was confirmed by targeted 
mutation of the D752 to the N752 genotype in a neurovirulent isolate which resulted in 
attenuation of virulence, reduced levels of viremia and reduced capacity to cause 
neurological disorders (Goodman et al., 2007). However, both viruses presented 
comparable peak titers of virus shedding, suggesting that both viruses can spread in a 
similar way into the horse population. Besides, a 23-year retrospective study of the 
prevalence of neurologic EHV-1 demonstrated that 24% of the EHM outbreaks are 
caused by N752 EHV-1 strains and 2% of the EHV-1-induced abortions are caused by 
D752 genotype strains (Perkins et al., 2009).  
Secondly, the development of abortion may depend on the hormonal activity and 
immune status of mares in late term pregnancy. Indeed, it was demonstrated that the 
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expression of adhesion molecules is induced by cytokines (IL-2) and hormones (17-
oestradiol and equine chorionic gonadotropin) present in the local environment of late 
stage of pregnancy (Smith et al., 2002). Moreover, the production of high levels of 
cortisone, progesterone and oestrogens at late stage of pregnancy may alter the 
immune system of the mare (Smith et al., 1996). So far, the host and environmental 
factors determining the occurrence of EHM are still unclear. Goehring et al. (2006) 
showed that the age, breed and gender of the horse and seasonal influences (late 
autumn, winter and spring) might affect the risk of EHM outbreaks.  
 
3. Clinical signs 
 
An overview of the different symptoms following EHV-1 infection is shown in 
Figure 6. 
 
3.1. Respiratory disease 
 
Respiratory EHV-1 infection is usually mild or subclinical in adult horses. However, 
young horses can develop more severe clinical signs consisting of fever, nasal 
discharge, swelling of the submandibular and retropharyngeal lymph nodes and 
sometimes anorexia, depression and conjunctivitis with ocular discharge (Allen & 
Bryans, 1986; Coggins, 1979; Patel et al., 1982). The nasal discharge can become 
mucopurulent, due to secondary bacterial infections, often associated with isolation of 
β-haemolytic streptococci. This may contribute to the development of 
rhinopneumonitis (Thomson et al., 1979; Pusterla et al., 2009; Dunowska et al., 
2014). The incubation period for respiratory symptoms varies between 1 to 10 dpi. 
Disease may occur in individual horses, or in a group of animals. EHV-4 also causes 
respiratory tract disease, which is clinically indistinguishable from EHV-1 (Ostlund, 
1993). 
 
3.2. Abortion 
 
EHV-1 induced abortion typically occurs in the last trimester of pregnancy, although 
one case of abortion has been reported in the fourth month of gestation (Allen & 
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Bryans, 1986; Prickett, 1969). EHV-1 infected mares can abort without showing any 
clinical respiratory signs (Allen, 2002). Following viremia, the incubation period can 
vary between 9 days and 4 months after infection. Depending on the spread of EHV-1 
infection to the endometrial blood vessels, infected mares can abort a virus-positive 
or virus-negative fetus. During abortion, the placenta is usually expelled together 
with the fetus that is often still enveloped in its amniotic membrane. The fetus usually 
dies from asphyxia due to the separation of the placenta from the endometrium. 
Fetuses that are still alive usually succumb quickly by respiratory insufficiency due to 
virus-induced pulmonary lesions. If infection occurs during late gestation, the fetus 
may be born alive, a condition known as neonatal foal disease. These foals develop 
jaundice and respiratory distress and mostly die within a few days (Murray et al., 
1998; Perkins et al., 1999). Following abortion, the virus is rapidly cleared from the 
genital tract and the reproductive potential of the mare is usually not affected. 
Abortion outbreaks can occur over a period of several weeks. Due to reactivation of 
latent virus, mares may also abort several months or years after a primary infection 
(Allen et al., 1999). 
 
3.3. Neurological disease 
 
EHV-1-induced neurological disease is not restricted by age, sex and pregnancy and 
can also occur in foals and stallions (Greenwood & Simson, 1980). Clinical signs can 
vary from mild ataxia, swaying, stumbling and falling to complete paralysis 
(Stierstorfer et al., 2002; van Maanen et al., 2001). The hind limbs are generally the 
most affected even though some cases of quadriplegia have been observed. Other 
clinical signs include bladder infection, fecal and/or urinary incontinence, head 
tilting, tail paralysis, oedema of testis and blindness (Borchers et al., 2006; Jackson et 
al., 1977; van Maanen et al., 2001). The incubation period of EHV-1 induced 
neurological disorders can vary between 6 to 8 days (Jackson & Kendrick, 1971; 
Mumford et al., 1994). The endotheliotropism of EHV-1 is central to the neurological 
disease (Edington et al., 1986; Kohn & Fenner, 1987; Patel et al., 1982; Whitwell & 
Blunden, 1992). EHM is the result of an inflammatory cascade (expanded levels of 
immune complexes and cytokines derived from cytotoxic T lymphocytes (CTL)) that 
is associated with EHV-1 infection of the endothelial cells of the CNS (Jackson & 
Kendrick, 1971; Wilson, 1997). The prognosis for non-recumbent horses is favorable. 
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However, horses that remain recumbent for more than 24 hours usually develop fatal 
complications and are euthanized. 
 
3.4. Ocular disease 
 
EHV-1 can also induce chorioretinopathy, causing permanent focal or multifocal 
lesions of the chorioretina in a substantial proportion of infected horses. Most EHV-
1-induced ocular infections are subclinical but sometimes, diffuse lesions may lead to 
extensive retinal destruction and blindness. The frequency of EHV-1 ocular lesions 
varies between 50 to 90% in experimentally infected horses (Hussey et al., 2013). It 
was proposed that EHV-1 infection of the ocular vasculature may offer an alternative 
model to study EHM because the vasculature of the equine ocular fundus is likely to 
be physiologically and anatomically similar to that of the CNS, with tight junctions 
analogous to the “blood brain barrier” (Matthews, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Clinical signs associated with EHV-1. (A) Respiratory disease 
(http://www.ckequinehospital.com/); (B) Neurological disease 
(http://www.vetsonline.com/);  (C) Abortion (http://www.ca.uky.edu/); 
(D) Chorioretinopathy (Hussey et al., 2013). 
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4. Immunity to EHV-1 infection 
 
4.1. Introduction 
 
Herpesviruses are experts in establishing lifelong infections of immunocompetent 
hosts. Understanding the immune response associated with protection against EHV-1 
infection is essential to design efficient EHV-1 vaccines. Immunity to EHV-1 can be 
established after a natural infection or after vaccination. However, protective 
immunity against re-infection by EHV-1 is short-lived (4 to 8 months) (Doll et al., 
1955).  
 
4.2. Innate immunity 
 
Innate immune response mechanisms provide a first line of host defense upon viral 
infection and have been shown to be critically important for protection and induction 
of adaptive immune responses. So far, equine innate immunity to EHV-1 infection 
has been poorly characterized.  
The respiratory mucosa is the first line of defense against EHV-1 infection. Airway 
epithelial cells regulate both innate and adaptive immunity through production of 
functional molecules and via physical interactions with cells of the immune system. 
They express pattern recognition receptors including toll-like receptors (TLR) that 
bind to pathogens and trigger the secretion of cytokines and chemokines that 
subsequently lead to the activation and recruitment of innate immune cells 
(macrophages, neutrophils, DC, natural killer cells (NK)) to the site of infection 
(Kato & Schleimer, 2007). EHV-1 infection of an in vitro equine respiratory 
epithelial cell system showed an increased expression of TLR3 and 9 as well as 
inflammatory cytokines (IL-1, TNF-α, IFN-α and IL-6) and chemokines (IL-8 and 
MCP-1) (Soboll Hussey et al., 2014). The most effective mechanisms of the innate 
response against viral infections are mediated by IFN and by the activation of NK 
cells. Equine type 1 interferon (IFNα/β) has been detected in nasal secretions and 
serum during the first and second week after experimental infection of ponies with 
EHV-1 (Chong & Duffus, 1992; Edington et al., 1989). The production of type I IFN 
was directly associated with the self-limited EHV-1 infection in the respiratory 
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epithelium and the duration of nasal shedding (Gryspeerdt et al., 2010). NK cells 
helped by DC are central components of the innate reaction to several herpesvirus 
infections such as HSV-1 or HCMV but it was suggested that these cells do not have 
an impact on EHV-1 infection (Chong & Duffus, 1992). 
 
4.3. Adaptive immunity 
 
The mucosal immune system consists of specialized local inductive sites such as the 
MALT (mucosal associated lymphoid tissue) where adaptive immune responses are 
likely to be initiated. Virus-specific IgA dominate the mucosal antibody response. 
Virus-specific IgG can also be detected in respiratory secretions but their levels 
rapidly decline. This is caused by inflammation-dependent exudation of virus specific 
serum IgG antibody into the airway lumen, which ceases abruptly upon restoration of the 
respiratory epithelium (Breathnach et al., 2001). Serum antibody (virus neutralization, 
complement fixation, IgM and IgG) responses to EHV-1 infection are usually short-
lived. Both virus neutralizing (VN) (mostly against gD, gB and gC) and complement 
fixing (CF) antibodies are elicited starting from 2 weeks after field or experimental 
infection with EHV-1 (Doll & Bryans, 1962; Thomson et al., 1976). CF antibodies 
are short-lived and do not last more than 3 months while VN antibodies can last 
longer than a year. The role of circulating antibodies in protection is still 
controversial. Some studies did not find a correlation between the level of VN 
antibody and the level of virus shedding in nasal secretions while some others 
reported that the presence of VN antibodies prior to infection reduces the amount and 
duration of virus shedding (Gleeson & Coggins, 1980; Hannant et al., 1993; Heldens 
et al., 2001). 
Still, the humoral response is generally not sufficient to efficiently protect against 
EHV-1 symptoms and cellular immunity mediated by CD8+ cytotoxic T lymphocytes 
(CTLs) is considered to be an essential defense mechanism against EHV-1 infection. 
CTLs have been shown to be important in controlling both primary and latent EHV-1 
infection (Allen et al., 1995; Smith et al., 1998b). The frequency of precursor CTLs 
specific for EHV-1 antigens was found to directly correlate with protection against 
disease (Kydd et al., 2003; O'Neill et al., 1999). EHV-1 specific CTLs remain 
detectable for more than a year after infection (Allen et al., 1995). CTL can recognize 
antigen that are presented by polymorphic MHC I receptors expressed on all 
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nucleated cells. It was demonstrated that the IE gene elicits CTL responses by 
encoding a protein that contains CTL epitopes and the CTL activity was found to be 
restricted to the ELA-A haplotype (Soboll et al., 2003). Although CTL activity was 
found to be efficient in controlling cell-associated viremia and in reducing severe 
symptoms, EHV-1 can still cause viremia in the presence of virus-specific antibodies 
and CTL-precursors in the host (Kydd et al., 2006a; O'Neill et al., 1999). This 
suggests that EHV-1 uses specific immune evasive strategies to persist in its host 
(See Chapter 1.8). 
 
 
5. Diagnosis  
  
Since EHV-1 is a highly contagious pathogen, rapid diagnosic tests for the detection 
of EHV-1 infections are critical to guide management strategies, especially during 
outbreaks of abortions and EHM. In virological laboratories, diagnosis of EHV-1 
infections is commonly based on virus culture and isolation followed by immuno-
identification of the isolated virus. Virus can be isolated from nasal and 
nasopharyngeal swabs collected during the early stages of the respiratory disease, 
from unclotted blood samples or from fetal tissues (liver, lung, thymus and spleen) 
collected from aborted fetuses. EHV-1 can be isolated on a variety of cell lines (such 
as rabbit kidney epithelial cells (RK-13), ED cells, equine embryonic lung cells 
(EEL)) and a positive EHV-1 isolation is characterized by the appearance of 
cytopathic effects (CPE) in inoculated cultures within 7 days. As EHV-1 and EHV-4 
infections can both cause CPE in equine cell cultures, positive identification of virus 
isolates is usually performed by immunofluorescence with type-specific monoclonal 
antibodies. Several rapid diagnostic techniques based on enzyme-linked 
immunosorbent assay (ELISA), polymerase chain reaction (PCR) or 
immunohistochemical staining with peroxidase are also available for detection of 
EHV-1 infection with their own advantages and limitations (Drummer et al., 1995; 
Varrasso et al., 2001; Whitwell et al., 1992). They can supplement traditional 
diagnostic methods but are often restricted to specialized reference laboratories. 
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Serological diagnosis of recent infection by EHV-1 is based on a 4-fold or greater 
increase in antibody titers in paired sera taken during acute illness and 2-3 weeks later 
during the convalescent stage of the disease (Kydd et al., 2006b). The ‘acute phase’ 
sera from mares after abortion or from horses with neurological disorders may 
already contain maximal titers of EHV-1 antibody with no increase in titers 
detectable in sera collected at convalescence. However, serological testing of paired 
serum samples from clinically unaffected horses in the herd may provide useful 
information for the retrospective diagnosis of EHV-1 within the herd. Serological 
tests include serum-neutralization test (SN), ELISA or complement-fixation (CF) 
tests but these tests do not distinguish between antibodies to EHV-1 and EHV-4. 
Thus, a type-specific ELISA has been developed which is based on differences in the 
C-terminal portion of the glycoprotein G of both viruses (Crabb et al., 1995). 
 
 
6. Treatment 
 
Currently, there is no efficacious antiviral treatment available for EHV-1 infections 
and treatment is mainly limited to supportive therapy. Studies assessing the efficacy 
of standard anti-herpesvirus drugs, including acyclovir or its derivative valacyclovir, 
which has improved oral bioavailability, did not show any reduction in clinical signs, 
viral shedding and viremia of EHV1-infected ponies, even after continuous 
administration at high doses (Garré et al., 2009). However, it has been reported that 
(1’S,2’R)-9-[[10,20-bis(hydroxymethyl) cycloprop-10-yl]methyl]guanine (A-5021), a 
guanosine analogue that possesses anti-herpetic activity against most human 
herpesviruses could inhibit EHV-1 replication both in vitro and ex vivo (Glorieux et 
al., 2012). No EHV-1 induced plaques were observed in the epithelium of infected 
nasal explants and no single infected mononuclear cells were detected below the BM. 
Thus, it was proposed that therapy with A5021 might reduce respiratory disease and 
protect against viremia. The efficacy of A5021 against EHV-1 infection still needs to 
be evaluated in the horse.  
An alternative therapeutic approach is the development of RNA interference (RNAi) 
mediated by small inhibitory RNA (siRNA). siRNA's have recently been intensively 
examined for their ability to prevent and/or treat viral infections. siRNA's bind to 
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complementary target mRNA and, upon interaction with the cellular RNA 
interference mechanisms, specifically target these sequences for degradation, 
resulting in inhibition of protein expression (Dykxhoorn & Lieberman, 2006).  
Interestingly, synthetic siRNAs against envelope gB and the origin-binding protein 
helicase were designed, and it was reported that RNA interference reduced plaque 
formation in cell cultures, clinical signs (weight loss) and viral replication within lung 
tissue and in a murine model of EHV-1 infection (Fulton et al., 2009). Thus, siRNA 
treatment of in contact or exposed horses could be applied during an outbreak of 
EHV-1 to reduce virus shedding within the herd and could be a promising 
complementation to vaccination. It is believed that treatment costs for siRNA would 
be similar to most protein-based therapies like antibodies.  
Although it has been reported that metaphylactic intranasal administration of siRNA 
targeted against critical EHV-1 genes did not reduce clinical disease, nasal shedding 
of virus and viremia in horses experimentally infected with EHV-1, euthanasia 
necessitated in case of neurological disease was significantly reduced after 
application of EHV-1 specific siRNA (Brosnahan et al., 2009). Still, some caution 
should be taken in the interpretations of these results and the experiments should be 
reproduced in which host factors are more intensively monitored and controlled in 
order to provide additional support for the effectiveness of RNA interference as a 
suitable therapy to combat EHV-1 infections. 
The medical treatment of horses with EHM mainly focuses on decreasing the 
inflammation associated with the induced vasculitis. The use of corticosteroids and 
anti-inflammatory drugs for a short duration has been recommended in EHM 
treatment, although no data are available that demonstrate their potential efficacy. 
 
 
7.  Control and prevention 
 
7.1. Management 
 
Control measures for managing herpesviruses in horses aim at: (1) preventing or 
reducing the likehood of an outbreak of abortion or neurological disease; (2) limiting 
the spread of EHV-1 within the horse population.  
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Recommended herd management practices for prevention of abortion or neurological 
disorders in pregnant mares have been published as a ‘code of practice’ (Allen, 2002) 
(codes.hblb.org.uk; http://www.aaep.org/.), which is updated annually and described 
by the acronym SISS. The actions recommended are divided into 4 categories:  
(a) Segregation of the pregnant mare population from all other horses from the 
premises. 
(b) Isolation of new mares arriving on the farm for a period of no less than 3 
weeks (quarantine). 
(c) Subdivision of the pregnant mares into small foaling groups by stage of 
gestation. 
(d) Stress reduction by avoiding physical stress such as prolonged transportation 
of mares in late stage of pregnancy, weaning and social disruption. 
 
Recommended measures to limit the spread of EHV-1 following an outbreak of 
EHV-1 abortion or neurological disease are described by the acronym DISH and 
consist of: 
(a) Disinfection of the contaminated area of the aborted foetus and cleaning of the 
aborting mare. 
(b) Isolation of the aborting mare from other horses, particularly mares in late 
stage of pregnancy. 
(c) Submission of clinical samples for laboratory diagnosis. 
(d) Implementation of hygienic procedures to restrict the spread of infection. 
 
7.2. Vaccination 
 
Vaccination is one of the most cost-effective approaches to prevent EHV-1 related 
disease, in combination with management measures. Successful vaccination should 
aim to: (1) reduce viral replication in the URT, thus minimizing viral shedding and 
respiratory symptoms, (2) reduce/eliminate cell-associated viremia and limit the 
reactivation of the virus, thus preventing the development of secondary severe 
symptoms (abortion and/or neurological disease) (van der Meulen et al., 2007). 
Vaccination against EHV-1 infection requires both humoral and cellular immune 
responses. 
40  Chapter 1 
__________________________________________________________________________________ 
 
Over the last 50 years, extensive research has aimed at the development of efficient 
vaccines including inactivated vaccines, traditional modified live virus (MLV) 
vaccines, recombinant live vaccines, live-vectored vaccines and DNA vaccines 
(Minke et al., 2004). So far, none of the commercially available vaccines provide full 
protection against EHV-1 infection. While current vaccines can reduce viral shedding 
and the severity of respiratory symptoms upon challenge infection of vaccinated 
horses, they do not guarantee full protection against viremia and severe EHV-1 
symptoms (Burrows & Goodridge, 1984; Goodman et al., 2006; Heldens et al., 
2001). Here, we will briefly review the potential and limitations of the current 
commercially available vaccines and experimental vaccines in the prevention of 
EHV-1 infection. 
 
Current vaccines 
Inactivated EHV-1 vaccines have been the main type of vaccine commercially 
available in Europe and in the United States. Inactivated vaccines either contain 
inactivated whole virus or viral envelope glycoproteins, in combination with an 
adjuvant. Subunit and inactivated vaccines are characterized by their absence of 
pathogenicity and virus replication. Inactivated vaccines can stimulate high titres of 
serum neutralizing antibody, which can reduce the amount and duration of virus 
shedding and can also prime the mucosal compartment (Breathnach et al., 2001). 
However, these vaccines fail to stimulate CTL responses, which have been associated 
with protection against EHV-1 infection (Kydd et al., 2003). 
In the 80-90s, studies examined the efficacy of Pneumabort-K vaccine, a whole virus 
inactivated and oil-adjuvanted vaccine containing EHV-1, administrated to pregnant 
mares, yearlings and two-year old ponies (Burrows & Goodridge, 1984) (Burki et al., 
1990). None of these studies demonstrated a significant reduction in clinical signs, 
viremia and EHV-1-induced abortions between vaccinated and control mares. 
However, a study from Goehring et al. (2010) demonstrated a significant reduction in 
the number of days of viremia upon EHV-1 challenge of vaccinated ponies. 
Several vaccination/challenge studies have also been performed in pregnant mares 
and naïve foals with Duvaxyn 1,4, a whole inactivated virus and carbomer-
adjuvanted vaccine containing EHV-1 and EHV-4 (Foote et al., 2002; Heldens et al., 
2001). Duvaxyn 1,4 was shown to induce both VN and CF antibody responses in 
foals and pregnant mares after 1 or 2 vaccinations. After experimental infection, 
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clinical signs and the duration of virus shedding were reduced in vaccinated pregnant 
mares and foals while the duration of cell-associated viremia was only reduced in 
vaccinated foals. In addition, the incidence of EHV-1 induced abortions was reduced 
in vaccinated mares. However, responses to inactivated EHV-1 vaccines are variable 
in the field. EHV-1 has been shown to circulate in vaccinated populations of mares 
and their unweaned foals in several countries (Foote et al., 2006a; Foote et al., 2004). 
Recently, Bresgen et al. (2012) demonstrated a reduction in the number of abortions 
in vaccinated mares. In Belgium, an EHV-1 inactivated vaccine is currently marketed 
as Equip 1,4 (Zoetis). 
Besides inactivated vaccines, live attenuated vaccines are also used to prevent EHV-
1-induced disease. These vaccines offer several advantages, namely the induction of a 
cell-mediated immune response (CTL response), relatively long duration of immunity 
and the induction of local mucosal immunity. However, the risk of reversion to 
virulent EHV1 strains remains a concern for this strategy of vaccination. Prevaccinol 
is a commercial live-attenuated vaccine in Europe (Merck MSD-Intervet, Munich, 
Germany) developed by attenuation of the RacH strain upon serial passages on swine 
embryonic kidney cells. This live virus was passaged further in rabbit kidney cells 
and then equine dermal cells and licensed as Rhinomune in the United States 
(Boehringer Vetmedica, Inc., St Joseph, MO). These live attenuated vaccines have a 
good safety record and can protect horses against clinical disease, but their efficacy in 
preventing viremia, abortion and neurological disease are unclear (Kydd et al., 
2006b). Protection against neurological disease under experimental conditions and 
abortions under field conditions has been reported by using these type of vaccines 
(Bresgen et al., 2012; Goodman et al., 2006). 
 
Experimental vaccines 
Novel vaccines, which are not commercially available yet, have been designed and 
tested to prevent EHV-1 infection. Similar to RacH, a vaccine based on the live-
attenuated Kentucky A (KyA) strain was obtained by serial passage on murine 
fibroblast cells. This vaccine could only reduce the duration of viremia in vaccinated 
horses upon challenge (Matsumura et al., 1996). A temperature sensitive live-
attenuated EHV-1 vaccine was also developed based on a German abortion isolate. 
Upon vaccination, virus shedding, cell-associated viremia and mild clinical signs 
were observed but the protection efficacy against subsequent challenge was not 
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consistent in different studies (Patel et al., 2003a; Patel et al., 2004; Patel et al., 
2003b). Vaccination with an EHV-1 modified live vaccine virus based on a recent 
non-neurovirulent strain, NY03, showed promising results in terms of reduction of 
clinical signs, nasal shedding and viremia levels in horses (Van de Walle et al., 
2010). By deleting virulence-associated genes, several EHV-1 mutants were 
constructed and tested for vaccine efficacy. A mutant lacking the thymidine kinase 
(TK) gene was unable to prevent viremia after EHV-1 challenge (Slater et al., 1993; 
Tewari et al., 1993). A live attenuated vaccine based on a gE-/gI- mutant was unable 
to reduce the amount and duration of viremia (Matsumura et al., 1998). Later, a 
vaccination trial with a gE- strain showed a reduction of respiratory symptoms, load 
of viral shedding and viremia in ponies upon challenge (Tsujimura et al., 2009). 
Novel inactivated vaccines based on the expression of EHV-1 specific glycoproteins 
presented by immune stimulating complexes (ISCOM) have also been designed. 
Mares and foals vaccinated with a subunit vaccine containing both gB and gD mixed 
with the ISCOM reduced virus shedding but not viremia after experimental infection 
(Foote et al., 2006b). A recombinant canarypox-based vaccine expressing EHV-1 gB, 
gC, and gD genes markedly reduced virus shedding after challenge but failed to 
protect against cell-associated viremia (Minke et al., 2006). A recombinant poxvirus 
vector encoding the IE protein, a known CTL target protein, could stimulate cell-
mediated immune responses but failed to protect against challenge infection (Paillot 
et al., 2006). DNA vaccination with plasmids coding for gB, gC, gD and IE were 
shown to induce a limited immune response and protection against EHV-1 challenge 
of vaccinated ponies (Soboll et al., 2006). 
Overall, none of the current and experimental vaccines can completely eliminate 
virus shedding and/or cell-associated viremia, and consequently, fully protect against 
EHV-1 induced abortion and neurological disease. Up till now, inactivated vaccines 
are the only vaccines that claim protection against EHV-1 induced abortions if 
administered during pregnancy at fifth, seventh and ninth months of gestation 
(Heldens et al., 2001). Foals should be vaccinated over 3-5 months of age, with a 
second immunization 4 to 6 weeks later and a third dose at 10-12 months. As 
immunity following vaccination is short-lived, it is recommended to re-vaccinate the 
animal at 6-month intervals. No vaccines that claim protection against EHV-1-
induced neurological diseases are available on the market. This is partially due to the 
lack of reliable experimental models that can induce neurological disorders in horses. 
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Moreover, some studies have reported vaccination as a potential risk factor for the 
development of EHM, supporting the theory of an immune-mediated pathogenesis for 
EHM (Henninger et al., 2007). Despite the controversy, it is important to be clear that 
general vaccination at herd level plays an important role in reducing viral shedding, 
limiting spread of EHV-1 infection and enhancing herd immunity (Pusterla & 
Hussey, 2014). The induction of protective immunity against EHV-1 infection still 
remains a challenge and is likely caused by immunomodulatory properties of the 
virus. Thus, future vaccine strategies may benefit from a better understanding of 
EHV-1 viral immune evasive strategies and should focus on stimulating both CTL 
responses and mucosal/plasma VN antibodies.  
 
8. Immune evasive strategies of EHV-1 
 
8.1.  Introduction 
 
One strategy mastered by all herpesviruses, is the capacity to establish life-long 
latency in immunocompetent hosts. Herpesvirus persistence is facilitated by 
dedicated viral immune evasion mechanisms that evolved during their long history of 
co-evolution with the host. This sub-chapter will give a brief overview on the recent 
knowledge of the specific immune evasive strategies used by EHV-1. 
 
8.2. Evasion from humoral immunity 
 
Following infection, viral glycoproteins are usually expressed at the plasma 
membrane of the infected cells. Virus-specific antibodies can recognize viral antigens 
on the cell surface and thus, the antibody-dependent immune system (complement-
mediated cell lysis and cell-mediated cytotoxicity) can clear the infected cells. 
However, EHV-1 is able to interfere with antibody-dependent lysis by hampering 
proper viral protein expression on the cell surface. 
Both in vitro and in vivo studies have shown that the majority of EHV-1-infected 
PBMCs do not express viral glycoproteins on their cell surface (van der Meulen et 
al., 2006; van der Meulen et al., 2003). Only IE and some E proteins were expressed 
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in the cell nuclei. Later, a study from Gryspeerdt et al. (2012) showed that the 
expression of late gC and gD protein was seriously hampered in EHV-1 infected 
leukocytes both in vitro and in vivo. These studies indicate that there is an early 
block(s) in the replication cycle of EHV-1 in target cells that may protect infected 
leukocytes from efficient recognition by the immune system and hence allow these 
carrier cells to reach target organs. This has been already described for other 
herpesviruses such as pseudorabies virus (PRV) and human cytomegalovirus 
(HCMV) (Nauwynck & Pensaert, 1994; Rice et al., 1984). Contact between PBMC 
and endothelial cells has been suggested to provide signals to trigger the late phase 
replication of EHV-1 in PBMC (van der Meulen et al., 2006). 
However, the minority of PBMC that expressed viral glycoproteins at their cell 
surface was still resistant to the antibodies and complement, indicating that EHV-1 
uses another strategy to evade complement pathway activation (van der Meulen et al., 
2003). Indeed, EHV-1 gC has been reported to bind C3, the pivotal component of the 
alternative complement cascade, with highest affinity to C3 of the natural host 
(Huemer et al., 1995). This alternative pathway can be activated in the absence of 
antibodies and is crucial during early infection when humoral immunity is not 
achieved. Binding of gC on EHV-1 virions with C3 results in inhibition of 
downstream events of the alternative complement pathway, thus protecting EHV-1 
from complement-mediated cell lysis. Similar findings were also described for gC of 
HSV-1, EHV-4, BoHV-1 and PrV (Azab et al., 2010; Huemer et al., 1992; Huemer et 
al., 1993). 
The expression of a viral Fc receptor, consisting of the viral gE/gI complex, has been 
widely studied for HSV-1 and PRV, as part of an immune evasion from antibody-
dependent immunity. Binding of gE/gI to the constant portion of IgGs (Fc) tethers the 
antibody in a position where it cannot trigger downstream immune functions (steric 
hindrance) and also participate in antibody bipolar bridging (ABB) such that the Fabs 
bind a viral antigen and the Fc binds gE-gI. This gE/gI complex of HSV-1, PRV, but 
not BoHV-1, has been shown to protect infected cells from complement-mediated 
cell lysis (Favoreel et al., 1997; Nagashunmugam et al., 1998; Whitbeck et al., 1996; 
Whitley & Gnann, 1993). So far, it is not clear whether the gE/gI complex of EHV-1 
interferes with Fc-mediated activities. 
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8.3. Evasion from CTL immunity 
 
Another aspect of immune evasion activity of herpesviruses is their ability to interfere 
with CTL-mediated cell lysis. This is clearly illustrated by the fact that EHV-1 can 
cause a viremia in the presence of virus-specific antibodies and CTL precursors 
(Kydd et al., 2006b; O'Neill et al., 1999). CTLs form an essential part of the immune 
defense against many virus infections. CTL-based immunity is dependent on the 
efficient recognition of viral peptides presented by MHC-I on the infected cell surface 
(Townsend & Bodmer, 1989). Upon infection, viral proteins are degraded in the 
cytoplasm by the proteasome and transported into the ER via the transporter 
associated with Ag processing (TAP). In the ER, the peptides are loaded to the MHC-
I α chain associated with β2-microglobulin (β2M) and form stable tri-molecular 
complex that are expressed on the cell surface (Androlewicz et al., 1993; Ortmann et 
al., 1994). This complex can be recognized by CTL, which will induce lysis of the 
infected cells (Williams et al., 2002). 
Like other alphaherpesviruses, EHV-1 has been reported to down-regulate MHC-I 
cell surface expression in equine cells (Ambagala et al., 2004; Rappocciolo et al., 
2003). EHV-1 has been shown to down-regulate MHC class I via two classes of 
genes, IE and E, which enhance endocytosis of MHC-I molecules (Rappocciolo et al., 
2013). In addition, Ambagala et al. (2004) demonstrated that an early EHV-1 protein 
was responsible for the down-regulation of MHC-I molecules by interfering with the 
peptide transport activity of TAP. This down-regulation directly resulted in a reduced 
availability of peptides in the ER and thus, in a reduced maturation and cell surface 
presentation of tri-molecular complexes (peptide/MHC-I/β2M). The EHV-1 
pUL49.5, pUL56 and pUL43 proteins have been shown to modulate cell surface 
MHC-I expression (Koppers-Lalic et al., 2005; Ma et al., 2012, Huang et al., 2015). 
EHV-1 pUL49.5 is a small type I transmembrane protein that interacts with gM and 
inhibits the formation of peptide-loaded MHC-I molecules by preventing ATP 
binding to TAP. pUL56, a type II transmembrane protein, cooperates with pUL43 to 
enhance the internalization of MHC-I through dynamin-dependent endocytosis 
(Huang et al., 2014, 2015). EHV-1 infection also resulted in down-regulation of 
MHC-I molecules in infected PBMC in vitro. However, after an in vivo infection, no 
difference in the level of MHC-I expression was observed between infected and 
control ponies (van der Meulen et al., 2003). The absolute percentage of MHC-I 
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positive PBMCs was determined rather than the amount of MHC-I per infected cell, 
which could explain this discrepancy. 
After an in vivo infection, EHV-1 was also shown to inhibit T cell responses 
(Hannant et al., 1991). The immunosuppressive activity was associated with the 
presence of soluble TGFβ1 in the serum of infected ponies (Charan et al., 1997). 
Another study showed that the immunosuppression of T cell function was associated 
with circulating PBMC and/or their products rather than circulating soluble factors 
such as antigen or immune complexes (Hannant et al., 1999). 
 
8.4. Evasion from NK cell activity 
 
Herpesviruses downregulate surface MHC class I molecules in order to avoid 
recognition by CTL. However, the loss of MHC class I molecules renders the cells 
susceptible to NK cells. The activation of NK cells is regulated through the 
integration of signals delivered by inhibitory and/or activating receptors, where 
particular MHC-I molecules represent important ligands for inhibitory NK cell 
receptors (Biassoni et al., 2001). EHV-1 may be able to evade detection by and 
activation of NK cells by lowering the concentration of some MHC-I molecules on 
infected cells and by affecting the expression of MHC-I molecules in an allele-
specific manner, as  has been suggested for PRV (Rappocciolo et al., 2003; Sparks-
Thissen & Enquist, 1999).  
 
8.5. Interference with cytokine and chemokine responses 
 
Viral infection stimulates the production of cytokines and chemokines that play a 
crucial role in the regulation of innate and adaptive immune response (Guidotti & 
Chisari, 2000). It is not surprising that herpesviruses, including EHV-1 divert the 
cytokine/chemokine responses for their own benefit (Alcami, 2003). EHV-1 gG has 
been identified as a chemokine binding protein (vCKBP), which binds to a broad 
range of chemokines, such as CXCL1 and IL-8, with high affinity and subsequently 
blocks their activity (Bryant et al., 2003). EHV-1 gG deleted mutant was shown to 
induce a more pronounced inflammatory response in horses compared to the wild-
type virus (von Einem et al., 2007). In addition, a study from Van de Walle et al., 
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(2008b) demonstrated that EHV-1 gG was able to inhibit migration of equine 
neutrophils in response to equine recombinant IL-8.  
Interestingly, no chemokine binding activity has been attributed to the gG protein of 
EHV-4 despite its 58% identity with the gG protein of EHV-1. It has been suggested 
that the immunomodulatory property of EHV-1 gG may contribute to its ability to 
cause systemic infection in contrast to EHV-4 (Bryant et al., 2003; Van de Walle et 
al., 2007). 
 
8.6. Cell-to-cell spread 
 
Enveloped viruses can spread via two distinct routes, either through the cell-free 
aqueous environment or by direct cell-cell contact. While transmission by cell-free 
virus can allow the spread across long distances within the infected host, viruses often 
rely on cell-to-cell spread to bypass several barriers (antibody-mediated immune 
responses, anti-viral restriction factors) present in the cell-free path for efficient 
spreading.  
The intraneuronal spread of HSV is an essential component in disease pathogenesis. 
For instance, HSV-1 can spread in both directions along neurons, and their capsids 
can undergo anterograde and retrograde transport along microtubules (Smith et al., 
2001). Bidirectional transport along neurons allows herpesvirus to reach ganglions to 
establish latency. Upon reactivation, viruses can travel back to the periphery at the 
primary site of infection. Glycoproteins gH and gL, along with gB and gD, are 
required for cell-to-cell spread of HSV-1 (Even et al., 2006). The complex gE/gI is 
required for efficient spread of HSV-1 in epithelial cells and neuronal tissues 
(Dingwell et al., 1994; Dingwell et al., 1995). In addition, gK has also been shown to 
play an essential role in cell-to-cell spread in corneal and trigeminal ganglia cells 
(David et al., 2008). 
Like other herpesviruses, EHV-1 can spread from cell-to-cell and this mode of 
transmission plays a crucial role in the pathogenesis of EHV-1 infections. Cell-to-cell 
contacts between PBMC and EC of the pregnant uterus and CNS are essential for the 
transfer of EHV-1 in the presence of neutralizing antibodies (Goehring et al., 2011; 
Smith et al., 2001). The glycoproteins gB, gD, gE/gI, gK and gM are mainly involved 
in this process (Table 1).  
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8.7. Conclusions 
 
EHV-1 has evolved multiple immune evasion strategies to persist in its host. This 
helps to explain the short-lived immunity after primary infection and the inefficacy of 
current vaccines to prevent EHV-1 infection. Thus, a better understanding of the 
interplay between EHV-1 and the host immune system is crucial for a rational design 
of vaccination strategies. 
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After primary replication in the epithelial cells of the upper respiratory tract, EHV-1 
disseminates through the body via a cell-associated viremia in PBMC to target organs 
such as the pregnant uterus or central nervous system. Secondary replication in the 
endothelial cells lining the blood vessels of those organs can cause vasculitis and 
ischemic thrombosis and may lead to severe clinical signs such as abortion and/or 
neurological disorders. Up till now, commercially available (inactivated and live-
attenuated) vaccines do not provide full protection against EHV-1 associated disease. 
These vaccines fail to completely prevent virus shedding and cell-associated viremia, 
and consequently fail to protect against severe EHV-1 signs. Indeed, EHV-1 can 
cause a viremia despite the presence of virus-neutralizing antibodies and CTL 
precursors. Like other herpesviruses, EHV-1 has developed multiple strategies to 
evade antibody- and cell-mediated immunity in order to survive and spread in its host. 
It is clear now that a detailed understanding of the complete pathogenesis of EHV-1 
and its immune evasive strategies are needed to design efficient and adequate 
vaccines as well as antiviral therapeutics. 
In vivo and ex vivo studies have identified CD172a+ monocytic cells as one of the 
main carrier cells of EHV-1 in the URT and blood. In addition, it was shown that the 
expression of particular late proteins in EHV-1-infected PBMC was hampered at early 
stages of infection. Based on these results, the general aim of this thesis was to 
investigate in detail in vitro how EHV-1 hijacks specific CD172a+ monocytic cells 
and modulates its replication in order to disseminate within the host. 
 
Therefore the specific aims of this thesis are presented below. 
 
Ø The first aim was to examine EHV-1 replication kinetics in equine CD172a+ 
monocytic cells from the nasal mucosa and blood, and compare these with 
replication kinetics in rabbit kidney epithelial cells (RK-13), a cell line known 
to be fully susceptible to EHV-1 infection (Chapter 3).  
 
Ø Because in Chapter 3 a restriction of EHV-1 replication in CD172a+ 
monocytic cells was observed, the second aim of this thesis was to investigate 
whether this restriction occurred at the level of binding and entry (Chapter 4). 
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Ø Third, to determine the mechanism(s) underlying the transmission of EHV-1 
from CD172a+ monocytic cells to endothelial cells (EC). We studied the 
ability of EHV-1 inoculated CD172a+ cells to adhere and subsequently 
transmit EHV-1 infection to equine venous EC in the presence of virus 
neutralizing antibodies (Chapter 5). 
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A. Replication of non-neurovirulent EHV-1 is delayed in 
CD172a+ monocytic cells and controlled by histone 
deacetylases 
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 Abstract 
 
Equine herpesvirus type 1 (EHV-1) replicates in the epithelial cells of the upper 
respiratory tract and disseminates through the body via a cell-associated viremia in 
monocytic cells, despite the presence of neutralizing antibodies. However, the 
mechanism by which EHV-1 hijacks immune cells and uses them as ‘Trojan horses’ 
in order to disseminate inside its host is still unclear. Here, we hypothesize that 
EHV-1 delays its replication in monocytic cells in order to avoid recognition by the 
immune system. We compared replication kinetics in vitro of EHV-1 in RK-13, a 
cell line fully susceptible to EHV-1 infection, and primary horse cells from the 
myeloid lineage (CD172a+). We found that EHV-1 replication was restricted to 4% 
of CD172a+ compared to 100% in RK-13. In susceptible CD172a+, the expression of 
immediate-early (IEP) and early (EICP22) proteins was delayed in the cell nuclei by 
2-3 hpi compared to RK-13, and the formation of replicative compartments by 15 
hpi. The viral production in CD172a+ was significantly lower (from 101.7 to 3.1 
TCID50/105 inoculated cells) than in RK-13 (from 105 to 5.7 TCID50/105 inoculated 
cells). Less than 0.02% of inoculated CD172a+ produced and transmitted infectious 
virus to neighbour cells. Pre-treatment of CD172a+ with inhibitors of HDAC activity 
increased and accelerated viral protein expression at very early time of infection and 
induced productive infection in CD172a+. Our results demonstrated that the 
restriction and delay of EHV-1 replication in CD172a+ is part of an immune evasive 
strategy and involves silencing of EHV-1 gene expression associated with histone 
deacetylases. 
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Introduction 
 
Viruses are defined as obligatory intracellular parasites. They replicate inside the 
host cell using the host metabolic machinery. Following a primary infection, viruses 
can elicit a strong immune response. The host’s immune system employs a variety of 
strategies to eliminate the virus (Vossen et al., 2002). However, during co-evolution 
with their host, viruses have developed an impressive array of immune evasion 
mechanisms to escape their elimination by the host’s immune system (Alcami & 
Koszinowski, 2000; Favoreel et al., 2003). One strategy mastered by all 
herpesviruses, is the capacity to establish life-long latency in immunocompetent 
hosts. During periods of reactivation, the virus may spread to contact individuals. 
During latency, the virus remains hidden from the immune system and can persist in 
its host (Efstathiou & Preston, 2005). 
Equine herpesvirus type 1 (EHV-1), a member of the Alphaherpesvirinae, is a major 
pathogen of horses worldwide. The virus is responsible for respiratory disorders, 
abortion, neonatal foal death and neurological disorders (Allen & Bryans, 1986; Patel 
& Heldens, 2005; Dunowska, 2014). After a primary replication in the epithelial cells 
of the upper respiratory tract, the virus can spread through the basement membrane to 
the connective tissues by the use of individual infected migrating monocytic cells 
(Vandekerckhove et al., 2010; Gryspeerdt et al., 2010). The virus disseminates via a 
cell-associated viremia in peripheral blood mononuclear cells (PBMC) to target 
organs such as the pregnant uterus or central nervous system. There, the virus 
initiates a secondary replication that may lead in some cases to severe symptoms 
such as abortion and/or neurological disorders (Edington et al., 1991; Smith et al., 
1996 Stierstorfer et al., 2002). Current vaccines do not provide full protection as 
EHV-1 can cause a viremia in the presence of virus-specific antibodies and CTL 
precursors (Kydd et al., 2006; O’Neill et al., 1999). This shows that recognition of 
EHV-1-infected carrier cells by the immune system is seriously hampered. Indeed, 
like other herpesviruses, EHV-1 appears to have developed sophisticated immune 
evasive strategies to counteract the immune response and to facilitate spread in an 
immune horse (van der Meulen et al., 2006). 
Previous in vivo and ex vivo studies of the pathogenesis of EHV-1 in the equine 
upper respiratory tract identified CD172a+ monocytic cells as one of the main carrier 
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cells of EHV-1. It was found that the expression of some late proteins in EHV-1-
infected carrier monocytic cells is hampered at early stages of infection (Gryspeerdt 
et al., 2012; van der Meulen et al., 2000). These results suggest that infected 
leukocytes in the upper respiratory tract with restricted late viral protein expression 
could be the source of the cell-associated viremia. An early block in the replication 
cycle of EHV-1 may protect infected leukocytes from efficient recognition by the 
immune system and hence allow these carrier cells to reach target organs. 
Interestingly, retroviruses, such as human immunodeficiency virus (HIV), Maedi-
Visna virus (MVV) and other herpesviruses such as pseudorabies virus (PRV), 
human cytomegalovirus (HCMV), are known to influence early response systems by 
blocking several steps of their replication cycle in their target cells in order to evade 
immune responses and promote viral pathogenesis (Bergamaschi & Pancino, 2010; 
Thormar, 2005; Nauwynck & Pensaert, 1994; Rice et al., 1984). However, until now, 
the mechanism of how EHV-1 uses CD172a+ cells as “Trojan horses” to evade the 
immune system and disseminate within the host has not been described. 
In order to understand the immune evasive strategies used by EHV-1, in vitro EHV-1 
replication kinetics in equine nasal mucosal and blood CD172a+ monocytic cells, two 
major target cells, were examined and compared with replication kinetics in rabbit 
kidney epithelial cells (RK-13), a cell line known to be fully susceptible to EHV-1 
infection.  
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Material and methods 
 
Virus  
 
The Belgian EHV-1 non-neurovirulent strain 97P70 first isolated in 1997 from the 
lungs of an aborted fetus was used in this study (van der Meulen et al., 2000). Virus 
stocks used for inoculation were at the 6th passage; 5 passages in equine embryonic 
lung cells (EEL) and 1 subsequent passage in RK-13. 
 
Cells 
 
A. Isolation of equine blood CD172a+ cells 
Healthy horses, between 8 to 10 years old were used as blood donors. Horses were 
seropositive for EHV-1. The collection of blood was approved by the ethical 
committee of Ghent University (EC2013/17). Blood was collected by jugular 
venipuncture on heparin (15U ml-1) (Leo) and diluted in an equal volume of 
Dulbecco's phosphate-buffered saline (DPBS) without calcium and magnesium 
(Gibco). PBMC were isolated by density centrifugation on Ficoll-Paque (d=1.077g 
ml-1) (GE Healthcare, Life Sciences) at 800xg for 30 min at 18°C. The interphase 
cells, containing the PBMC, were collected and washed three times with DPBS. Cells 
were resuspended in leukocyte medium based on Roswell Park Memorial Institute 
(RPMI, Gibco) supplemented with 5% fetal calf serum (FCS) (Grainer), 1% 
penicillin, 1% streptomycin, 0.5% gentamycin (Gibco). Afterwards, cells were seeded 
on 24-well plates (Nunc A/S) at a concentration of 106 cells per ml and cultivated at 
37°C with 5 % CO2. After 12 h, non-adhering lymphocytes were removed by washing 
cells three times with RPMI. The adherent cells consisted of > 90% of monocytic 
cells, as assessed by flow cytometry after indirect immunofluorescence staining with a 
mouse monoclonal (mAb) anti-CD172a (VMRD, clone DH59B, 1:100, IgG1) 
directed against cells from myeloid lineage, followed by goat anti-mouse IgG FITC 
(Molecular probes, 1:100). 
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B. Isolation of equine nasal mucosal CD172a+ cells 
Tissues of the deep intranasal part of the septum were collected from horses, between 
4 to 7 years old at the slaughterhouse and transported to the lab as described 
previously (Vandekerckhove et al., 2011).  The isolation of equine nasal mucosal 
CD172a+ cells was adapted from the protocol described by Bannazadeh Baghi et al. 
(2014). Mucosal explants were cut into small pieces of 0.5 cm2 and incubated in 
medium based on DPBS, 5% FCS, 1% penicillin, 1% streptomycin, 0.5% gentamycin 
and supplemented with 1 mM EDTA (VWR), at 150 rpm for 30 min at 37°C on a 
shaker. Tissues were washed twice in RPMI to inactivate EDTA and incubated in 
digestion medium based on DPBS, 5% FCS, 1% penicillin, 1% streptomycin, 0.5% 
gentamycin, supplemented with 1µg ml-1 DNAse type I (Stem cell Technologies) and 
1mg ml-1 collagenase type IV (Life Technologies) at 150 rpm for 2 h at 37°C on a 
shaker. The cell suspension was passed through a 100 µm cell strainer to remove 
undigested tissues and centrifuged at 400xg, 10 min at 4°C. Cells were resuspended in 
DPBS and layered onto Ficoll-Paque (d=1.077g ml-1) as described above. 
The CD172a+ cell fraction was sorted from the total mucosal leukocyte population 
using magnetic-activated cell sorting (MACS) approach. Briefly, the isolated mucosal 
leukocyte population was first incubated with a mAb anti-CD172a for 20 min at 4°C, 
followed by a goat anti-mouse IgG antibody-coated magnetic beads MicroBead Kit 
(Miltenyi Biotec, Ltd). After 20 min incubation at 4°C, cells were washed with 1ml of 
PBS buffer and centrifuged at 300×g, 10 min at 4°C. The cell pellet was resuspended 
in 1ml ice-cold elution buffer (DPBS supplemented with 1mM EDTA and 2% FCS) 
and the cell suspension was brought onto a LS column. The unlabeled CD172a- cells 
pass through the column, whereas the CD172a + cells remain in the column due to the 
magnetic field. After three washings with 1 ml of PBS buffer, the column was 
removed from the magnetic field and the CD172a+ cell fraction was eluted. The purity 
of the CD172a+ cell fraction was >95%, as assessed by flow cytometry, as described 
previously. 
 
C. Rabbit kidney epithelial (RK-13) cells 
RK-13 cells were used as a control for the blood and nasal CD172a+ cells in this study 
and were maintained in Modified Eagle's medium (MEM) supplemented with 
antibiotics and 5% FCS. 
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D. Cell viability 
Cell viability was determined by flow cytometry, using 1µg ml-1 propidium iodide 
(Sigma-Aldrich), prior to virus inoculation and was > 90% in all cell populations. 
 
EHV-1 inoculation  
 
Cell populations were inoculated in vitro with EHV-1 strain 97P70 at a MOI of 5 in 
200µl leukocyte medium for 1 h at 37°C with 5% CO2. Cells were gently washed 
twice with RPMI to remove the inoculum and further incubated with fresh medium. 
Mock infections were carried out in parallel.  At 1, 3, 5, 7, 9, 12 and 24 hours post-
inoculation (hpi), cells were collected for quantification of EHV-1 infected cells, viral 
production and production of infectious EHV-1 by immunofluorescence staining and 
virus titration, respectively. 
Where indicated, 400µM of phosphonoacetate (PAA), an inhibitor of viral DNA 
polymerase, was added at the time of inoculation and maintained in medium 
throughout the course of infection. Histone deacetylase inhibition was achieved by 
pre-treating cells with 100 nM trischostatin A (TSA) or 0.5 mM of sodium butyrate 
(NaBut) for 2 h at 37°C prior to EHV-1 inoculation. HDAC inhibitors were 
maintained throughout the course of infection. All inhibitors were purchased from 
Sigma-Aldrich. The concentration of inhibitors used in this study did not decrease the 
cell viability (> 95%) determined by flow cytometry, as described above. 
 
Virus titration 
 
To quantify EHV-1 replication, both intracellular and extracellular virus titers were 
determined at different hpi. The supernatant containing the extracellular virus was 
collected, centrifuged at 400xg for 10 min at 4°C and stored at -70°C until titration. 
Cell extracts were harvested by centrifugation at 400xg for 10 min at 4°C, followed 
by three cycles of freezing and thawing to lyse the cells. For the inactivation curve, 
EHV-1 was incubated for different times at 37°C. Virus titers were conducted on RK-
13 cells, incubated at 37°C for 7 days. The virus titer was calculated as 50% tissue 
culture infective dose (TCID50) according to the Reed and Muench formula (1938).  
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Cocultivation assay 
 
A cocultivation assay was used to detect and quantify EHV-1 producing CD172a+ 
cells by co-cultivation of these EHV-1-inoculated CD172a+ cells with a permissive 
equine cell culture (RK-13), where a semi-solid overlay technique was applied. 
Briefly, EHV-1-inoculated and mock-inoculated cells were harvested at 12 hpi. 105 
cells per ml were tenfold diluted in leukocyte medium and 0.5 ml of each dilution was 
added on RK-13 monolayers in a 6-well plate and overlaid with a 0.94% 
carboxymethylcellulose medium (Sigma-Aldrich) prepared in RPMI-2X and 
centrifuged at 800xg for 30 min at 18°C, as described previously by Van der Meulen 
et al. (2000). Cells were further incubated for 5 days at 37°C, 5% CO2. The cell 
monolayers were stained with 5% crystal violet and the number of plaques was 
counted. The percentage of infected cells producing infectious EHV-1 was calculated 
based on the number of plaques counted and the number of cells seeded per ml 
according to the volume plated. This experiment was performed three times. 
 
Indirect immunofluorescence staining of EHV-1 proteins 
 
To determine which kinetic classes of proteins were expressed in EHV-1-infected 
cells, a double immunofluorescence staining was performed on cells fixed in 100% 
methanol at -20°C for 20 min. Cells were incubated for 1 h at 37°C with a rabbit 
polyclonal Ab anti-IEP (1:1000) (Smith et al., 1994; Jang et al., 2001) to detect 
immediate early protein (IEP) expression and either a mouse monoclonal anti-EICP22 
(K2 to IR4) (1:500), anti-gB (4B6) (1:100) or anti-gC (1B6) (1:100) antibodies 
against early (EICP22), late gB and gC proteins expression, respectively. The IEP and 
EICP22 antibodies were kindly provided by Dr. O’Callaghan (USA). The 4B6 and 
1B6 were provided by Dr. N. Osterrieder (Germany) and Dr. H. Huemer (Austria), 
respectively. Subsequently, samples were incubated for 50 min at 37°C with goat 
anti-rabbit IgG FITC (1:100) or goat anti-mouse IgG Texas-Red® (1:100) antibodies 
(Molecular probes). All antibodies were diluted in DPBS. The nuclei were 
counterstained with Hoechst 33342 (10 µg ml-1; Molecular Probes) for 10 min at 
37°C. As negative control, mock-inoculated cells were stained following the 
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aforementioned protocols. In addition, appropriate isotype-matched controls were 
included. The percentage of viral antigen positive cells was calculated based on three 
hundred cells counted in distinct fields. Samples were analyzed by confocal 
microscopy (Leica TCS SP2 Laser scanning spectral confocal system, Leica 
microsystems GmbH, Germany). All individual images were representative of the cell 
population infected. 
 
Statistical analysis 
 
Data were analyzed with GraphPad Prism 5 software (GraphPad software Inc., San 
Diego, CA, USA). Analyzed data for statistical significance were subjected to a two-
way analysis of variance (ANOVA). All results shown represent means and standard 
deviation (SD) of three independent experiments. Results with p-value ≤ 0.05 were 
considered statistically significant. 
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Results 
 
1. EHV-1 replication is delayed in CD172a+ cells compared to RK-13 cells 
 
In a first experiment, equine nasal mucosal and blood CD172a+ cells were examined 
for their ability to support EHV-1 replication compared to RK-13 cells. To this end, 
the expression kinetics of the three major classes proteins: immediate-early (IEP), one 
early (EICP22) and two late (gB and gC) proteins were evaluated by indirect 
immunofluorescence staining.  
In EHV-1-inoculated RK-13 cells, IEP was detected in the nuclei of 3% of the cells as 
early as 3 hpi, the EICP22 protein in the nuclei of 5% of the cells as early as 7 hpi and 
the late gB and gC glycoproteins in the cytoplasm of 2% of the cells starting from 7 
and 9 hpi, respectively (Fig. 1a). The number of RK-13 cells positive for all viral 
proteins increased over time. At 12 hpi, 64% of the cells were found IEP-positive, 
37% EICP22-positive, 32 and 10% gB- and gC-positive. At 24 hpi, 100% of the cells 
were positive for all viral proteins.  
In EHV-1 inoculated equine nasal mucosal and blood CD172a+ cells, IEP was first 
detected at 5 hpi. The number of IEP-positive cells was significantly higher in blood 
CD172a+ cells than in nasal mucosal CD172a+ cells at 5 and 7 hpi (p-value < 0.01) 
(Fig. 1b and 1c). From 5 hpi to 7 hpi, the percentage of IEP-positive cells increased 
from 0.3 to 0.9% and 2.8 to 3.6% in nasal mucosal and blood CD172a+ cells, 
respectively. A maximum of 3.6 and 3.8% of IEP-positive cells was reached at 7 and 
12 hpi in blood and nasal mucosal CD172a+ cells. The EICP22 protein was first 
detected at 7 hpi in 0.2% of blood CD172a+ cells and at 9 hpi in 0.6% of equine nasal 
mucosal CD172a+ cells. Similarly to IEP expression, the percentage of EHV-1-
inoculated CD172a+ cells expressing EICP22 did not increase after 12 hpi. At 24 hpi, 
the EICP22 protein was expressed in 2 and 1.3% of blood and nasal mucosal 
CD172a+ cells, respectively. The late gB protein was only detected in 0.3 % of blood 
CD172a+ cells at 12 hpi and in 0.6 and 1.3% of blood and nasal mucosal CD172a+ 
cells at 24 hpi. The late gC protein was only found expressed in 0.3% of nasal 
mucosal CD172a+ cells at 24 hpi. The use of a higher MOI (50) did not alter the 
number of IEP-positive cells (Fig. 2). Besides, EHV-1 replication was highly 
restricted in CD172a+ cells, independently of the abortigenic strains used (Fig. 3). 
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Overall, these results demonstrate that the replication of EHV-1 in equine nasal 
mucosal and blood CD172a+ cells is delayed based on the kinetics of viral protein 
appearance in these cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Expression kinetics of EHV-1 proteins in (a) RK-13 cells, (b) nasal mucosal and (c) blood 
CD172a+ cells. Immunofluorescence stainings of immediate-early (IEP), early (EICP22) and late (gB 
and gC) proteins were performed in triplicate and data are represented as means ± SD.  
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Figure 2: Expression kinetics of IEP in blood CD172a+ cells inoculated with EHV-1 at a MOI of 5 or 
50. Experiment was performed in triplicate and data are represented as means ± SD. No statistical 
differences were observed between the two groups by a two-way ANOVA test.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Expression kinetics of EHV-1 proteins in blood CD172a+ cells inoculated with EHV-1 
abortigenic 94P247 and 96P100 strains. Immunofluorescence staining of IEP, EICP22 and gC 
proteins were performed in triplicate and data are represented as means ± SD. 
 
 
 
 
 
 
 
 
 
 
7 9 12
0
2
4
6
8
10
 MOI 5
MOI 50
hpi
%
 o
f  
IE
P-
po
sit
iv
e c
ell
s
94P247 
1 3 5 7 9 12 24
0
1
2
3
4
5
hpi
%
 o
f E
H
V
-1
-in
oc
ul
ate
d 
ce
lls
 ex
pr
es
sin
g 96P100 
1 3 5 7 9 12 24
0
1
2
3
4
5
IEP 
EICP22
gC
hpi
%
 o
f E
H
V
-1
-in
oc
ul
ate
d 
ce
lls
 ex
pr
es
sin
g 
80  Chapter 3 
____________________________________________________________________ 
 
2. Spatio-temporal distribution of EHV-1 viral proteins in CD172a+ compared to 
RK-13 cells  
 
To determine whether the delay of EHV-1 replication in CD172a+ cells was correlated 
to a change in the distribution of EHV-1 viral proteins within the cell, we analyzed the 
spatio-temporal distribution dynamics of IEP, EICP22, gB and gC in EHV-1-
inoculated CD172a+ and RK-13 cells by immunofluorescence staining. The co-
localization of IEP and EICP22 was also examined by means of immunofluorescence 
double staining. 
In EHV-1-inoculated RK-13 cells, a weak and diffuse IEP signal was first detected at 
1 hpi with a few foci of intranuclear staining, with intensity increasing by 3 and 5 hpi 
(Fig. 4). At 7 hpi, IEP colocalized in one or two small globular structures while IEP 
was also found specklingly distributed in the rest of the cell nuclei (see arrows). The 
localization of IEP in globular structures coincided with the appearance of EICP22 in 
the nuclei of cells. Both IEP and EICP22 colocalized in nuclear globular structures 
resembling to pre-replicative sites at 7 hpi. However, the IEP showed a change in 
nuclear distribution as infection progressed. The IEP signal progressively dispersed in 
the cytoplasm and the size of the nuclear globular compartments increased and varied 
from 0-2 to 2-5 µm between 7 and 9 hpi. At 12 hpi, IEP signal was found associated 
in massive globular compartments (5-8 µm), resembling to replicative compartments, 
which occupy most of the nucleus space, while IEP was found dispersed in the 
cytoplasm of infected RK-13 cells. EICP22 did not colocalize with IEP in the nucleus 
of cells but rather formed a shell around IEP-associated compartments. The IEP 
expression progressed from individual IEP foci to large compartments each consisting 
of several IEP foci. To confirm whether the formation of large IEP-associated 
compartments in the nuclei of EHV-1-inoculated RK-13 cells was dependent on viral 
DNA replication; we compared the nuclear distribution of IEP in EHV-1-inoculated 
cells in the presence or absence of phosphonoacetate (PAA), a specific inhibitor of the 
viral DNA polymerase. As expected, in PAA-treated cells, only small-punctuated 
IEP-associated nuclear structures were observed at later stage of infection while no 
large IEP-associated compartments were detected (data not shown). These results 
confirmed that IEP associates within distinct structures, called pre-replicative sites (7 
hpi) that mature into replicative compartments (9 and 12 hpi) as infection progressed 
and which constitute sites for viral DNA synthesis. Finally, we examined the 
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expression pattern of late gB and gC in EHV-1-inoculated RK-13 cells. They were 
found exclusively expressed in the cytoplasm, in restricted areas and their expression 
intensified as infection progressed (data not shown). At 24 hpi, EHV-1-infected RK-
13 cells were completely destroyed as confirmed by the presence of CPE, which did 
not allow any further examination of viral protein expression pattern.   
In both EHV-1-inoculated nasal mucosal and blood CD172a+ cells, a weak IEP signal 
was first detected in some parts of the nucleus which intensity increased from 5 to 7 
hpi (Fig. 5 and 6). At 9 hpi, IEP signal was diffuse throughout the nucleus and 
cytoplasm of blood CD172a+ cells while in nasal mucosal CD172a+ cells, IEP signal 
was still found exclusively restricted in some nuclear areas. However, in both cases, 
this correlated with the appearance of EICP22, which colocalized with IEP in the 
nucleus of both CD172a+ cell types. At 12 hpi, a strong IEP staining was observed in 
the nucleus and at a lesser extent in the cytoplasm of both cell types while no IEP-
associated replicative compartments were detected. The EICP22 was found similarly 
expressed as at 9 hpi. Interestingly, the expression of IEP within replicative 
compartments and surrounded by EICP22 were only detected at 24 hpi in the nucleus 
of both CD172a+ cell types (see arrows). Finally, the cytoplasmic localization of gB 
and gC late proteins remained unchanged in nasal mucosal and blood CD172a+ cells 
compared to RK-13 cells (data not shown). These results showed that the delay of 
EHV-1 replication in CD172a+ cells compared to RK-13 cells is correlated to a 
change in the spatio-temporal distribution dynamics of EHV-1 viral proteins within 
the cell. 
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Figure 4: Double immunofluorescence of EHV-1 IEP (green) and EICP22 (red) proteins in RK-13 
cells. Nuclei are counterstained with Hoechst (blue). Each image represents a single section through a 
cell. Arrows indicate the formation of IEP-associated replicative compartments. Scale bar = 10 µm.
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Figure 5: Double immunofluorescence of EHV-1 IEP (green) and EICP22 (red) proteins in nasal 33 
mucosal CD172a+ cells. Nuclei are counterstained with Hoechst (blue). Each image represents a 34 
single section through a cell. Arrows indicate the formation of IEP-associated replicative 35 
compartments. Scale bar = 10 µm. 36 
IEP Nucleus EICP22 Merge 
3 
Hpi 
5 
7 
9 
12 
24 
! 23 
 cleus I P22 rge h
!! 
 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
     543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 !! 563 
B 
5 
7 
9 
12 
24 
84  Chapter 3 
____________________________________________________________________ 
 
 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Double immunofluorescence of EHV-1 IEP (green) and EICP22 (red) proteins in blood 
CD172a+ cells. Nuclei are counterstained with Hoechst (blue). Each image represents a single section 
through a cell. Arrows indicate the formation of IEP-associated replicative compartments. Scale bar = 
10 µm.  
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3. Kinetics of EHV-1 production in CD172a+ cells compared to RK-13 cells  
 
To determine the kinetics of viral production in blood and nasal mucosal CD172a+ 
cells compared to infected RK-13 cells, virus titrations of supernatants (extracellular 
fraction) and cells (intracellular fraction) were performed. 
No significant increase in intracellular and extracellular virus titers was observed in 
all cell types before 9 and 12 hpi, respectively. At 12 hpi, virus titration of the 
intracellular fraction showed a 10-fold lower virus titer in blood and nasal mucosal 
CD172a+ compared to RK-13 cells (p-value < 0.01) but no significant difference in 
extracellular virus titer was observed between infected CD172a+ and RK-13 cells 
(Fig. 7).  At 24 hpi, virus titration of the extracellular fraction revealed a 100-fold and 
1000-fold lower virus titer in blood (103.1 TCID50/105 inoculated cells) (p-value < 
0.01) and nasal CD172a+ cells (102.4 TCID50/105 inoculated cells) (p-value < 0.001) 
compared to RK-13 (105.7 TCID50/105 inoculated cells). In addition, virus titration of 
the intracellular fraction showed a 1000-fold and 10000-fold lower titer in blood (102 
TCID50/105 inoculated cells) and nasal CD172a+ cells (101.7 TCID50/105 inoculated 
cells) than in RK-13 (105 TCID50/105 inoculated cells). No increase in extracellular 
and intracellular virus titers was observed in nasal mucosal CD172a+ cells over time 
post-inoculation. The virus remained infectious throughout the experiment as 
confirmed by the inactivation curve. 
Next, we evaluated and compared the percentage of cells that produced and 
transmitted infectious EHV-1 to neighbor cells, between infected CD172a+ and RK-
13 cells. Co-cultivation of inoculated CD172a+ with RK-13 cell monolayers revealed 
that less than 0.01% and 0.02% of nasal mucosal and blood CD172a+ cells 
respectively, were productive. The number of EHV-1-producing CD172a+ cells was 
significantly less than the number of EHV-1-producing RK-13 cells (31%) (p-value < 
0.0001). 
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Figure 7: Kinetics of EHV-1 virus production in nasal mucosal and blood CD172a+ cells compared to 
RK-13 cells. Error bars show ± SD and a two-way ANOVA test was performed to evaluate significant 
differences between RK-13 and both CD172a+ cell types. ** denotes a p-value < 0.01 between RK-13 
and blood CD172a+ cells and *** a p- value <0.001 between RK-13 and both CD172a+ cell types. 
 
 
4. HDAC inhibitors relieve the delay of EHV-1 proteins expression in CD172a+ 
cells at very early time of infection  
 
Next, we determined whether histone deacetylases (HDACs) were involved in the 
temporary block of EHV-1 protein expression in CD172a+ cells at early time of 
infection. We tested whether treatment of EHV-1-inoculated CD172a+ cells with the 
deacetylase inhibitors trichostatin (TSA) or sodium butyrate (NaBut) increased IEP, 
EICP22 and gB protein expression in these cells at early time of infection. These 
experiments were performed using blood CD172a+ cells only as the kinetics of EHV-1 
replication was found similar in both nasal and blood CD172a+ cells. 
We found that the number of IEP-, EICP22- and gB-positive blood CD172a+ cells was 
significantly higher in NaBut- and TSA-treated CD172a+ cells compared to untreated 
cells from 7-9 to 24 hpi (p-value < 0.05) (Fig. 8). In NaBut-treated cells, IEP was 
detected in the nuclei of 0.6% of the cells as early as 1 hpi, EICP22 protein in the 
nuclei of 1.6% of the cells as early as 5 hpi and gB in the cytoplasm of 2.3% of the 
cells starting from 7 hpi. At 12 hpi, 12% of the cells were found IEP-positive, 9% 
EICP22-positive and 7.3% gB-positive. At 24 hpi, 14% of the cells were positive for 
all viral proteins. Similar results were observed in TSA-treated cells. The titration of 
supernatant of NaBut- and TSA- treated cells showed a significant rise in virus titer 
compared to non-treated cells at 12 and 24 hpi, respectively (p-value < 0.05) (Fig. 9). 
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This result confirmed productive EHV-1 infection in these cells. TSA and NaBut cell 
treatment did not affect the kinetics of EHV-1 protein expression in EHV-1-
inoculated RK-13 cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Replication kinetics of EHV-1 in blood CD172a+ cells following treatment with HDAC 
inhibitors, trichostatin A (TSA) and sodium butyrate (Nabut). Experiments were performed in 
triplicate.  Error bars show ± SD and a two-way ANOVA test was performed to evaluate significant 
differences between HDAC inhibitor-treated and untreated cells, * denotes a p-value  <  0.05. 
 
  
 
 
 
 
 
 
 
Figure 9: EHV-1 extracellular virus titer in NaBut- and TSA-treated blood CD172a+ cells compared to 
untreated cells at 1, 12 and 24 hpi. Experiment was performed in triplicate. Error bars show ± SD and 
a two-way ANOVA test was performed to evaluate significant differences between HDAC inhibitor-
treated and untreated cells, * denotes a P-value < 0.05. 
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EHV-1 proteins were expressed earlier in HDAC inhibitor-treated CD172a+ cells than 
in untreated cells and comparable to those found in non-treated and EHV-1-infected 
RK-13 cells. At 1 hpi, IEP signal was bright and homogenously distributed in the 
nucleus of NaBut-treated cells within few foci of intranuclear staining. At 7 hpi, 
EICP22 was found expressed in the cell nuclei around newly formed IEP-associated 
compartments (Fig. 10). At 12 hpi, cells harbored a massive nuclear IEP-associated 
replicative compartment and gB was found expressed in the cytoplasm and at the 
plasma membrane of the cell (Fig 11a). From 12 to 24 hpi, intercellular contacts were 
observed between CD172a+ cells, which resulted in the formation of ‘ring-shaped’ 
cell clusters, consisting of at least two to 20 cells. A single cell containing a nuclear 
IEP-associated replicative compartment initiated intercellular contacts with neighbor 
cells via membrane extensions that were found IEP- and gB- positive (Fig. 11b). 
Recruited neighbor cells progressively formed clusters that were characterized by a 
cytoplasmic IEP expression as well as a cell surface and polarized cytoplasmic gB 
expression while no IEP-associated replicative compartment was detected in these 
neighbor cell nuclei (Fig. 11c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Double immunofluorescence staining of EHV-1 IEP (green) and EICP22 (red) proteins in 
EHV-1-inoculated and Nabut-treated blood CD172a+ cells at 1 and 7 hpi. Nuclei are counterstained 
with Hoechst (blue). Each image represents a single section through a cell. Scale bar = 10 µm.
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Figure 11: Double immunofluorescence staining of IEP (green) and gB (red) proteins expressed in 17 
EHV-1-inoculated and Nabut-treated blood CD172a+ cells at 12 hpi. Nuclei are counterstained with 18 
Hoechst (blue). (a) Formation of IEP-associated replicative compartment in the nucleus and 19 
cytoplasmic expression of gB in CD172a+ treated cells (b) Intercellular contact between one infected 20 
cell and a non-infected cell (c) ‘Ring shaped’ CD172a+ cell clusters of EHV-1 infection. Scale bar = 21 
10 µm. 22 
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23 
Discussion 
 
In the present study, we demonstrated that approximately 4% of equine nasal mucosal 
and blood CD172a+ cells, two target cells of EHV-1 were susceptible to EHV-1 
infection in vitro. This is in agreement with van der Meulen et al. (2000), 
demonstrating that EHV-1 replication is highly restricted in equine PBMC. As little is 
known about the regulation of monocytic cell tropism and susceptibility to EHV-1, 
we hypothesize that a low efficiency of binding of EHV-1 to CD172a+ cells may be 
responsible for the restriction of EHV-1 replication in these cells, suggesting the 
presence of specific cell surface receptors with restricted expression patterns. 
Preliminary in vitro studies demonstrated significant differences in the binding 
efficiency of EHV-1 between CD172a+ and RK-13 cells, in terms of percentage of 
infected cells and number of virus particles bound per cell. The authors found that 
EHV-1 does not bind efficiently to CD172a+ cells compared to RK-13 cells and the 
low efficiency of EHV-1 binding to CD172a+ cells was not shown to be virus-dose 
dependent. This already indicates that a block at the virus entry level is partially 
responsible for the restricted viral replication in CD172a+ cells. 
Next to the restriction of EHV-1 replication in CD172a+ cells, we demonstrated 
significant differences in the kinetics of EHV-1 protein expression between 
susceptible CD172a+ cells and control RK-13 cells at very early time of infection. We 
found that IEP was detected later in the nuclei of blood and nasal CD172a+ (5 hpi) 
than in the nuclei of control RK-13 cells (3 hpi). Similarly, EICP22 and late (gB and 
gC) protein expression were delayed in both CD172a+ cell types. Moreover, we 
observed that EICP22 and late gB and gC proteins accumulate slower in blood 
CD172a+ cells than IEP, suggesting a delay associated with a consecutive block of 
viral protein expression in CD172a+ cells. Besides, a progression of stages could be 
defined for the nuclear association of IEP with EICP22 during EHV-1 infection, as 
shown for HSV-1 infection (Knipe et al., 1987; Taylor et al., 2003; Chang et al., 
2011). In EHV-1-inoculated RK-13 cells, IEP showed a diffuse nuclear distribution 
and co-localized with EICP22 at early time of infection while both proteins presented 
a distinct nuclear distribution at later time of infection. By the use of PAA, an 
inhibitor of viral DNA polymerase, we confirmed that IEP-associated nuclear 
structures, so called replication compartments (RCs) were essential for viral DNA 
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replication (Quinlan et al., 1984). Interestingly, we observed that IEP localized into 
RCs slower in CD172a+ (24 hpi) than in RK-13 cells (7 hpi). In addition, we found 
that the viral production and percentage of EHV-1 producing cells was significantly 
lower than in RK-13 cells. Taken together, we demonstrated that the replication of 
EHV-1 in CD172a+ cells was delayed at a very early time of infection, starting from 
the nuclear expression of IEP, which successively slowed down the replication 
machinery in these cells, thus leading to a non-productive infection. We believe that 
the restriction/delay of replication in CD172a+ cells is part of an immune evasive 
strategy employed by EHV-1. By slowing its replication down, EHV-1 allows a better 
survival of CD172a+ cells while the virus uses them as ‘Trojan horses’ to disseminate 
undetected throughout the body. However, we think that not all infected leukocytes 
will transfer the virus to endothelial cells, not every transfer will lead to effective 
spread to neighboring endothelial cells and not every successful infection of 
endothelial cells will cause infection of surrounding tissues. Indeed, studies 
demonstrated that EHV-1 viremia is detected in pregnant mares, which do not abort 
and only a minority of viremic horses (10%) develop neurological disorders during 
equine herpes myeloencephalopathy (EHM) outbreaks (Slater et al., 2007; Goehring 
et al., 2006). In addition, we are also convinced that the outcome of infections of 
leukocytes with neurovirulent and non-neurovirulent leukocytes are quite different 
based on preliminary in vitro experiments we performed demonstrating strikingly 
different outcomes in EHV-1 replication between the two strains in target CD172a+ 
cells. 
Further, we showed that the delay of EHV-1 protein expression in susceptible blood 
CD172a+ cells could be relieved following treatment with TSA and NaBut, two 
histone deacetylase (HDAC) inhibitors. HDACs are known to condense the chromatin 
structure by deacetylation of histones in order to repress cellular and/or viral 
transcription. According to this, our results suggest that HDACs play a role in the 
silencing of gene expression in EHV-1 target cells. This was confirmed by the 
expression of EICP22 (nucleus) and gB (cytoplasm) starting from 5 and 7 hpi in 
HDAC inhibitor-treated CD172a+ cells, accompanied by the rapid formation of 
nuclear IEP-associated RC (7-9 hpi) and resulting in a productive EHV-1 infection in 
these cells. These results were consistent with recent work demonstrating the 
importance of protein acetylation and control of IE gene expression via HDACs 
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during herpesvirus infections (Meier, 2001; Everett et al., 2009). In addition, we 
found that a higher number of CD172a+ cells (12-14%) were susceptible to EHV-1 
infection following treatment with HDAC inhibitors compared to untreated cells 
(4%). This suggests that the permissiveness for EHV-1 infection might be linked to 
repression of IE promoter, as described for HCMV infection (Murphy et al., 2002; 
Wright et al., 2005). Besides, we found that treatment of cells with TSA or sodium 
butyrate selectively increased EHV-1 replication in target CD172a+ cells but not in 
control epithelial cells (RK-13). It is possible that the effectiveness of HDAC 
inhibitors treatment is cell-dependent or that RK-13 cells possess a low level of 
HDAC, which directly correlates with their increased EHV-1 permissiveness (Cody et 
al., 2014). Further studies are still needed to determine which individual HDAC(s) 
might be the most critical for inhibition and which cellular and viral transcription 
factors are involved in the association of IE promoter with hypoacetylated histones 
and mediate silencing of EHV-1 genome within CD172a+ cells. Control of EHV-1 
infection by specific HDAC inhibitors is likely to be a key step in the pathogenesis of 
EHV-1 in vitro and in vivo. We hypothesize that in vivo, acute EHV-1 infection 
promotes activation of blood monocytes that subsequently migrate into different 
tissues (pregnant uterus and/or central nervous system) and differentiate into 
permissive macrophages, as described for HCMV infection (Smith et al., 2004). The 
changes in cellular differentiation from monocytes into macrophages may be directly 
correlated to the association of specific cellular chromatin remodeling factors around 
the IE promoter and could play a role in controlling EHV-1 infection. Thus, specific 
HDAC inhibitors may represent useful therapeutic tools, which could serve to 
reactivate EHV-1 latent virus and/or to clear virus from cellular reservoirs. To date, 
valproic acid (VPA), a carboxylate HDAC inhibitor, has been used to induce EBV 
lytic-phase gene expression and to sensitize EBV+ tumor cells to cytotoxicity in 
presence of the anti-herpesvirus drug ganciclovir, in the treatment of patients with 
EBV+ lymphomas (Feng & Kenney, 2006). Göttlicher et al., 2001 demonstrated that 
VPA relieves repression of transcription factors, which recruit histone deacetylases, 
and causes hyperacetylation of the N-terminal tails of histone H3 and H4 in vitro and 
in vivo.  
Finally, we observed the formation of clusters of CD172a+ cells composed of one cell 
containing a nuclear IEP-associated RC and surrounded by cells presenting 
cytoplasmic IEP and gB expression at a later stage of infection in HDAC-treated cells 
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(12-24 hpi). This result indicates that EHV-1 can efficiently spread by cell-to-cell 
contacts in productive infected CD172a+ cells and transfer cytoplasmic viral proteins 
to uninfected neighbor cells. This finding is partially in agreement with previous 
studies from Van der Meulen et al. (2000), which demonstrated the formation of 
intercellular contacts between EHV-1-inoculated PBMC within clusters after mitogen 
stimulation, thus facilitating transmission of virus between cells. As little is known 
about the mechanism underlying efficient EHV-1 cell-to-cell transmission in 
CD172a+ cells, we hypothesize that after productive viral infection in individual 
CD172a+ cells, EHV-1 recruits neighbor cells either by direct contact(s) via induction 
of membrane extensions (synapses) driven by cellular adhesion molecules (CAMs), or 
by indirect contact via a paracrine signaling, which induces cell migration to the 
developing focus of infection, similarly as in HIV infection (Nikolic et al., 2011; 
Boomker et al., 2005). Both contacts may result in the formation of cell clusters, 
which trigger cell-to-cell fusion events. These ‘microfusion’ events are likely to be 
responsible for infectious virus transfer and cytoplasmic transfer of viral material 
between an infected cell to uninfected surrounded cells, as described in the 
transmission of HCMV infection in vitro (Gerna et al., 2000; Digel et al., 2006). The 
adhesion molecules involved in cell-to-cell interactions as well as the exact 
composition of the cytoplasmic material transferred from an infected to uninfected 
CD172a+ cells still remain to be investigated. However, the results of direct cell-to-
cell transmission of EHV-1 between CD172a+ cells, which undergo complete viral 
replication under HDAC inhibition, constitute relevant findings in light of the 
pathogenesis of EHV-1 in vivo and in vitro. 
In conclusion, we have demonstrated that the replication of EHV-1 is restricted and 
delayed at the level of viral gene transcription in nasal and blood CD172a+ cells 
compared to RK-13 cells. These data substantiate the hypothesis that EHV-1 hijacks 
CD172a+ cells and silences its replication within the cells, acting like a ‘Trojan 
horse’, in order to survive in the blood circulation and reach targets organs and to 
evade immunosurveillance. Silencing of EHV-1 gene expression in CD172a+ cells 
was shown to be tightly regulated by histone deacetylation events. A better 
understanding of the molecular details of chromatin regulation could give new 
insights into the pathogenesis of EHV-1, both in vivo and in vitro, and provide future 
therapeutic strategies.  
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Abstract 
 
Equine herpesvirus type 1 (EHV-1) is responsible for respiratory disorders, abortion 
and myeloencephalopathy (EHM) in horses. Two pathotypes of EHV-1 strains are 
circulating in the field: neurovirulent (N) and non-neurovirulent (NN). For both 
strains, CD172a+ monocytic cells are one of the main carrier cells of EHV-1 during 
primary infection, allowing the virus to invade the horse’s body. Recently, we showed 
that NN EHV-1 strains showed a restricted and delayed replication in CD172a+ cells. 
Here we characterize the in vitro replication kinetics of two N EHV-1 strains in 
CD172a+ cells and investigate if the replication of the N EHV-1 strain is similarly 
silenced as shown for the NN EHV-1 strain. We found that N EHV-1 replication was 
restricted to 7-8% in CD172a+ cells compared to 100% in control RK-13 cells. N 
EHV-1 replication was not delayed in CD172a+ cells but virus production was 
significant lower (103.0 TCID50/105 inoculated cells) than in RK-13 cells (108.5 
TCID50/105 inoculated cells). Approximately 0.04% of CD172a+ cells produced and 
transmitted infectious EHV-1 (0.04%) to neighbour cells compared to 65% of RK-13 
cells. Unlike what we observed for the NN strain, pretreatment of CD172a+ cells with 
histone deacetylases inhibitors did not influence the replication of the N EHV-1 strain 
in these cells. Overall, these results show that the EHV-1 replication of N strain in 
CD172a+ cells differs from that observed for the NN strain, which may contribute to 
their different pathogeneses in vivo.  
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Introduction 
 
Equine herpesvirus type 1 (EHV-1) is a major pathogen of horses worldwide. After 
primary replication in the epithelial cells of the upper respiratory tract (URT), EHV-1 
disseminates through the body via a cell-associated viremia in PBMC to target organs 
such as the pregnant uterus or the central nervous system. Secondary replication in the 
endothelial cells lining the blood vessels of those organs can cause vasculitis and 
ischemic thrombosis, leading to severe symptoms such as abortion and/or equine 
myeloencephalopathy (EHM) (Edington et al., 1991; Smith et al., 1996; Wilson, 
1997). Different EHV-1 strains circulating in the field have been characterized as 
neurovirulent (N) or non-neurovirulent (NN). It was demonstrated that a single 
nucleotide polymorphism (SNP) in the catalytic subunit of the viral DNA polymerase 
was associated with the neurovirulence of naturally occurring strains (Goodman et al., 
2007; Nugent et al., 2006). CD172a+ monocytic cells were identified as one of the 
main carrier cells of EHV-1 in the URT mucosa and bloodstream (Gryspeerdt et al., 
2012; van der Meulen et al., 2000). In vivo studies demonstrated that the number of 
infected CD172a+ cells in tissues of the URT was 3 to 7 times higher after inoculation 
with the Belgian EHV-1 N strain (03P37) than with the Belgian EHV-1 NN strain 
(97P70) (Gryspeerdt et al., 2010). In addition, the expression of some late proteins in 
EHV-1-infected PBMC was hampered at early stages of infection and it was proposed 
that CD172a+ monocytic cells may serve as a ‘Trojan horse’ to facilitate the 
dissemination of EHV-1 to target organs (Laval et al., 2015a; van der Meulen et al., 
2003b).  
Recently, we demonstrated that the replication of EHV-1 was restricted and delayed 
at the level of viral gene transcription in CD172a+ cells compared to the RK-13 
control cell line (Laval et al., 2015a). We showed that EHV-1 gene expression in 
CD172a+ cells was silenced and that inhibition of histone deacetylases could relieve 
repression of viral gene expression. However, this study was carried out with the 
EHV-1 NN strain only. At present, it is not know whether EHV-1 N strain behave 
similarly. Knowledge of the replication kinetics with these strains is important, as 
different outcomes in EHV-1 replication in CD172a+ cells between the two strains 
may account for differences in the neuropathogenic vs abortigenic potential of EHV-1 
in vivo. Thus, the main purpose of this study was to characterize in vitro the 
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replication kinetics of EHV-1 N strains in CD172a+ cells and to investigate if 
replication of the EHV-1 N strain is silenced similar as shown for EHV-1 NN. 
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Materials and methods 
 
Virus  
 
The Belgian EHV-1 N strains 95P105 and 03P37 were originally isolated in 1995 and 
2003 from the blood of paralytic horses (Garré et al., 2009; van der Meulen et al., 
2003a). The Belgian EHV-1 NN strain 97P70, which was isolated from an aborted 
fetus in 1997, was included in this study as a positive control for HDAC inhibition. 
Virus stocks used for inoculation were at the fourth passages in equine embryonic 
lung cells (EEL) and one subsequent passage in RK-13. 
 
Cells 
 
A.Isolation of equine blood CD172a+ cells 
Blood CD172a+ cells were isolated as described by Laval et al. (2015a). Briefly, 
PBMC were isolated by density centrifugation on Ficoll-Paque, resuspended in 
leukocyte medium (LM) (RPMI supplemented with 5% FCS and antibiotics) and 
cultured for 12 h. Non-adhering lymphocytes were washed and the adherent cells 
consisted of >90% of viable CD172a+ cells, as assessed by flow cytometry. 
 
B. Rabbit kidney epithelial (RK-13) cells 
RK-13 cells were maintained in Modified Eagle's medium (MEM) supplemented with 
antibiotics and 5% FCS. 
 
EHV-1 inoculation  
 
Cell populations were inoculated in vitro with EHV-1 strains 03P37, 95P105 or 
97P70 (control strain) at a MOI of 1 in 200µl leukocyte medium for 1 h at 37°C with 
5% CO2. Cells were gently washed twice with RPMI to remove the inoculum and 
further incubated with fresh medium. Mock inoculations were carried out in parallel.  
At 1, 3, 5, 7, 9, 12 and 24 hours post-inoculation (hpi), cells were collected for 
quantification of EHV-1 infected cells, viral production and production of infectious 
EHV-1 by immunofluorescence staining, virus titration and cocultivation assay, 
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respectively. 
Histone deacetylase inhibition was done by pre-treating cells with 100 nM 
trischostatin A (TSA) or 0.5 mM of sodium butyrate (NaBut) for 2 h at 37°C prior to 
EHV-1 inoculation, as described previously by Laval et al. (2015a). HDAC inhibitors 
were maintained throughout the course of infection. All inhibitors were purchased 
from Sigma-Aldrich. The concentration of inhibitors used in this study did not 
decrease the cell viability (> 95%) determined by flow cytometry, as described above. 
CD172a+ cells pretreated or not with HDAC inhibitors and inoculated with EHV-1 
NN (97P70) strain were included as a positive control in this study (data not shown).  
HDAC inhibitors treatment did not affect the kinetics of EHV-1 protein expression in 
inoculated RK-13 cells (data not shown). 
 
Virus titration 
 
To quantify EHV-1 replication, extracellular virus titers were determined at different 
hpi, as described previously by Laval et al. (2015a). Briefly, the supernatant 
containing the extracellular virus was collected, centrifuged at 400xg for 10 min at 
4°C and stored at -70°C until titration. For the inactivation curve, EHV-1 was 
incubated for different times at 37°C.  
 
Indirect immunofluorescence staining of EHV-1 proteins 
 
After fixation with methanol, cells were washed with PBS and incubated with a rabbit 
polyclonal antibody anti-IEP (1:1000) to detect IEP expression and either a mouse 
monoclonal anti-EICP22 (K2 to IR4) (1:500) or anti-gB (4B6) (1:100) antibodiy 
against early (EICP22) and gB proteins expression, respectively. The IEP and EICP22 
antibodies were kindly provided by Dr D. J. O’Callaghan (Louisiana State University, 
USA) and the 4B6 antibody by Dr N. Osterrieder (Freie Universität Berlin, Germany). 
Subsequently, samples were incubated with FITC-conjugated goat anti-rabbit IgG 
(1: 100) or Texas Red-conjugated goat anti-mouse IgG (1 : 100) antibodies (Molecular 
Probes). The percentage of viral antigen-positive cells was calculated based on 300 
randomly selected cells. Samples were analyzed by confocal microscopy (Leica TCS 
SP2 Laser Scanning Spectral Confocal System; Leica Microsystems). 
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Cocultivation assay 
 
A cocultivation assay was used to detect and quantify EHV-1 producing CD172a+ 
cells by co-cultivation of these EHV-1-inoculated CD172a+ cells with a permissive 
rabbit cell culture (RK-13), where a semi-solid overlay technique was applied, as 
described previously by Laval et al. (2015a). 
 
Statistical analysis 
 
Data were analyzed with GraphPad Prism 5 software (GraphPad software Inc., San 
Diego, CA, USA). Analyzed data for statistical significance were subjected to a two-
way analysis of variance (ANOVA). All results shown represent means and standard 
deviation (SD) of three independent experiments. Results with p-value ≤ 0.05 were 
considered statistically significant. 
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Results 
 
1. Replication of EHV-1 neurovirulent strain is restricted in CD172a+ cells 
compared to RK-13 cells 
 
In CD172a+ cells inoculated with EHV-1 N strain (03P37), IEP, EICP22 and gB 
proteins were first detected at 3, 7, and 7-9 h post-inoculation (pi), respectively (Fig. 
1(A), left panel). The kinetics of EHV-1 protein detection in CD172a+ cells were 
similar with those observed in RK-13 cells (data not shown). The percentage of IEP-, 
EICP22- and gB-positive CD172a+ and RK-13 cells increased over time pi. At 24 hpi, 
100% of RK-13 cells were positive for all viral proteins (data not shown). In contrast, 
a maximum of 7.4 ± 0.7% IEP-positive, 5.3 ± 0.5% EICP22-positive and 4% of gB-
positive CD172a+ cells was reached at 24 hpi. Similar results were observed for 
CD172a+ cells inoculated with EHV-1 N strain (95P105) (Fig. 1(A), right panel). IEP 
was expressed in the nucleus of CD172a+ cells within replicative compartments while 
IEP signal was diffuse throughout the cytoplasm (Fig. 1(B)). EHV-1 gB protein was 
exclusively expressed in the cytoplasm of CD172a+ cells, as previously described by 
Laval et al. (2015b) (data not shown). The use of a higher MOI (10) did not alter the 
number of IEP-positive cells (Fig. 1(C)). To quantify EHV-1 replication, extracellular 
virus titers were determined at 1, 12 and 24 hpi in CD172a+ cells and compared to 
virus titers in control RK-13 cells. As shown in Fig. 1(D), no significant increase in 
EHV-1 extracellular virus titers was observed in CD172a+ cells (approx. 103.0 
TCID50/105 inoculated cells) over time post-inoculation. A significant lower virus titer 
was observed in CD172a+ compared to RK-13 cells (108.5±0.4 TCID50/105 inoculated 
cells) at 24 hpi (p < 0.0001). A cocultivation assay was used to detect and quantify 
EHV-1 producing CD172a+ cells by co-cultivation of these EHV-1-inoculated 
CD172a+ cells with RK-13 cells. We found that the number of EHV-1-transmitting 
CD172a+ cells (0.04%) was significantly lower than the number of EHV-1-
transmitting RK-13 cells (65%) (p < 0.0001). These results showed that the 
replication of EHV-1 N strains are highly restricted in CD172a+ cells compared to 
RK-13 cells.  
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Figure 1: Expression kinetics of EHV-1 immediate-early (IEP), early (EICP22) and late gB proteins in 
CD172a+ cells inoculated with neurovirulent EHV-1 strains 03P37 and 95P105. (B) Double 
immunofluorescence of EHV-1 (03P37) IEP (green) and EICP22 (red) proteins in CD172a+ cells. 
Nuclei are counterstained with Hoechst (blue). Each image represents a single optical section through 
a cell. Arrow indicates the formation of IEP-associated replicative compartment. Scale bar = 10 µm. 
(C) Expression kinetics of IEP in CD172a+ cells inoculated with EHV-1 (03P37) at a MOI of 1 or 10. 
No statistical differences were observed between the two groups by a two-way ANOVA test. (D) 
Kinetics of EHV-1 production in CD172a+ cells compared to RK-13 cells. Experiments were performed 
in triplicate and data are represented as means ± SD. A two-way ANOVA test was performed to 
evaluate significant differences between CD172a+ and RK-13 cells (ns = not significant and **** = p 
< 0.0001). 
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2. The restricted replication of EHV-1 neurovirulent strain in CD172a+ cells is 
not controlled by histone deacetylases 
 
Since histone deacetylation events were shown to play a crucial role in the silencing 
of EHV-1 gene expression in CD172a+ cells inoculated with a EHV-1 NN strain 
(Laval et al., 2015a), we investigated whether histone deacetylases (HDACs) were 
similarly involved in the restricted replication of a EHV-1 N strain in CD172a+ cells. 
TSA- or NaBut treatment did not affect the percentage of IEP- and EICP22-positive 
CD172a+ cells for EHV-1 N strain (03P37). A slight but not significant increase in 
gB-positive CD172a+ cells was observed starting from 7 hpi (Fig. 2(A)). In addition, 
the titration of supernatant of NaBut- and TSA- treated cells did not show a 
significant rise in virus titer compared to non-treated cells at 12 and 24 hpi, 
respectively (Fig. 2(B)).  
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Figure 2: Replication of EHV-1 (03P37) in CD172a+ cells following treatment with HDACi, 
trichostatin A (TSA) and sodium butyrate (Nabut). (A) Comparison of the expression kinetics of IEP, 
EICP22 and gB in HDACi-treated and non-treated CD172a+ cells. (B) EHV-1 extracellular virus titer 
in NaBut- and TSA-treated CD172a+ cells compared to untreated cells at 1, 12 and 24 hpi. 
Experiments were performed in triplicate. Error bars show ± SD. No statistical differences were 
observed between HDACi-treated and non-treated cells by a two-way ANOVA test. 
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Discussion 
 
Taken together, we showed that the replication of two EHV-1 neurovirulent (N) 
strains was restricted to 7-8% of CD172a+ cells compared to 100% of RK-13 cells. 
This is in agreement with a study from van der Meulen et al. (2000), demonstrating 
that EHV-1 replication was highly restricted in equine PBMC. We reported 
previously that only a maximum of 4% of cells were susceptible to infection with 
non-neurovirulent strains (Laval et al., 2015a). This is in line with the in vivo work 
from Gryspeerdt et al. (2012) that showed that a significantly higher percentage of 
CD172a+ cells became infected with EHV-1 N versus EHV-1 NN strains. Recently, 
we demonstrated that EHV-1 only binds to 15-20% of CD172a+ cells compared to 
70% of RK-13 cells after 1 h inoculation and independent of the EHV-1 strains used 
(N and NN) (Laval et al., 2015c). We showed that the narrow tropism of EHV-1 
among CD172a+ cells was predominantly determined by the presence of specific 
cellular receptors. This study confirmed that a block at the virus binding level was 
partially responsible for the restricted replication of both EHV-1 N and NN strains in 
CD172a+ cells. However, our results suggest that additional block(s) exist in the 
replication cycle of EHV-1 N and NN strains in CD172a+ cells, at the level of virus 
DNA replication, assembly and/or egress, which may contribute to the immune 
evasive strategies of EHV-1. 
We found that the spatio-temporal distribution of EHV-1 proteins was comparable 
between CD172a+ cells and control RK-13 cells after inoculation with EHV-1 N 
strains, in striking contrast with our previous findings on EHV-1 NN strains. In the 
current study, we could demonstrate that treatment of CD172a+ cells with TSA and 
NaBut, two HDAC inhibitors, did not significantly influence the replication of an 
EHV-1 N in these cells. In contrast, HDAC inhibitors treatment increased and 
unblocked replication of an EHV-1 NN in CD172a+ cells (Laval et al., 2015a). These 
data showed that HDAC activity in the control of EHV-1 replication in target 
CD172a+ cells is likely to be strain dependent. Thus, we believe that the differential 
control of HDACs in EHV-1-infected CD172a+ cells may partially contribute to 
different EHV1 pathogeneses in vivo, in addition to the single nucleotide 
polymorphism in the viral DNA polymerase associated with N EHV-1 (Goodman et 
al., 2007). Indeed, we found that the number IEP-positive CD172a+ cells expressing 
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gB at 24 hpi was significantly higher upon inoculation of cells with EHV-1 N (75%) 
versus EHV-1 NN (20%) strains, as reported in our previous work. We hypothesize 
that a delay in the replication associated with HDAC activity early in infection of 
CD172a+ cells with EHV-1 NN strain may slow down the expression of some 
glycoproteins at the cell surface. This may allow EHV-1 NN strain to behave as a 
‘stealth virus’ persisting longer in CD172a+ cells and functionally hiding itself from 
the immune system in a better way than EHV-1 N strain. It is possible that EHV-1 
NN strains have evolved from EHV-1 N strains and developed additional immune 
evasive strategies, such as the manipulation of HDAC activity in target CD172a+ 
cells. However, the fact that both EHV-1 pathotypes can still cause a viremia in the 
presence of virus-neutralizing antibodies and CTL precursors indicates that EHV-1 
has evolved multiple strategies to bypass detection by the immune system. Future 
studies will sequence and compare the complete genome sequence of the used EHV-1 
N and NN strains. We think that differences in the coding sequences of some EHV-1 
regulatory proteins between the 2 strains might directly affect their functional 
interaction with HDACs. In addition, future studies should include more EHV-1 N 
and NN strains in order to draw any firm conclusions on the regulation of EHV-1 
replication by HDACs. 
Overall, we can conclude that the replication of EHV-1 N strains in CD172a+ cells is 
restricted compared to RK-13 cells. We found that the replication of the tested EHV-1 
N strain is not delayed or controlled by HDAC, in contrast to previous observations 
using an EHV-1 NN strain. We believe that different outcomes in EHV-1 replication 
between N and NN strains may contribute to differences in the neuropathogenic vs 
abortigenic potential of EHV-1 in vivo. Further study of these mechanisms may 
contribute to the development of new therapeutic strategies to prevent EHV-1 related 
diseases. 
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Abstract 
 
Equine herpesvirus type 1 (EHV-1) causes respiratory disease, abortion and 
neurological disorders in horses. Cells from the myeloid lineage (CD172a+) are one of 
the main target cells of EHV-1 during primary infection. Recently, we showed that 
EHV-1 restricts and delays its replication in CD172a+ cells, as part of an immune 
evasive strategy to disseminate to target organs. Here, we hypothesize that a low 
efficiency of EHV-1 binding to and entry in CD172a+ cells is responsible for this 
restriction. Thus, we characterized EHV-1 binding and entry into CD172a+ cells and 
showed that EHV-1 only bound to 15-20% of CD172a+ cells compared to 70% of 
RK-13 control cells. Enzymatic removal of heparan sulphate (HS) did not reduce 
EHV-1 infection, suggesting that EHV-1 does not use HS to bind and enter CD172a+ 
cells. In contrast, we found that treatment of cells with neuraminidase (NA) reduced 
infection by 85-100% compared to untreated cells while NA-treatment of virus had no 
effect on infection. This shows that sialic acids residues present on CD172a+ cells are 
essential in the initiation of EHV-1 infection. We found that αVβ3 integrins are 
involved in the post-binding stage of CD172a+ cell infection. Using pharmacological 
inhibitors, we showed that EHV-1 does not enter CD172a+ cells in a clathrin- or 
caveolae-dependent endocytic pathway, nor by macropinocytosis, but requires 
cholesterol, tyrosine kinase, actin, dynamin and endosomal acidification, pointing 
towards a phagocytic mechanism. Overall, these results show that the narrow tropism 
of EHV-1 among CD172a+ cells is determined by the presence of specific cellular 
receptors. 
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Introduction 
 
The entry of enveloped animals viruses into their host cells is mediated either by 
direct fusion of the viral envelope with the plasma membrane or by endocytosis, 
which can be pH-independent or -dependent (Marsh & Helenius, 2006). The entry of 
the prototype Alphaherpesvirus, herpesvirus simplex virus type 1 (HSV-1), into 
permissive cells can be mediated by both mechanisms and has been shown to be cell-
type dependent (Nicola et al., 2003; Wittels & Spears, 1991; Nicola et al., 2005).  
Equine herpesvirus type 1 (EHV-1), a member of the subfamily Alphaherpesvirinae, 
is a major pathogen of horses worldwide. EHV-1 is one of the main causes of 
respiratory disease, abortion and encephalomyelopathy (Allen & Bryans, 1986; Patel 
& Heldens, 2005). Like HSV-1, EHV-1 can enter cells, including rabbit kidney 
epithelial cells (RK-13) and equine dermal cells (ED) via direct fusion with the 
plasma membrane (Frampton et al., 2007). The initial binding of EHV-1 to target 
cells is mediated via an interaction between virus glycoproteins gB and/or gC and 
cellular heparan sulphate (Neubauer et al., 1997; Osterrieder et al., 1999). The 
interaction of glycoprotein gD with a putative receptor (MHC-1) followed by the 
activation of a gH/gL complex, in combination with gB and gD, are required to 
complete the fusion between the viral envelope and the cell membrane (Kurtz et al., 
2010; Sasiki et al., 2011; Atanasiu et al., 2007). Van de Walle et al. (2008) 
demonstrated that EHV-1 enters via the endocytic/phagocytic pathway into CHO-K1 
and PBMC and that α v integrins are involved. In addition, Hasebe et al. (2009) 
indicated that EHV-1 entry pathways are cell-type dependent.  
CD172a+ monocytic cells were identified as one of the main target cells of EHV-1 in 
the upper respiratory tract and the bloodstream during primary infection (van der 
Meulen et al., 2000; Vandekerckhove et al., 2010; Gryspeerdt et al., 2012). EHV-1 
replication was found to be restricted and delayed in CD172a+ cells at a very early 
stage of infection (Laval et al., 2015a). It was proposed that CD172a+ cells may serve 
as a ‘Trojan horse’ to facilitate the spread of EHV-1 to target organs and evade 
immune-surveillance. However, until now, little is known about the regulation of the 
CD172a+ cell tropism. Here, we investigated the binding and entry of EHV-1 into 
CD172a+ cells. Using Dio-labeled virus particles, we compared the kinetics of EHV-1 
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binding to CD172a+ cells and to RK-13 cells, a cell line known to be fully susceptible 
to EHV-1 infection. Using pharmacological inhibitors and confocal microscopy, we 
investigated the entry mechanism(s) of EHV-1 into CD172a+ cells.  
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Material and methods 
 
Virus  
 
Two Belgian EHV-1 strains were included in this study. The neurovirulent strain 
03P37 was originally isolated in 2003 from the blood of a paralytic horse (Garré et 
al., 2009; van der Meulen et al., 2003a), and the non-neurovirulent strain 97P70 was 
first isolated in 1997 from the lungs of an aborted fetus (van der Meulen et al., 2000).  
 
Cells 
 
A. Isolation of equine blood CD172a+ cells 
Blood CD172a+ cells were isolated as described by Laval et al., 2015. Briefly, PBMC 
were isolated by density centrifugation on Ficoll-Paque, resuspended in leukocyte 
medium (RPMI supplemented with 5% FCS and antibiotics) and cultured for 12 h. 
Non-adhering lymphocytes were washed and the adherent cells consisted of >90% of 
CD172a+ cells, as assessed by flow cytometry. 
 
B.  Rabbit kidney epithelial (RK-13) cells 
RK-13 cells were used as a control cell line for blood CD172a+ cells and were 
maintained in MEM supplemented with antibiotics and 5% FCS. 
 
C. Cell viability 
Cell viability was determined by flow cytometry prior to virus inoculation, using 1 µg 
ml-1 propidium iodide and was > 90% in all cell populations. 
 
EHV-1 purification and Dio-labeling 
 
Viral purification was performed as described by Yang et al., 2014. Briefly, culture 
fluids of EHV-1-infected (03P37 and 97P70) RK-13 cells were clarified and virus was 
collected after centrifugation. The virus suspension was brought on a discontinuous 
Optiprep gradient containing 10-30% (w/v) of iodixanol and centrifuged. The visible 
opalescent virus bands were harvested separately. The buffer was exchanged to HNE 
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(5mM HEPES, 150 mM NaCl, 0.1mM EDTA, pH 7.4) buffer by the use of a 50kDa 
filter device. Purified EHV-1 in solution was labeled with 3,3’-
Dioctadecyloxacarbocyanine perchlorate (Dio) dissolved in DMSO (Molecular 
Probes). Dio-labeling did not significantly decrease virus infectivity. The purity of 
EHV-1 suspensions was evaluated by lipophilic labeling and immunofluorescence 
staining of EHV-1 gB as similarly described by Yang et al. (2014). The staining was 
analyzed with confocal microscope by randomly selecting 10 regions. The ratio of 
EHV-1 gB-positive particles (virions) versus Dio-positive particles was calculated 
and referred to as the degree of viral purity (>90%). 
 
Kinetics of EHV-1 attachment 
 
Cells were cooled down to 4°C and were washed with ice-cold RPMI and inoculated 
at a MOI of 1 or 10 with Dio-labeled EHV-1 (03P37 or 97P70) for 1 h on ice. Cells 
were washed 2X with cold RPMI to remove unbound virus particles and were further 
incubated on ice for 0, 5, 10, 15, 30, and 60 min.  Cells were fixed with 1% PFA for 
10 min. Cell nuclei were stained with Hoechst 33342 (10 µg ml-1; Molecular Probes) 
for 10 min at 37°C. Finally, coverslips were mounted on microscope slides and 
analysed by confocal microscopy. 
The percentage of EHV-1 positive cells was calculated based on the number of cells 
with viral particles bound on the plasma membrane of 300 randomly selected cells. 
The average number of virus particles attached per cell was calculated based on the 
number of particles attached at the plasma membrane of 10 randomly selected EHV-1 
positive cells. For each cell, the entire plasma membrane was screened for the 
presence of virus particles by generating a Z-stack. 
 
Antibody-blocking assay 
 
CD172a+ cells were pre-incubated with 10 or 50 µg/ml of neutralizing antibodies 
directed against CD29 (clone TDM29, IgG1, Merck Millipore), CD49d (clone 9F10, 
IgG2b, BD Pharmingen), CD11a/CD18 (clone CVS9, IgG1, AbD Serotec), CD51/61 
(clone 23C6, IgG1, BioLegend), or with isotype-matched control antibodies for 30 
min at 37°C. Cells were washed twice with RPMI and inoculated with EHV-1 (03P37 
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and 97P70, MOI 1) for 1 h and further incubated for 12 h at 37°C. Cells were fixed 
with methanol and incubated with a rabbit polyclonal antibody anti-IEP (1:1000) 
(kindly provided by Dr. D. O’Callaghan, Louisiana State University, USA) to detect 
immediate-early protein (IEP) expression, followed by a goat anti-rabbit IgG FITC 
(1:100) antibody. The nuclei were counterstained with Hoechst and the percentage of 
IEP-positive cells was determined as previously described. 
To determine the role of αVβ3 (CD51/61) integrin in EHV-1 binding to CD172a+ cells, 
CD172a+ cells were pre-incubated with 10 µg/ml of CD51/61 or with isotype-matched 
control antibodies for 30 min on ice. Cells were inoculated with Dio-labeled EHV-1 
(03P37 or 97P70) particles (MOI 1) for 1 h on ice. Cells were fixed with PFA 1% and 
immunofluorescence staining was performed as described above. 
 
Enzymatic treatment 
 
For enzymatic removal of cell surface heparan sulphate or sialic acids, CD172a+ cells 
were incubated with 1 and 10 U/ml of heparinase I and III from Flavobacterium 
heparinum (Sigma) or 50 mU/ml neuraminidase (NA) from Vibrio cholera (Roche 
Diagnostics) diluted in DPBS for 1 h at 37°C. The concentration of heparinase and 
neuraminidase used in this study did not decrease the cell viability (> 90%). After 
washing, untreated and enzymatic-treated cells were inoculated with EHV-1 03P37 or 
97P70 strains at a MOI of 1 for 1 h at 37°C. Cells were washed and further incubated 
for 12 h at 37°C.  
To remove sialic acids from the virus, EHV-1 03P37 and 97P70 suspensions were 
incubated on a shaker for 1 h at 37°C with 50 mU/ml Glycocleave NA (Vibrio 
cholera) enzyme beads (GALAB Technologies) diluted in DPBS. Beads were washed 
two times with DPBS before incubation with the virus to remove buffers. Before 
inoculation, NA beads were separated from the virus by centrifugation (200 x g, 10 
min, 4°C). Untreated virions were incubated in DPBS without beads and underwent 
the same manipulation as the NA-treated virus. Untreated cells were inoculated with 
either NA-treated or untreated virus at a MOI of 1 for 1 h at 37°C. Cells were washed 
and further incubated for 12h. The percentage of IEP-positive cells was determined as 
previously described. 
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Effect of different entry inhibitors on EHV-1 infection  
 
Cells were pre-treated for 30 min at 37°C with inhibitory compounds:  10 mM 
methyl-β-cyclodextrin (mβCD) dissolved in PBS, 5 µg/ml filipin III (fil) dissolved in 
DMSO, 10 µg/ml genistein in DMSO, 500 µM amantadine in PBS, 1 µg/ml 
chlorpromazine in PBS, 100 µM amiloride in DMSO, 100 µM dynasore in DMSO 
and 20 µM latrunculin B in DMSO. Then, cells were inoculated with EHV-1 03P37 or 
97P70 strains (MOI 1) in the presence of inhibitors and incubated for 1 h at 37°C. 
After washing, cells were incubated for 12 h in the absence of inhibitors. Only mβCD 
and fil were removed at the time of virus inoculation in order to avoid any effect on 
cholesterol in the viral envelope. The maximal concentration of inhibitors was 
optimized to ensure that viability of cells was always over 85-90%. The percentage of 
IEP-positive cells was determined as previously described.  
To assess the effectiveness of chlorpromazine, amantadine and amiloride on 
endocytosis inhibition, CD172a+ cells (untreated or pre-treated with 1 µg/ml 
chlorpromazine, 500 µM amantadine or 100 µM amiloride) were incubated with 
Alexa Fluor 647-labeled transferrin (100 µg/ml) and FITC-labeled dextran (1 mg/ml) 
for 1h at 37°C in the presence of the relevant inhibitor or medium. Alexa Fluor 647-
labeled transferrin and FITC-labeled dextran, used as positive controls for clathrin-
mediated endocytosis and macropinocytosis, were obtained from Thermo Fischer and 
Sigma-Aldrich, respectively. After 1h, cells were washed with PBS and the uptake of 
transferrin or dextran in CD172a+ cells was analysed by flow cytometry. The 
internalization of fluorescent marker was calculated as the mean fluorescence 
intensity (MFI) and expressed as a percentage of uptake. The 100% uptake was 
determined from CD172a+ cells, which have not been exposed to any inhibitor and 
have been incubated with the marker. 
 
Colocalization with clathrin or caveolin-1 
 
CD172a+ cells were inoculated with Dio-labelled EHV-1 (03P37 or 97P70) (MOI 1) 
for 0, 15 and 60 min at 37°C, washed and fixed with methanol. Cells were incubated 
with a rabbit polyclonal antibody anti-clathrin (1:200) (Biorbyt) or a goat polyclonal 
antibody anti-caveolin-1 (1:200) (Abcam), followed by a goat anti-rabbit IgG Texas-
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Red® (1:200) or rabbit anti-goat IgG Texas-Red® (1:200) antibodies. The nuclei were 
counterstained with Hoechst. As a negative control, mock-inoculated cells were 
stained following the aforementioned protocols.  
 
Effect of acidotropic agents on EHV-1 infection 
 
Cells were treated with several acidotropic agents: ammonium chloride (NH4Cl), 
chloroquine, or monensin. Cells were pre-incubated with different concentrations of 
NH4Cl (0, 10, 20 or 30 mM) dissolved in DMSO, chloroquine (0, 1, 10 or 50 µM) in 
PBS or monensin (0, 1, 10 or 50 µM) in DMSO, for 2 h at 37°C. Untreated and 
treated cells were inoculated with EHV-1 (MOI 1) for 1 h in the presence of the 
drugs. After washing, cells were incubated in presence of the drugs for 12 h at 37°C. 
The inhibitor concentrations used did not decrease the cell viability (>90%). The 
percentage of IEP-positive cells was determined as previously described. 
 
Statistical analysis 
 
Data were analyzed with GraphPad Prism 6 software (GraphPad software Inc., San 
Diego, CA, USA).  Data analyzed for statistical significance were subjected to a two-
way ANOVA. Prior to statistical analyses, all variables were checked for assumptions 
of ANOVA (equal variances and normal distribution of the standardized residuals) by 
Levene’s test. When the variables were not equal, a Kruskal–Wallis’ test followed by 
pairwise comparisons were performed. All results shown represent means and 
standard deviation (SD) of three independent experiments. Results with P-value ≤
0.05 were statistically significant.  
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Results 
 
1. EHV-1 does not bind efficiently to CD172a+ cells compared to RK-13 cells 
 
To characterize the attachment of EHV-1 to target CD172a+ cells, we compared the 
binding kinetics of Dio-labeled EHV-1 particles to CD172a+ cells and RK-13 cells. 
EHV-1 particles were observed on the plasma membrane of approximately 70% of 
RK-13 cells with a MOI of 1 at 60 min post-binding and this percentage was 
independent of the EHV-1 (03P37 or 97P70) strains used. At a MOI of 10, 100% of 
RK-13 cells showed virus particles bound on their surface (Fig. 1(A), left panel). In 
contrast, EHV-1 97P70 particles were observed on the plasma membrane of 14% of 
CD172a+ cells with a MOI of 1 and this percentage was not significantly higher in 
cells incubated with EHV-1 03P37 particles (23 %) or with a higher MOI (10) (Fig. 
1(A), right panel). The number of EHV-1 particles attached to RK-13 cells 
significantly increased from 15 to 60 min (p < 0.001)  (Fig. 1(B), left panel and Fig. 
2(A)). The use of a higher MOI (10) increased the number of virus particles attached 
per RK-13 cell and made the counting of individual EHV-1 particles impossible.  
The binding of EHV-1 particles to CD172a+ cells increased from 1 to 60 min with a 
maximum of 3 ± 1 EHV-1 03P37 particles and 1.9 ± 0.1 EHV-1 97P70 particles 
bound per CD172a+ cell at 60 min post-binding at a MOI of 1 (Fig. 1(B), right panel 
and Fig. 2(B)). Taken together, these data demonstrate that EHV-1 does not bind 
efficiently to CD172a+ cells compared to RK-13 cells. The low percentage of 
CD172a+ cells with bound EHV-1 particles may suggest that EHV-1 particles attach 
to specific receptors on the surface of a restricted population of CD172a+ cells.
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Figure 1: EHV-1 binding to RK-13 cells and CD172a+ cells. Cells were inoculated with Dio-labelled 19 
EHV-1 (03P37) or (97P70) particles (MOI 1 or 10) and incubated on ice for different durations. (A) 20 
Percentage of EHV-1 positive cells at 60 min post-binding. (B) Time-course of EHV-1 particles binding 21 
per cell. Three independent experiments were performed and data are represented as means + SD, ns 22 
= not significant;  * = p < 0.05; *** = p < 0.001. 23 
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Figure 2: Confocal images of EHV-1 binding to RK-13 (A) and CD172a+ cells (B). EHV-1 particles 51 
(green) were visualized at the plasma membrane at 1, 15 and 60 min post-binding. Nuclei were 52 
counterstained with Hoechst (blue). All confocal images shown represent merged Z-stacks. Scale bar, 53 
10 µm. 54 
 55 
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2. EHV-1 infection of CD172a+ cells depends on αVβ3 integrin 
 
Since αv integrins have been reported to play a role in the entry of EHV-1 into PBMC 
(van de Walle et al., 2008) and αvβ3 integrin was found to be expressed in only 17% 
of CD172a+ cells (Laval et al., 2015b), we investigated whether αvβ3 integrin could be 
a potential cellular receptor involved in the restricted binding and/or entry of EHV-1 
into CD172a+ cells.  
We first performed infection-blocking experiments using a function-blocking 
antibody against αvβ3 integrin. Blocking antibodies against α4β1 and αLβ2 integrins, 
which are found expressed on 10-14% and 94% of CD172a+ cells (Laval et al., 2015) 
were also included in this study to rule out their involvement in EHV-1 infection.  
Pre-treatment of EHV-1 inoculated CD172a+ cells with anti-αVβ3 integrin (CD51/61) 
antibody resulted in a dose-dependent significant decrease of EHV-1 infection in 
CD172a+ cells, compared to isotype control (p < 0.01). When used at a concentration 
of 50 µg/ml, we found that the anti-αVβ3 integrin antibody inhibited EHV-1 infection 
levels by 70 and 80% in CD172a+ cells inoculated with EHV-1 03P37 and 97P70 
strains, respectively (p < 0.001) (Fig. 3). In contrast, no significant decrease of EHV-1 
infection was observed in CD172a+ cells after pre-incubation with α4β1 
(CD49d/CD29) or αLβ2 (CD11a/CD18) blocking antibodies at a concentration of 
either 10 or 50 µg/ml. 
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Figure 3: αVβ3 integrin-blocking antibody inhibits EHV-1 infection of CD172a+ cells. Cells were pre- 24 
incubated with α4β1 (CD49d/CD29), αLβ2 (CD11a/CD18) and αVβ3 (CD51/CD61) antibodies or isotype- 25 
controls followed by EHV-1 inoculation (03P37 or 97P70 (MOI 1)). The percentage of immediate- 26 
early protein (IEP) positive cells was determined at 12h. Error bars show + SD, ns = not significant; 27 
** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001. 28 
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To determine whether the interaction of EHV-1 with αvβ3 integrin occurred during 
binding or at a post-binding step, we carried out EHV-1 binding-blocking experiments 
with blocking antibody to αvβ3 integrin. After pre-incubation with 10 µg/ml of αvβ3 
(CD51/61) integrin or specific isotype control, CD172a+ cells were inoculated with 
Dio-labeled EHV-1 (03P37 or 97P70) particles for 1 h on ice. The percentage of cells 
with bound virus particles was analyzed as previously described. As shown in Fig. 4, 
no significant decrease of EHV-1 03P37 or 97P70 binding to CD172a+ cells was 
observed after pre-incubation of cells with αVβ3 integrin-blocking antibody, compared 
to isotype control. We could not visualize αvβ3 integrin expressed at the plasma 
membrane of CD172a+ cells. It is possible that CD172a+ cells do not express high 
levels of αvβ3 integrin on their surface and confocal microscopy is not as sensitive as 
flow cytometry to detect low expression levels of αvβ3 integrin. Taken together, these 
results suggest that αVβ3 integrin is not used by EHV-1 for its initial attachment to the 
CD172a+ cell surface but is rather involved at a post-binding step.    
 
 
 
 
 
 
 
 
 
 
 
Figure 4: αVβ3 integrin-blocking antibody does not inhibit EHV-1 binding to CD172a+ cells. Cells were 
pre-incubated with αVβ3 (CD51/CD61) integrin-blocking antibody or isotype control for 30 min at 4°C, 
followed by inoculation with Dio-labeled EHV-1 03P37 or 97P70 strains (MOI 1) at 4°C. Cells were 
washed, fixed with 1% PFA without permeabilization and stained with Hoechst. The percentage of 
EHV-1 positive CD172a+ cells was determined at 60 min post-binding. Experiments were performed 
three times. Error bars show + SD. No statistical differences (ns) were observed from isotype control 
by a two-way ANOVA test.  
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3. Sialic acids, but not cellular heparan sulphate, play a role in EHV-1 infection 
of CD172a+ cells 
 
Heparan sulphate (HS) moieties are known to play a role in the binding step of several 
herpesviruses, including HSV-1, PRV and CMV (Skula & Spears, 2001, Shieh et al., 
1992; Trybala et al., 1998; Compton et al., 1993). However, the role of HS in EHV-1 
entry into target CD172a+ cells as an attachment receptor has not been confirmed yet. 
To determine whether the interaction of EHV-1 with CD172a+ cells also involves HS 
molecules, cells were pre-treated with 1 or 10 U/ml of heparinase I and III, prior to 
inoculation with EHV-1 (03P37 or 97P70). As a positive control, RK-13 cells were 
pre-treated with 1U/ml of this enzyme before EHV-1 inoculation. As shown in Fig. 
5(A), a significant reduction of EHV-1 infection was observed in heparinase-treated 
RK-13 cells compared to non-treated cells  (p < 0.05). In contrast, we found that 
enzymatic removal of cell surface HS did not significantly reduce EHV-1 infection in 
CD172a+ cells compared to non-treated cells (Fig. 5(B)). This suggests that HS does 
not play a role in EHV-1 entry into CD172a+ cells. 
To further investigate the nature of the cellular receptor involved in the restricted 
attachment of EHV-1 to CD172a+ cells, we examined the role of sialic acids in EHV-
1 infection of CD172a+ cells. Sialic acids constitute another group of carbohydrates 
other than glycosaminoglycans, and are known to serve as receptors for several 
viruses, such as influenza virus, respiratory syncytial virus or polyomaviruses 
(Gamblin et al., 2004; Baretto et al., 2003; Cahan et al., 1983). Attachment to sialic 
acids present on cells is usually mediated by receptor binding proteins that are 
constituents of viral envelopes, such as the hemagglutinin protein for influenza virus 
(Skehel & Wiley, 2000). In addition, sialic acid binding immunoglobulin (Ig)-like 
lectins (siglecs) that are expressed on immune cells can recognize sialic acid moieties 
on the virus, as shown for HIV and PRSSV infections (Zou et al., 2011; Delputte & 
Nauwynck, 2004). 
To assess the role of sialic acids in EHV-1 infection on CD172a+ cells, cells were pre-
treated with 50 mU/ml NA prior to inoculation with EHV-1. We found that EHV-1 
infection was reduced by 100% and 85% in NA-treated CD172a+ cells inoculated with 
EHV-1 03P37 and 97P70, respectively, compared to untreated cells (p < 0.001) (Fig. 
5(C)). As the presence of sialic acids on the virion surface has been shown to be 
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important in HSV-1 infection (Teuton et al., 2007), we examined whether sialic acids 
on EHV-1 were involved in infection of CD172a+ cells by enzymatic removal of 
sialic acids from the surface of EHV-1. As shown in Fig. 5(D), no significant decrease 
in EHV-1 infection of untreated CD172a+ cells was observed between NA-treated and 
untreated virus. Taken together, these results indicate that EHV-1 depends on terminal 
sialic acid residues present on the cell surface for the initiation of its infection.  
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Figure 5: Removal of sialic acids but not heparan sulfate from CD172a+ cells reduces EHV-1 
infection. (A) To confirm the activity of heparinase I and III, RK-13 cells were pre-treated or not with 1 
U/ml of this enzyme prior to EHV-1 (03P37) inoculation. CD172a+ cells were pre-treated with 
heparinase I and III (B) or neuraminidase (C) prior to EHV-1 inoculation (03P37 or 97P70 (MOI 1)). 
Cells were further incubated for 12 h. (D) Effect of NA treatment of EHV-1 on the replication in 
untreated cells. Virus suspensions were pre-treated with Glycocleave NA beads before addition on 
CD172a+ cells. The percentage of immediate-early protein (IEP) positive cells was determined at 12h. 
Error bars show + SD,* = p < 0.05, *** = p < 0.001, **** = p < 0.0001 and ns = not significant.  
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4. EHV-1 entry into CD172a+ cells depends on cholesterol-rich lipid rafts but 
does not occur via clathrin- or caveolae -mediated endocytosis  
 
We characterized the endocytic route of EHV-1 entry into CD172a+ cells using 
pharmacological/chemical inhibitors and co-localization assays. Pre-treatment of 
CD172a+ cells with chlorpromazine and amantadine, two specific inhibitors of 
clathrin-mediated endocytosis did not result in a significant decrease of EHV-1 
infection compared to non-treated cells (control) and was independent of the EHV-1 
strain used (Fig. 6(A)). To control the effectiveness of these inhibitors, CD172a+ cells 
untreated or pre-treated with chlorpromazine or amantadine were analysed for 
transferrin uptake, a marker for clathrin-dependent endocytosis. Chlorpromazine and 
amantadine caused a significant reduction in the uptake of transferrin in CD172a+ 
cells compared to untreated cells (p < 0.01) (Fig. 6(D)). Moreover, no clear signal of 
co-localization between clathrin molecules and EHV-1 particles was detected in 
CD172a+ cells at 0, 15 and 60 min post-inoculation (Fig. 6(E)).  
The lipid raft/caveolae-mediated pathway is characterized by the formation of primary 
endocytic vesicles dependent on cholesterol, lipid rafts, cellular tyrosine kinase and/or 
phosphatase activities (Pelkmans, 2005). To disrupt lipid rafts and determine their 
role in EHV-1 entry into CD172a+ cells, cells were pre-treated with filipin (Fil), a 
sterol-binding drug that sequesters cholesterol within the membrane or with methyl-β-
cyclodextrin (mβCD) that removes cholesterol from the plasma membrane. As shown 
in Fig. 6(B), EHV-1 infection was significantly reduced by 80% in CD172a+ cells 
cultured in the presence of Fil (p < 0.0001) and by 40-50% in cells cultured in the 
presence of mβCD (p < 0.05), independent of the EHV-1 strain used. In addition, pre-
treatment of cells with the tyrosine kinase inhibitor genistein reduced EHV-1 
infection by 40% in CD172a+ cells (p < 0.001) (Fig. 6(C)). However, no clear signal 
of co-colocalization between caveolin-1 molecules and EHV-1 particles was detected 
in CD172a+ cells at 0, 15 and 60 min post-inoculation (Fig. 6(F)). Taken together, we 
concluded that the entry route of EHV-1 into CD172a+ cells is not via a clathrin or 
caveolae-dependent mechanism. Moreover, these results suggest that cholesterol-rich 
lipid raft domains at the plasma membrane and cellular tyrosine kinase activity 
contribute to EHV-1 infection of CD172a+ cells. 
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Figure 6: EHV-1 enters CD172a+ cells in clathrin- and caveolae-independent pathways. (A) Cells 
were pre-treated with chlorpromazine (1 µg/ml), amantadine (500 µM) or (B) with two sterol-binding 
drugs (mβCD (10 mM) and fil (5 µg/ml)) or (C) genistein (10 µg/ml) prior to EHV-1 inoculation 
(03P37 and 97P70 (MOI 1). Cells were further incubated for 12 h. The percentage of IEP-positive 
cells was calculated as a percentage relative to that obtained in the control. (D) CD172a+ cells 
(untreated or pre-treated with 1 µg/ml chlorpromazine or 500 µM amantadine) were incubated with 
Alexa Fluor 647-labeled transferrin (100 µg/ml) for 1h at 37°C in the presence of the relevant inhibitor 
or medium. After 1h, cells were washed and the uptake of transferrin (%) was analyzed by flow 
cytometry. * = p < 0.05; ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001; ns = not significant. 
Visualization of EHV-1 03P37 particles (green) and  (E) clathrin protein (red) or (F) caveolin-1 
protein (red) in CD172a+ cells. Nuclei were counterstained with Hoechst (blue). All confocal images 
represent a single section through a cell. Scale bar, 10 µm. 
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5. EHV-1 infection of CD172a+ cells requires actin and dynamin but does not 
occur via macropinocytosis. 
 
Previous studies showed a possible role for macropinocytosis in HSV-1 infection 
(Nicola et al., 2003; Nicola et al., 2005). To test whether macropinocytosis is 
involved in EHV-1 infection of CD172a+ cells, cells were pre-treated with amiloride, 
a specific inhibitor of macropinocytosis and latrunculin B, an inhibitor of actin 
polymerization. As shown in Fig. 7(A), EHV-1 infection was not reduced in CD172a+ 
cells treated with amiloride. In contrast, EHV-1 infection was significantly reduced by 
55-65% in cells treated with latrunculin B (p < 0.0001). To control the effectiveness 
of amiloride, CD172a+ cells untreated or pre-treated with amiloride were analyzed for 
dextran uptake, a marker for macropinocytosis. Pre-treatment of CD172a+ cells with 
amiloride caused a significant reduction in the uptake of dextran compared to 
untreated cells (p < 0.0001) (Fig. 7(B)). 
The GTPase dynamin is a key component of clathrin- and caveolae-mediated 
endocytosis and phagocytosis (Mettlen et al., 2009; Nabi and Le, 2003; Gold et al., 
1999). Interestingly, the inhibition of uptake by dynamin constitutes a major 
difference between phagocytosis and macropinocytosis (Pelkmans & Helenius, 2003). 
To test whether EHV-1 infection of CD172a+ cells requires dynamin activity, cells 
were pre-treated with dynasore, a specific inhibitor of dynamin-1 and dynamin-2, 
which blocks dynamin-dependent endocytosis (Macia et al., 2006). We found that 
EHV-1 (03P37 or 97P70) infection was significantly reduced in CD172a+ cells treated 
with dynasore compared to untreated cells (p < 0.0001) (Fig. 7(C)). Taken together, 
we concluded that EHV-1 infection is dependent on actin and dynamin but does not 
occur via macropinocytosis. 
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Figure 7: EHV-1 infection of CD172a+ cells is dependent on actin and dynamin but does not require 
macropinocytosis. (A) Cells were pre-treated with amiloride (100 µM), latrunculin B (20 µM) or 
dynasore (100 µM) (C), prior to EHV-1 inoculation (03P37 or 97P70 (MOI 1). Cells were further 
incubated for 12 h. The percentage of IEP-positive cells is expressed as percentage of control. (B) 
CD172a+ cells (untreated or pre-treated with 100 µM amiloride) were incubated with FITC-dextran (1 
mg/ml) for 1h at 37°C in the presence of the inhibitor or medium. After 1h, cells were washed and the 
uptake of dextran (%) was analyzed by flow cytometry. Error bars show + SD, **** = p < 0.0001 and 
ns = not significant. 
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6. Entry of EHV-1 into CD172a+ cells requires a low-pH step  
 
To determine whether a pH drop was a crucial step in the infectious entry of EHV-1 
into CD172a+ cells, we examined the effects of acidotropic agents: amonium chloride, 
chloroquine and monensin on EHV-1 infection. Pre-treatment of CD172a+ cells with 
increased concentrations of these inhibitors resulted in a dose-dependent significant 
decrease of EHV-1 infection compared to non-treated cells (p < 0.01) and was 
independent of the EHV-1 strain used (Fig. 8). EHV-1 infection was reduced by 90% 
in CD172a+ cells treated with 30 mM ammonium chloride or 50 µM chloroquine and 
was completely blocked in cells treated with 50 µM monensin. No significant 
difference in the efficiency of inhibition of EHV-1 infection was observed in 
CD172a+ cells treated with inhibitors before inoculation, at the time of virus 
inoculation or 1 h post-inoculation, indicating that these agents did not affect binding 
of EHV-1 to cells but rather blocked EHV-1 infection at a post-binding step (data not 
shown). Taken together, these results show that EHV-1 enters CD172a+ cells in a 
low-pH dependent manner. 
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Figure 8: Acidotropic agents block EHV-1 infection of CD172a+ cells. Cells were pre-incubated with 
ammonium chloride, chloroquine and monensin prior to EHV-1 inoculation (03P37 or 97P70 (MOI 1). 
The percentage of IEP-positive cells was calculated as a percentage of control. Error bars show + SD, 
different letters indicate significant differences (p < 0.05).  
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Discussion 
 
In this study, we observed that EHV-1 only bound to a limited number of CD172a+ 
cells (15-20%, compared to 70% of RK-13 cells at 1 h post inoculation). These results 
suggest that EHV-1 binds to specific receptors on the cell surface of a small 
population of CD172a+ cells. Recently, we demonstrated that EHV-1 replication was 
highly restricted in CD172a+ cells in vitro (Laval et al., 2015). We can confirm now 
that a block at the virus binding level is partially responsible for the restricted viral 
replication in CD172a+ cells. 
To date, equine major histocompatibility complex class I (MHC-I) molecules have 
been identified as a unique gD receptor for EHV-1 entry into equine cells, including 
endothelial cells of the central nervous system (CNS) (Kurtz et al., 2010, Sasaki et al., 
2011). As MHC-I molecules are expressed on the cell surface of all nucleated cells, 
MHC-I cannot explain the restricted EHV-1 attachment and entry into a relatively 
small subset of CD172a+ cells. In line with this, it was shown that MHC-I antibodies 
did not efficiently block EHV-1 entry into PBMC, suggesting the presence of a 
different receptor(s) (Azab et al., 2012). Here we could demonstrate that αVβ3 
integrins play a role in the post-binding stage of EHV-1 infection in CD172a+ cells. 
This result correlates with a study by van de Walle et al., 2008, which showed that the 
RSD integrin motif, present in EHV-1 gD can bind to αVβ3 integrins found on PBMC 
and facilitates EHV-1 entry via endocytosis. Virus binding and entry are distinct 
processes involving different receptors. It is often assumed that viruses can bind to 
target cells to specific receptors and may require additional receptors to enter the 
cells. Cellular integrins have been shown to serve as receptors and/or co-receptors for 
several herpesviruses, including HSV, HCMV, Epstein-Barr virus (EBV), Kaposi’s 
sarcoma-associated herpesvirus (KSHV) (Gianni et al., 2010; Wang et al., 2005; 
Chesnokova et al., 2009; Garrigues et al., 2008). Based on these findings, it is our 
understanding now that αVβ3 integrin is not used as the cellular receptor, crucial for 
the binding, but rather as a co-receptor for EHV-1 entry into CD172a+ cells. Although 
speculative at this point, the interaction of EHV-1 with αVβ3 integrin may induce 
conformational changes of the cellular receptor and initiate signaling cascades that 
trigger uptake of EHV-1 within the cell. EHV-1 may use αvβ3 integrin to route its 
entry via endocytosis into CD172a+ cells in order to shorten its exposure at the cell 
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surface. Thus, we believe that the restricted expression of αVβ3 integrins on CD172a+ 
cells may be an important determinant of EHV-1 tropism. Taken together, we suggest 
that co-receptor tropism on CD172a+ cells might have direct implications in the 
pathogenesis on EHV-1, as is the case for example in HIV infections (Goodenow & 
Collman, 2006). 
In this study, we could rule out that HS is involved in EHV-1 infection of CD172a+ 
cells. The lack of involvement of HS in herpesvirus entry is rather exceptional. 
However, a recent study from Garrigues et al. (2014) showed that binding of the 
gammaherpesvirus KSHV is not dependent on HS and that receptors other than HS 
can mediate attachment to cells. To further examine the nature of the main receptor 
involved in the binding of EHV-1 to CD172a+ cells, we focused our research on the 
role of sialic acids in EHV-1 infection of CD172a+ cells. To date, several viruses such 
as influenza virus or polyomaviruses have been shown to bind specifically to sialic 
acids present on the surface of target cells, while its possible role in EHV-1 infection 
has not yet been described (Matrosovich et al., 2013). We found that removal of sialic 
acids from cells inhibited EHV-1 infection of CD172a+ cells by 90-100%. In contrast, 
neuraminidase treatment of EHV-1 had no effect on infection of untreated CD172a+ 
cells. These results suggest that EHV-1 may interact with a sialic acid-containing cell-
surface receptor on CD172a+ cells. So far, influenza virus is the best study example of 
sialic acids involvement in viral entry. Influenza virus uses hemagglutinin (HA) as an 
attachment receptor to bind to sialic acids on the cell surface (Wu et al., 2004). The 
type of linkage between terminal sialic acid and the second sugar is one of the major 
determinants of influenza virus tropism and host specificity (Connor et al., 1994; 
Matrosovich et al., 2000). Further work will determine which sialylated glycans are 
present on CD172a+ cells and which are involved in EHV-1 binding and entry. The 
identity of EHV-1 envelope glycoprotein(s) involved as viral glycan-binding proteins 
should also be further investigated. Recent work from Andoh et al. (2014), 
demonstrated that EHV-1 gC protein had hemagglutination activity against equine red 
blood cells and that this activity was not inhibited by heparin. These results may 
suggest a potential role of EHV-1 gC as a viral lectin, involved in the binding of sialic 
acids residues on CD172a+ cells. 
Following binding to cell-surface receptors, EHV-1 must be internalized to initiate 
infection. EHV-1 can enter target cells via direct fusion with the plasma membrane or 
via an endocytic/phagocytic entry pathway, which has been proposed to be the choice 
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of entry of EHV-1 into PBMC (Frampton et al., 2007; van de Walle et al., 2008). 
Based on this published information, the last part of our study further defined the 
endocytic mechanism(s) of EHV-1 entry into CD172a+ cells using pharmacological 
inhibitors and co-localization assays. We demonstrated that EHV-1 enters into 
CD172a+ cells via an endocytic pathway that is independent of clathrin and caveolae 
but is dependent on cholesterol, tyrosine kinase, actin, dynamin and requires a low-pH 
step. In addition, we found that treatment of CD172a+ cells with amiloride, a 
commonly used inhibitor of macropinocytosis, had no effect on EHV-1 
infection.  Hence, our data indicate that EHV-1 does not enter CD172a+ cells by 
clathrin- or caveolae-dependent endocytosis or macropinocytosis, and suggest that 
EHV-1 enters CD172a+ cells via phagocytosis or via a non-classical endocytic 
pathway. Several indications point towards a phagocytic mechanism for EHV-1 in 
CD172a+ cells. Phagocytosis is triggered by the recognition of large particles by cell 
surface phagocyte receptors, which leads to the polymerization of actin underneath 
the contact zone and the formation of phagocytic “cup” around the ingested particle 
(Mercer et al., 2009). This is usually a property of specialized cell types including 
macrophages and dendritic cells. Phagocytosis is sensitive to the depletion of 
cholesterol, implying the involvement of lipid rafts. However, it has been proposed 
that phagosomes are not formed entirely of lipid rafts but rather contain both lipid raft 
and non-raft regions of the membrane, called mixed membrane domains (Kannan et 
al., 2008; El-Sayed & Harashima, 2013). Phagocytosis is also dependent on dynamin, 
a coordinating molecule that regulates the formation of membrane extensions around 
the particle (Di et al., 2003). Finally, maturation of phagosomes is associated with a 
pH decrease (Flannagan et al., 2012), in line with our observation that EHV-1 entry in 
CD172a+ cells requires a pH drop. Phagocytosis-like uptake of alphaherpesviruses has 
been reported before in a study by Clement et al. (2006) on HSV entry, which further 
supports the possibility that EHV-1 might enter CD172a+ cells via phagocytosis.  One 
argument against this entry route is the fact that EHV-1 virions are smaller 
(approximately 200 nm) than the generally accepted size limit for phagocytosis 
(approximately 500 nm). In any case, further studies are required to elucidate whether 
phagocytosis is the main mode of EHV-1 entry into CD172a+ cells, a task hampered 
by a lack of specific pharmacological inhibitors. 
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Surprisingly, we found that both neurovirulent and non-neurovirulent EHV-1 particles 
bound and entered CD172a+ cells in a similar way. These findings indicate that the 
mechanism of EHV-1 entry into CD172a+ cells may not account for differences in the 
neuropathogenic vs abortigenic potential of EHV-1 in vivo but may rather reflect 
differences in EHV-1 replication between the two strains. However, it is clear now 
that several block(s) exist in the replication cycle of EHV-1 in CD172a+ cells, which 
all may make part of an immune evasive strategy. While a small fraction of CD172a+ 
cells show EHV-1 particles bound to their surface, we think that not all viral particles 
will be internalized and not all viral genomes will be delivered to the nucleus and 
initiate efficient viral replication. Indeed, among 15-20% of CD172a+ cells with virus 
particles attached, we previously found that only 4 to 8% of cells were susceptible to 
EHV-1 infection, dependent of the EHV-1 strain used (Laval et al., 2015a; Laval et 
al., manuscript in preparation).  
In conclusion, we showed that EHV-1 binds to a restricted number of CD172a+ cells, 
indicating that EHV-1 may use specific receptor molecules. Based on our data, we 
propose that EHV-1 interacts with a sialic acid-containing cell-surface receptor on 
CD172a+ cells and that αVβ3 integrin acts as a co-receptor, which may explain the 
restricted tropism of the virus to particular CD172a+ cells. In addition, our data 
suggest a phagocytosis-like uptake mechanism for EHV-1 in CD172a+ cells. Further 
unravelling of this entry route of EHV-1 may provide new insights into the 
pathogenesis of EHV-1, both in vivo and in vitro, and may contribute to the 
development of new therapeutic strategies. 
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Abstract 166 
 167 
Equine herpesvirus type 1 (EHV-1) is a main cause of respiratory disease, abortion 168 
and encephalomyelopathy in horses. Monocytic cells (CD172a+) are the main carrier 169 
cells of EHV-1 during primary infection and are proposed to serve as a ‘Trojan horse’ 170 
to facilitate the dissemination of EHV-1 to target organs. However, the mechanism by 171 
which EHV-1 is transferred from CD172a+ cells to endothelial cells (EC) remains 172 
unclear. The aim of this study was to investigate EHV-1 transmission between these 173 
two cell types. We hypothesized that EHV-1 employs specific strategies to promote 174 
the adhesion of infected CD172a+ cells to EC to facilitate EHV-1 spread. Here we 175 
demonstrated that EHV-1 infection of CD172a+ cells resulted in a 3 to 5-fold increase 176 
in adhesion to EC. Antibody-blocking experiments indicated that α4β1, αLβ2 and αVβ3 177 
integrins mediated adhesion of infected CD172a+ cells to EC. We showed that 178 
integrin-mediated PI(3)K and ERK/MAPK signaling pathways were involved in 179 
EHV-1-induced CD172a+ cell adhesion at early time of infection. EHV-1 replication 180 
was enhanced in adherent CD172a+ cells, which correlates with the production of 181 
TNF-α. In the presence of neutralizing antibodies, approximately 20% of infected 182 
CD172a+ cells transferred cytoplasmic material to uninfected EC and 0.01% of 183 
infected CD172a+ cells transmitted infectious virus to neighbouring cells. Our results 184 
demonstrated that EHV-1 infection induces adhesion of CD172a+ cells to EC, which 185 
enhances viral replication, but that transfer of viral material from CD172a+ cells to EC 186 
is a very specific and rare event. These findings give new insights in the complex 187 
pathogenesis of EHV1. 188 
  189 
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Introduction 190 
 191 
Equine herpesvirus type 1 (EHV-1), a member of the sub-family Alphaherpesvirinae, 192 
is a ubiquitous pathogen in horses, causing serious economic losses in horse industry. 193 
Primary EHV-1 infection usually results in the establishment of a lifelong latent 194 
infection within the first months of life with subsequent viral reactivation causing 195 
clinical disease and viral shedding during periods of stress (Allen et al., 2004; Foote 196 
et al., 2004). EHV-1 infection is characterized by upper respiratory disease, 197 
neurological disorders, abortion or neonatal death (Allen & Bryans, 1986; Patel & 198 
Heldens, 2005). The virus first replicates in the epithelial cells of the upper respiratory 199 
tract and disseminates through the body via a cell-associated viremia in peripheral 200 
blood mononuclear cells (PBMC) to target organs such as the pregnant uterus or 201 
central nervous system. Secondary replication in the endothelial cells (EC) lining the 202 
blood vessels of those organs can cause vasculitis and ischemic thrombosis and may 203 
lead to severe symptoms such as abortion and/or neurological disorders (Edington et 204 
al., 1991; Smith et al., 1996; Wilson, 1997).  205 
Monocytic cells (CD172a+) have been shown to be the main carrier cell type of EHV- 206 
1 during primary infection (Gryspeerdt et al., 2012; van der Meulen et al., 2000; 207 
Vandekerckhove et al., 2010). We previously reported that CD172a+ cells serve as a 208 
‘Trojan horse’ to facilitate the spread of EHV-1 to target organs and evade 209 
immunosurveillance (Laval et al., 2015). This may contribute to the observation that 210 
current vaccines do not provide full protection against severe symptoms, as EHV-1 211 
can cause a viremia despite the presence of a virus-specific immune response in the 212 
horse (Kydd et al., 2006; Mumford et al., 1987; O'Neill et al., 1999). 213 
EC are actively involved in a wide variety of pathological processes such as 214 
thrombosis and vasculitis, and endothelial cell-monocyte interactions are known to 215 
play a central role in the pathogenesis of herpesviruses infections. For instance, 216 
human cytomegalovirus (HCMV) infection of EC has been shown to promote naïve 217 
monocytes adhesion to and migration through the endothelium and viral-mediated 218 
cellular activation was found to be responsible for HCMV-induced monocyte 219 
migration (Bentz et al., 2006; Smith et al., 2007). The mechanism of HCMV 220 
dissemination to host tissue is thought to be associated with HCMV-induced vascular 221 
diseases.  222 
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So far, several in vitro systems have demonstrated the potential utility of cultured EC 223 
in the study of the pathogenesis of EHV-1 (Chiam et al., 2006; Tearle et al., 2003). 224 
Studies showed that the infection of EC located in the vasculature of the late-gravid 225 
uterus or CNS was mediated by cell-to-cell contacts between infected PBMC and EC 226 
and occurred even in the presence of virus neutralizing antibodies (Goehring et al., 227 
2011; Smith et al., 2001). In addition, Smith et al. (2001) provided evidence that 228 
activation of EC adhesion molecules may be involved in the transfer of virus from 229 
infected PBMC to EC and may determine the restricted tissue specificity of EHV-1. 230 
However, the precise mechanism underlying the transmission of EHV-1 from 231 
monocytic cells to EC is still unclear.  232 
Given the importance of the interactions between monocytic cells and EC in the 233 
pathogenesis of EHV-1 infections, we studied the ability of EHV-1 inoculated 234 
CD172a+ cells to adhere and subsequently transmit EHV-1 infection to equine venous 235 
EC. We examined the contributions of specific cell adhesion molecules and the 236 
cellular signal transduction pathways involved in the adhesion process in vitro. 237 
Furthermore, we studied the replication kinetics of EHV-1 in CD172a+ cells upon 238 
adhesion to EC.   239 
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Material and methods 240 
 241 
Virus  242 
 243 
Two Belgian EHV-1 strains were included in this study. The neurovirulent strain 244 
03P37 was originally isolated in 2003 from the blood of a paralytic horse (Garré et 245 
al., 2009; van der Meulen et al., 2003a) and non-neurovirulent strain 97P70 was first 246 
isolated in 1997 from the lungs of an aborted fetus (van der Meulen et al., 2000). 247 
Virus stocks used for inoculation were at sixth passage, with five passages in equine 248 
embryonic lung cells (EEL) and one passage in RK-13 cells for strain 97P70, and four 249 
passages in EEL and one passage in RK-13 cells for strain 03P37. For virus 250 
inactivation, a thin layer of viral suspension was exposed to short-wave UV light for 251 
10 min. Absence of viral infectivity was checked by virus titration on RK-13.  252 
 253 
Cells 254 
 255 
A. Isolation of equine blood CD172a+ cells 256 
Healthy horses between 8 to 10 years old were used as blood donors. Horses were 257 
seropositive for EHV-1. The collection of blood was approved by the ethical 258 
committee of Ghent University (EC2013/17). Blood was collected by jugular 259 
venipuncture on heparin (15U ml-1) (Leo) and diluted in an equal volume of 260 
Dulbecco's phosphate-buffered saline (DPBS) without calcium and magnesium 261 
(Gibco). PBMC were isolated by density centrifugation on Ficoll-Paque (d = 1.077g 262 
ml-1) (GE Healthcare, Life Sciences) at 800 x g for 30 min at 18°C. The interphase 263 
cells, containing the PBMC, were collected and washed three times with DPBS. Cells 264 
were resuspended in leukocyte medium (LM) based on Roswell Park Memorial 265 
Institute (RPMI, Gibco) supplemented with 5% fetal calf serum (FCS) (Grainer), 1% 266 
penicillin, 1% streptomycin, 0.5% gentamycin (Gibco). Afterwards, cells were seeded 267 
in 6-well plates (Nunc A/S) at a concentration of 106 cells per ml and cultivated at 268 
37°C with 5 % CO2. After 12 h, non-adhering lymphocytes were removed by washing 269 
cells three times with RPMI. The adherent cells consisted of > 90% monocytic cells, 270 
as assessed by flow cytometry after indirect immunofluorescence staining with a 271 
mouse monoclonal (mAb) anti-CD172a (VMRD, clone DH59B, 1:100, IgG1) 272 
directed against cells from myeloid lineage, followed by goat anti-mouse IgG FITC 273 
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(Molecular probes, 1:200). 274 
 275 
B. Isolation of equine venous endothelial cells 276 
Equine endothelial cells were obtained from the vena cava of a healthy horse at the 277 
slaughterhouse. The vena cava was harvested in a bottle containing Dulbecco's 278 
Modified Eagle Medium (DMEM, Gibco) supplemented with 1% penicillin, 1% 279 
streptomycin, 0.5% gentamycin and 0.1% fungizone. One end of the vessel was 280 
closed using a hemostatic clamp. Pre-warmed enzyme mixture of 0.1% type I 281 
collagenase (Invitrogen) and 0.12% dispase (Sigma-Aldrich) in DMEM was infused 282 
into the segment until there was moderate distention of the vessel. After closing the 283 
segment with a second hemostatic clamp, the vessel was incubated during 30 - 40 min 284 
at 37°C. Then, one of the hemostatic clamps was opened. The loose endothelial cells 285 
were collected by flushing the vessel with warm DMEM. The effluent was collected 286 
with sterile syringes and transferred into chilled centrifuge tubes with FCS. Cells were 287 
pelleted by centrifugation at 200 x g at 4°C for 10 min. The supernatant was discarded 288 
and the cell pellet was resuspended in endothelial growth medium based on DMEM 289 
supplemented with 5% FCS, 1% penicillin, 1% streptomycin, 0,5% gentamycin, 1% 290 
sodium pyruvate, 1% non-essential amino acids 100X (Gibco), 50 ug/ml endothelial 291 
cell growth supplement (ECGS; Biomedical Technologies Inc.). Cells were plated on 292 
0.5% gelatin-coated plasticware (Nunc A/S) and incubated at 37°C with 5% CO2. 293 
After overnight incubation, non-adherent cells were removed by washing with pre- 294 
warmed DMEM and fresh endothelial growth medium was added. Thereafter, culture 295 
medium was refreshed every 2 - 3 days. 296 
 297 
C. Immortalization of endothelial cells 298 
Endothelial cell lines were immortalized by transduction of the genes encoding the 299 
Simian virus 40 large T-antigen (SV40LT) and human telomerase reverse 300 
transcriptase (hTERT). 50% confluent, primary endothelial cells were subsequently 301 
exposed to either a recombinant lentiviral vector containing the gene encoding 302 
SV40LT transforming protein or a lentiviral vector carrying the gene encoding 303 
hTERT or a combination of both (Applied Biological Materials Inc.). All primary EC 304 
were incubated in the presence of 8µg/ml polybrene (Applied Biological Materials 305 
Inc.). To avoid cytotoxicity, the viral supernatant was diluted after 30 min with 306 
heparin free EC growth medium (1:1) and further incubated overnight. The medium 307 
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was refreshed the next day, and then every other day until cells reached confluence. 308 
At 72 h post-transduction, cells were incubated with EC growth medium 309 
supplemented with 10µg/ml puromycin (Applied Biological Materials Inc.) to select 310 
for stable transduced cells. Selection continued until the cultures consisted of resistant 311 
surviving cells only. The latter were further expanded in standard medium and 312 
routinely passaged at a 1:3 split ratio using 10% trypsin (Sigma-Aldrich), 1% versene 313 
(Vel chemicals) in PBS. IEC were analyzed by indirect immunofluorescence for the 314 
expression of hTERT and SV40LT antigen.  315 
 316 
D. Purity of primary and immortalized EC  317 
The purity of primary and immortalized EC was analyzed by fluorescence staining 318 
with 1,1-diocatadecyl-1-3,3,3’,3’-tetramethylindocarbocyanine-perchlorate-acetylated 319 
low density lipoprotein (DiI-Ac-LDL; Biomedical Technologies Inc.) and was always 320 
> 90%. 321 
 322 
E. Cell viability 323 
Cell viability was determined by flow cytometry prior to virus inoculation, using 1µg 324 
ml-1 propidium iodide (Sigma-Aldrich), and was > 90% in all cell populations. 325 
 326 
EHV-1 inoculation 327 
 328 
Cells were inoculated in vitro with both replication competent and UV-inactivated 329 
EHV-1 (UV-EHV-1) strains 03P37 and 97P70 at a MOI of 1 in 1 ml of LM for 1 h at 330 
37°C with 5% CO2. Cells were gently washed twice with RPMI to remove the 331 
inoculum and further incubated with fresh medium. Mock inoculations were carried 332 
out in parallel. 333 
Inhibition of the MEK/ERK signaling pathway was performed by using the 334 
MEK/ERK signaling inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2- 335 
aminophenylthio]butadiene) (Cell Signaling). The stock solution of U0126 was 336 
prepared in dimethyl sulfoxide (DMSO) at a concentration of 10 mM. U0126 337 
interferes with MEK1 and MEK2 directly by inhibiting the catalytic activity of the 338 
active enzyme, and consequently blocks the phosphorylation and activation of ERK1 339 
and ERK2. Inhibition of the PI(3)K signaling pathway was performed by using the 340 
PI(3)K inhibitor LY294002 (Invivogen). The stock solution of LY294002 was 341 
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prepared in DMSO at a concentration of 50 mM. Cells were pre-incubated with 342 
U0126 (1 and 10 µM), LY294002 (25 and 50 µM) or DMSO-based diluent, used as a 343 
solvent control for 30 min at 37°C before EHV-1 inoculation. MEK/ERK and PI(3)K 344 
inhibitors were maintained in the culture media throughout the course of the 345 
experiment. The concentration of inhibitors used in this study and the DMSO-based 346 
diluent did not decrease the cell viability. 347 
Where indicated, 10 ng/ml of equine recombinant TNF-α or 10 ng/ml of TNF-α 348 
neutralizing polyclonal antibody (R&D Systems) were added at the time of 349 
inoculation and maintained in the medium throughout the course of inoculation. TNF- 350 
α was reconstituted in PBS and diluted in LM. 351 
 352 
Adhesion assay 353 
 354 
After virus inoculation, cells were incubated with EHV-1 neutralizing IgG antibodies 355 
for 1 h at 37°C, 5% CO2. Mock, EHV-1 or UV-EHV-1-inoculated CD172a+ cells 356 
were then detached using accutase solution (Sigma-Aldrich), counted and 357 
resuspended in LM supplemented with 10 µg ml-1 polymyxin B (LMPB) (Sigma- 358 
Aldrich). Polymyxin B is an antibiotic used to neutralize circulating LPS in the 359 
medium, and thus used in this study to prevent LPS-mediated adhesion of CD172a+ 360 
cells to endothelial cell monolayers. One hundred thousand CD172a+ cells were added 361 
to each well of EC, which were grown on Lab-Tek chamber slides with eight 362 
compartments (VWR). The monocyte/endothelial cell ratio in co-cultures was 1:3. 363 
CD172a+ cells adherent to the plastic plate were included as a control. At different 364 
time points of co-cultivation (2, 4, 6 and 12 h), adherent cells were fixed with 1 ml of 365 
methanol at -20°C for 20 min. Non-adherent cells were harvested, fixed with 1 ml of 366 
PFA 1% for 10 min at RT, permeabilized with 1 ml of 0.1% Triton X-100 and 367 
cytospinned on a slide. After 2, 4, 6 and 12 h of co-cultivation, both adherent and non- 368 
adherent cells were incubated for 1 h at 37°C with a rabbit polyclonal Ab anti-IEP 369 
(1:1000) to detect immediate early protein (IEP) expression. At 12 h of co-cultivation, 370 
cells were also double-stained with a rabbit polyclonal Ab anti-IEP (1:1000) and a 371 
mouse monoclonal anti-gB (4B6) (1:100) against late gB protein expression. The IEP 372 
and 4B6 antibodies were kindly provided by Dr. D. O’Callaghan (Louisiana State 373 
University, USA) and Dr. N. Osterrieder (Freie Universität Berlin, Germany), 374 
respectively. Where indicated, cells were fixed with 1 ml of PFA 1% for 10 min at 375 
156  Chapter 5 
___________________________________________________________________________________ 
 
 
RT, washed twice with PBS and stained with a horse polyclonal antibody against 376 
EHV-1 late proteins (1:100). The horse polyclonal anti-EHV-1 antibody was obtained 377 
by hyper-immunization of a horse (van der Meulen et al., 2003b). The polyclonal 378 
antibody was purified on a protein G column and subsequently biotinylated 379 
(Amersham International, Buckinghamshire, UK). This antibody could recognize the 380 
late proteins of EHV-1, as described in (9). Subsequently, samples were incubated for 381 
50 min at 37°C with goat anti-rabbit IgG FITC (1:200) and goat anti-mouse IgG 382 
Texas-Red® (1:200) or Streptavidin-FITC (1:200) antibodies (Molecular probes). All 383 
antibodies were diluted in DPBS. The nuclei were counterstained with Hoechst 33342 384 
(10 µg ml-1; Molecular Probes) for 10 min at 37°C. As a negative control, mock- 385 
inoculated cells were stained following the aforementioned protocols. In addition, 386 
appropriate isotype-matched controls were included. 387 
For each time point, the number of IEP- and gB-positive adherent CD172a+ cells was 388 
counted based on the total number of adherent CD172a+ cells counted in 5 randomly 389 
selected microscopic fields (5x 0.2mm2) using a fluorescent microscope (x40 390 
objective) (Leica Microsystems DMRBE Wetzlar, Germany). Results were shown as 391 
number of cells per mm2 and were also expressed as a percentage. In the non-adherent 392 
cell fraction, the number of IEP-positive CD172a+ cells was calculated based on three 393 
hundred cells counted in distinct fields and results were expressed as a percentage. 394 
Samples were analyzed by confocal microscopy (Leica TCS SP2 Laser scanning 395 
spectral confocal system, Leica microsystems GmbH, Germany).  396 
 397 
Adhesion blocking assay 398 
 399 
To determine the role of α4β1 (CD29/CD49d), αLβ2 (CD11a/CD18) and αVβ3 400 
(CD51/61) integrins in EHV-1-induced adhesion to endothelial cells, adhesion assays 401 
were performed as described above with some modifications. Prior to addition of 402 
CD172a+ cells to endothelial cells, EHV-inoculated CD172a+ cells were incubated 403 
with LMPB supplemented with 10 µg/ml of neutralizing monoclonal antibodies 404 
directed against CD29 (clone TDM29, IgG1, Merck Millipore), CD49d (clone 9F10, 405 
IgG2b, BD Pharmingen), CD11a/CD18 (clone CVS9, IgG1, AbD Serotec), CD51/61 406 
(clone 23C6, IgG1, BioLegend), a mixture of CD29, CD49d, CD11a/18 and CD51/61 407 
or with isotype-matched control antibodies for 30 min at 4°C. After washing, EHV-1- 408 
inoculated CD172a+ cells were added to wells of IEC. Cells were fixed after 2 h of 409 
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co-cultivation and stained for IEP expression, as previously described. 410 
 411 
Flow cytometry 412 
 413 
To evaluate integrin expression on CD172a+ cells, cells were incubated with 10 µg/ml 414 
of the anti-integrin monoclonal antibodies CD29, CD49d, CD11a/CD18 and CD51/61 415 
or with isotype-matched control antibodies for 30 min at 4°C. Cells were washed 416 
twice in PBS and incubated with Alexa Fluor 647-labeled goat anti-mouse IgG (1:200 417 
dilution; Molecular Probes) for 30 min at 4°C. After a final wash in PBS, 10,000 cells 418 
were analyzed with a FACSCanto flow cytometer equipped with a FACSDiva 419 
software (BD Biosciences, Mountain View, California USA). 420 
 421 
Western Blot analysis 422 
 423 
One million CD172a+ cells were mock-inoculated or inoculated with EHV-1 03P37 or 424 
97P70 strains (MOI 1) and harvested at 0, 5 and 15 min post-inoculation. Cells were 425 
resuspended in ice-cold lysis buffer (TNE buffer, 10% NP40, 1 mM NA3VO4, 10 mM 426 
NaF, protease inhibitor cocktail) and incubated for 20 min at 4°C. Then, samples were 427 
boiled for 10 min. SDS-PAGE and Western blotting were performed as described 428 
previously (32). Protein concentrations of 20 to 30 µg were used for all experiments. 429 
Protein concentration was determined using the bicinchoninic acid (BCA) protein 430 
assay reagent (Thermo Scientific) according to the manufacturer’s instructions. Blots 431 
were blocked in 5% nonfat dry milk in PBS-Tween 20 for 1 h at RT and incubated 432 
with primary antibodies for 1 h or overnight (according to the manufacturer’s 433 
instructions). After several washes in 0.1% Tris-buffered saline (TBS)-Tween 20, 434 
blots were incubated with HRP-conjugated secondary antibodies for 1 h at RT and 435 
developed using enhanced chemiluminescence. Phospho-specific ERK1/2 antibody 436 
(1:1000; Cell Signaling) and Phospho-Akt antibody (1:1000; Cell Signaling) signals 437 
were detected with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 438 
Scientific). Total ERK1/2 antibody (1:1000; Cell Signaling) and Total Akt (1:1000; 439 
LSBio) signals were detected with Pierce ECL (Thermo Scientific). As a control for 440 
loading, total β-actin (Abcam) levels were assessed. 441 
 442 
 443 
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ELISA 444 
 445 
Equine TNF-α content in culture supernatants of mock and EHV-1-inoculated 446 
CD172a+ cells cultured on plastic or on top of IEC was measured with an enzyme- 447 
linked immunosorbent assay (ELISA) kit obtained from Thermo Scientific. The assay 448 
was performed according to the manufacturer’s instructions. Recombinant equine 449 
TNF-α was used as a standard, and the assay sensitivity was 16 pg/ml. 450 
 451 
Co-cultivation assay 452 
 453 
A co-cultivation assay was used to detect and quantify EHV-1 producing CD172a+ 454 
cells by co-cultivation of these EHV-1-inoculated CD172a+ cells with EC, where a 455 
semi-solid overlay technique was applied. Briefly, EHV-1-inoculated and mock- 456 
inoculated cells were harvested at 12 hpi. One hundred thousand cells per ml were 457 
tenfold-diluted in LM and 0.5 ml of each dilution was added on EC monolayers in a 458 
6-well plate and overlaid with a 0.94% carboxymethylcellulose medium (Sigma- 459 
Aldrich) prepared in RPMI-2X and centrifuged at 800 x g for 30 min at 18°C, as 460 
previously described (8). Cells were further incubated for 5 days at 37°C, 5% CO2. 461 
The cell monolayers were then stained with 5% crystal violet and the number of 462 
plaques was counted. The percentage of infected cells producing infectious EHV-1 463 
was calculated based on the number of plaques counted and the number of cells 464 
seeded per ml according to the volume plated. This experiment was performed three 465 
times. 466 
 467 
Statistical analysis 468 
 469 
Data were analyzed with GraphPad Prism 6 software (GraphPad software Inc.). Data 470 
analyzed for statistical significance were subjected to a two-way analysis of variance 471 
(ANOVA). All results shown represent means and standard deviation (SD) of three 472 
independent experiments. Results with p-value ≤ 0.05 were considered statistically 473 
significant.  474 
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Results 475 
 476 
1. EHV-1 infection induces adhesion of CD172a+ cells to EC  477 
 478 
To determine whether EHV-1 infection may enhance adhesion of CD172a+ cells to 479 
EC, we compared the adhesion kinetics of mock-, UV-inactivated EHV-1- and EHV- 480 
1-inoculated CD172a+ cells to EC monolayers (Fig.1).  481 
EHV-1 infection resulted in a significant increase (p < 0.001) in adhesion of CD172a+ 482 
cells to primary and immortalized venous EC monolayers and was independent of the 483 
EHV-1 strain used (03P37 or 97P70) (Figs. 1A, 1B and 1C). A maximum of 200-230 484 
adherent cells per mm2 was reached with EHV-1-inoculated CD172a+ cells after 2 h of 485 
co-culture compared to approximately 50 adherent cells per mm2 with mock- 486 
inoculated CD172a+ cells. In addition, no significant difference in the adhesion 487 
kinetics of CD172a+ cells to EC monolayers was observed between UV-EHV-1- and 488 
EHV-1-treated cells. These data indicate that active EHV-1 gene expression was not 489 
required to induce adhesion of CD172a+ cells to EC monolayers and thus, viral entry 490 
was sufficient to activate CD172a+ cell adhesion to EC. As the kinetics of CD172a+ 491 
cell adhesion were similar in primary EC cultures and immortalized EC lines, the 492 
following experiments were performed using immortalized EC only. 493 
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Figure 1: Adhesion kinetics of mock-inoculated or EHV-1-inoculated blood CD172a+ cells to equine 530 
endothelial cells (EC). Cells were inoculated with replication competent EHV-1 or UV-inactivated 531 
EHV-1 (UV-EHV-1) strains 03P37 or 97P70 (MOI 1) and directly co-cultured with primary (A) or 532 
immortalized (B) monolayers for 2, 4 and 6 h. The number of adherent CD172a+ cells was calculated 533 
per mm2. Experiments were performed three times. Error bars show + SD and a two-way ANOVA test 534 
was performed to evaluate significant differences from EHV-1 to mock and UV-inactivated EHV-1 535 
samples, (ns = not significant and * = P < 0.001). (C) Low magnification, confocal images of blood 536 
CD172a+ cell adhesion to EC after 2 h co-culture (merged Z-stacks). Nuclei were counterstained with 537 
Hoechst (blue). Arrows point at adhering monocytic cells, arrowheads indicate EC. Scale bar, 100 µm.  538 
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2. EHV-1-mediated CD172a+ cell adhesion to EC depends on cellular adhesion 540 
molecules 541 
 542 
To determine the contribution of specific cellular adhesion molecules in EHV-1- 543 
induced adhesion of activated CD172a+ cells to EC, we performed adhesion-blocking 544 
experiments using blocking antibodies against α4β1, αLβ2 and αVβ3 integrins. These 545 
integrins are known to play a role in mediating firm adhesion of monocytes to the 546 
endothelium (Elangbam et al., 1997; Mazzone & Ricevuti, 1995; Weerasinghe et al., 547 
1998). The presence of α4β1 (CD49d/CD29), αLβ2 (CD11a/CD18) and αVβ3 548 
(CD51/CD61) integrins on CD172a+ cells was confirmed by flow cytometry (Fig. 2A) 549 
but it was not possible to compare the expression levels between mock- and EHV-1- 550 
infected CD172a+ cells due to the low percentage of infected cells detected at early 551 
stages of infection (data not shown). 552 
Pre-treatment of EHV-1-inoculated CD172a+ cells with blocking antibodies resulted 553 
in a 3-fold decrease in adhesion to EC after 2 h of co-culture, compared to isotype 554 
controls (p < 0.001) (Figs. 2B and 2C). After pre-incubation with blocking antibodies, 555 
the number of adherent CD172a+ cells per mm2 in EHV-1-inoculated cells decreased 556 
to levels at or slightly below those of mock-inoculated cells (± 50 adherent cells per 557 
mm2). Pre-treating cells with a mixture of blocking antibodies had no cumulative 558 
effect on decreasing CD172a+ cell adhesion to EC, compared to treatment of cells 559 
with a single antibody. Interestingly, no significant decrease in cell adhesion was 560 
observed with mock-inoculated CD172a+ cells. Taken together, these results show 561 
that interactions between EHV-1-inoculated CD172a+ cells and EC are in part 562 
mediated by integrins.  563 
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Figure 2: Adhesion of mock-inoculated or EHV-1 (03P37 or 97P70)-inoculated blood CD172a+ cells 616 
to EC monolayers after pre-incubation of monoclonal antibodies against α4β1 (CD49d/CD29), αLβ2 617 
(CD11a/CD18) and αVβ3 (CD51/CD61) integrins. (A) Flow cytometric analyses of the expression of 618 
CD49d, CD29, CD11a/CD18 and CD51/CD61 integrins on CD172a+ cells. (B) Cells were mock- 619 
inoculated or inoculated with EHV-1 strains 03P37 or 97P70 (MOI 1), pre-incubated with 10 µg/ml of 620 
specific blocking antibodies for 30 min at 4°C and co-cultured with immortalized EC for 2 h at 37°C.  621 
As a control, cells were pre-incubated with isotype-matched antibodies. The number of adherent 622 
CD172a+ cells was calculated per mm2. Experiments were performed three times. Error bars show + 623 
SD and a two-way ANOVA test was performed to evaluate significant differences from controls, (* = P 624 
< 0.001). (C) Low magnification, confocal images of mock-inoculated or EHV-1 (03P37 or 97P70)- 625 
inoculated blood CD172a+ cells adherent to EC after pre-incubation with αLβ2 (CD11a/18) blocking 626 
antibody. Nuclei were counterstained with Hoechst (blue). The white arrow points at an adhering 627 
monocytic cell. All confocal images shown represent merged Z-stacks. Scale bar, 100 µm.  628 
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3. EHV-1-induced adhesion of CD172a+ cells to EC is dependent on integrin- 644 
mediated PI(3)K and ERK/MAPK signaling pathways 645 
 646 
Next, we wanted to identify the mechanism by which EHV-1 induces adhesion of 647 
CD172a+ cells adhesion to EC. Binding of herpesviruses to integrins is known to 648 
activate cellular pathways, including PI(3)K/Akt (PI(3)k for phosphatidylinositol 3- 649 
kinase and Akt for protein kinase B), one of the early events of integrin-ligand 650 
interaction and the downstream ERK/MAPK (MAPK for mitogen-activated protein 651 
kinase and ERK for extracellular signal-regulated kinases). Both these pathways have 652 
been implicated in the manipulation of cellular functions such as adhesion and in the 653 
control of herpesviruses infection and replication in target cells (Chang et al., 2012; 654 
Naranatt et al., 2003; Smith et al., 2007). Hence, we hypothesized that EHV-1 would 655 
also bind to cellular integrins present on CD172a+ cells and induce PI(3)K/Akt and 656 
ERK/MAPK activation, leading to increased adhesion of CD172a+ cells to EC. 657 
We first tested whether EHV-1 infection up-regulates ERK/MAPK and PI(3)K 658 
activities in CD172a+ cells. We compared by Western blot analyses the levels of 659 
phospho-specific ERK1/2 and total ERK1/2 as well as the levels of phospho-specific 660 
Akt and total Akt, between mock and virus-inoculated CD172a+ cells in the presence 661 
or absence of the specific MEK/ERK non-competitive inhibitor U0126 and the PI(3)K 662 
reversible inhibitor LY294002. We found that mock- and EHV-1-inoculated CD172a+ 663 
cells showed similar levels of total ERK1/2 and total Akt expression at 0, 5 and 15 664 
min post-inoculation. However, we failed to detect any levels of ERK1/2 and Akt 665 
phosphorylation, even by using a highly sensitive detection kit (Fig. 3A). It is possible 666 
that the concentration of cells used in this assay (106 cells per ml) was not sufficient to 667 
detect any signal. Due to technical limitations, it was not possible to increase the cell 668 
concentration. Thus, we could not test whether EHV-1 infection up-regulates 669 
ERK/MAPK and PI(3)K activities in CD172a+ cells. 670 
However, we could analyse the potential role of ERK/MAPK and PI(3)K activation in 671 
EHV-1-induced CD172a+ cells adhesion to EC, by pre-treating CD172a+ cells with 672 
U0126 (1 and 10 µM), LY294002 (25 and 50 µM) or with DMSO-based diluent as a 673 
control, for 30 min before EHV-1 inoculation. Treated CD172a+ cells were then 674 
added to immortalized EC monolayers and co-cultured for 2 h. Inhibition of the 675 
ERK/MAPK signaling pathway prior to EHV-1 inoculation resulted in a dose- 676 
dependent significant decrease (p < 0.001) in CD172a+ cell adhesion to mock-levels 677 
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(Figs. 3B and 3C). When CD172a+ cells were pre-treated with 10 µM of U0126, the 678 
EHV-1 (03P37 and 97P70) induced CD172a+ cell adhesion to EC monolayers was 679 
reduced by 55 and 61%, respectively. Confocal images of the reduced adhesion of 680 
blood CD172a+ cells to EC upon inhibition of the ERK/MAPK signaling pathway 681 
were depicted in Fig. 3D. Inhibition of PI(3)K activity prior to EHV-1 inoculation 682 
resulted in a similar decrease of CD172a+ cell adhesion. Pre-treating mock-inoculated 683 
cells with the inhibitors U0126 or LY294002 had no significant effect on CD172a+ 684 
cell adhesion. Besides, we found that inhibition of ERK/MAPK and PI(3)K pathways 685 
did not significantly decrease EHV-1 infection of  CD172a+ cells compared to 686 
controls (Fig. 3E).Taken together, these data suggest that EHV-1 infection induces 687 
CD172a+ cell adhesion in a PI(3)K- and ERK/MAPK-dependent manner at a very 688 
early time of infection. 689 
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Figure 3: Effect of inhibition of the ERK/ MAPK and PI(3)K signaling pathways on EHV-1-induced 750 
CD172a+ cell adhesion to EC monolayers. (A) Western blot analyses of the levels of phospho-specific 751 
ERK1/2 and total ERK1/2 as well as the levels of phospho-specific Akt and total Akt, between mock- 752 
and EHV-1-inoculated CD172a+ cells in the presence or absence of ERK/MAPK and PI(3)K inhibitors. 753 
One million CD172a+ cells were pre-incubated with MEK/ERK inhibitor U0126 (10 µM), PI(3)K 754 
inhibitor LY294002 (50 µM) or DMSO-based diluent for 30 min at 37°C. Cells were (mock) inoculated 755 
with EHV-1 03P37 or 97P70 strains (MOI 1) and lysed at 0, 5 and 15 min post-inoculation. As a 756 
control for loading, total β-actin levels were assessed. (B) CD172a+ cells were pre-incubated with 757 
U0126 (1 or 10 µM) or LY294002 (25 or 50 µM) (C) for 30 min at 37°C. Cells were (mock) inoculated 758 
with EHV-1 strains 03P37 or 97P70 (MOI 1) and co-cultured for 2 h with immortalized EC. The 759 
number of adherent CD172a+ cells was calculated per mm2. (D) Low magnification, confocal images 760 
of the reduced adhesion of blood CD172a+ cells to EC upon inhibition of the ERK/MAPK signaling 761 
pathway. Nuclei were counterstained with Hoechst (blue). The white arrow points at an adhering 762 
monocytic cell. All confocal images shown represent merged Z-stacks. Scale bar, 100 µm. (E) U0126 763 
or LY294002 pre-treatments did not decrease EHV-1 infection of CD172a+ cells. CD172a+ cells 764 
adherent to plastic were pre-treated with U0126 (10 µM), LY294002 (25 µM) or DMSO-based diluent 765 
for 30 min at 37°C and inoculated with EHV-1 03P37 or 97P70 strains (MOI 1) for 1h at 37°C in LM 766 
supplemented with inhibitors. Cells were further incubated in LM for 12 h at 37°C. The percentage of 767 
IEP-positive cells was calculated based on 300 cells counted in distinct fields. Experiments were 768 
performed three times. Error bars show + SD and a two-way ANOVA test was performed to evaluate 769 
significant differences from controls, (ns = not significant, * = P ≤ 0.001 and ** = P < 0.0001). 770 
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4. EHV-1 replication is enhanced in CD172a+ cells upon adhesion to EC 771 
 772 
To determine whether EHV-1 replication was enhanced in CD172a+ cells upon 773 
adhesion to EC, we compared the expression kinetics of immediate-early protein 774 
(IEP) and gB protein in CD172a+ cells cultured on plastic (without EC) or on top of 775 
immortalized EC monolayers for 2, 4, 6 and 12 h.  776 
From 2 to 12 hours post-adhesion (hpa) on EC monolayers, the percentage of IEP- 777 
positive CD172a+ cells significantly increased from 4% to 14% for EHV-1 03P37 778 
strain (p < 0.01). At 12 hpa, the percentage of IEP-positive CD172a+ cells was 779 
significantly higher in cells adherent to EC than cells adherent to plastic (p < 0.01) 780 
(Fig. 4A, left panel). In contrast, the percentage of IEP-positive CD172a+ cells 781 
remained stable from 2 to 6 hpa (4%) and significantly increased to 10% at 12 hpa, 782 
for EHV-1 97P70 strain (p < 0.01) (Fig. 4A, right panel). No significant difference in 783 
the percentage of IEP-positive cells was observed in CD172a+ cells inoculated with 784 
EHV-1 03P37 or 97P70 strains and cultured on plastic. The percentage of IEP- 785 
positive cells decreased in the non-adherent CD172a+ cell fraction over time post- 786 
adhesion, for both EHV-1 strains (Fig. 4B). No gB protein was detected in cells from 787 
2 to 6 hpa. An upward trend and a significant increase in gB expression (p < 0.05) 788 
was observed in IEP-positive cells inoculated with EHV-1 03P37 and 97P70 strains, 789 
respectively and co-cultured for 12 h with EC monolayers, compared to cells cultured 790 
on plastic (Fig. 4C). Confocal images showed the expression of IEP and gB protein in 791 
EHV-1-infected CD172a+ cells after 12 h co-culture with immortalized EC (Fig. 4D). 792 
The expression of gB in IEP-positive CD172a+ cells upon adhesion to EC was 793 
comparable between the two strains (60%). 794 
Taken together, these results show that the adhesion of EHV-1 inoculated CD172a+ 795 
cells to EC speeds up the viral replication process in CD172a+ cells inoculated with 796 
EHV-1 97P70 strain, but to a lesser extent in CD172a+ cells inoculated with EHV-1 797 
03P37 strain, compared to EHV-1 inoculated CD172a+ cells adherent to plastic. 798 
Moreover, the enhancement of EHV-1 replication in CD172a+ cells upon adhesion to 799 
EC suggests that direct cell-to-cell contacts provide a favorable environment for 800 
EHV-1 replication in CD172a+ cells. 801 
 802 
 803 
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Figure 4: Expression kinetics of EHV-1 proteins in blood CD172a+ cells upon adhesion to EC. (A) 850 
Expression kinetics of EHV-1 immediate-early (IEP) protein in adherent blood CD172a+ cells. Cells 851 
were inoculated with EHV-1 03P37 or 97P70 strains (MOI 1) and co-cultured with immortalized EC 852 
monolayers for 2, 4, 6 and 12 h. As a control, EHV-1-inoculated CD172a+ cells were incubated on 853 
plastic (without EC). (B) Expression kinetics of EHV-1 immediate-early (IEP) protein in the non- 854 
adherent CD172a+ cell fraction after 2, 4, 6 and 12 h co-culture with immortalized EC. (C) Expression 855 
of EHV-1 gB protein in infected CD172a+ cells after 12h co-culture with immortalized EC in the 856 
presence of neutralizing EHV-1 antibodies. Three independent experiments were performed and data 857 
are represented as means + SD. A two-way ANOVA test was performed to evaluate significant 858 
differences from control, (* = P < 0.05 and ** = P < 0.01). (D) Double immunofluorescence of EHV-1 859 
immediate-early protein (IEP) (green) and gB (red) proteins in blood CD172a+ cells adherent to 860 
immortalized EC for 12 h in the presence of neutralizing EHV-1 antibodies. Nuclei are counterstained 861 
with Hoechst (blue). All confocal images represent merged Z-stacks. Scale bar = 50 µm. 862 
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5. Increased EHV-1 replication in CD172a+ cells upon adhesion to EC correlates 875 
with the production of tumor necrosis factor alpha (TNF-α)   876 
 877 
Since TNF-α has been described as a potent inducer of viral gene expression in 878 
monocytes/macrophages, we investigated whether TNF-α is produced during 879 
interaction of EHV-1-inoculated CD172a+ cells and EC and whether TNF-α enhances 880 
EHV-1 replication in CD172a+ cells. 881 
The concentration of TNF-α in supernatants of mock-inoculated and EHV-1- 882 
inoculated CD172a+ cells cultured on plastic or on top of immortalized EC 883 
monolayers was determined by ELISA. At 12 hpa, the concentration of TNF-α in 884 
supernatants of CD172a+ cells inoculated with EHV-1 03P37 or 97P70 strains and co- 885 
cultured with EC was significantly higher (p < 0.05 and p < 0.001, respectively) than 886 
the TNF-α concentration in supernatants of EHV-1-inoculated cells cultured on 887 
plastic (Fig. 5A). No significant difference was detected in TNF-α concentrations 888 
between supernatants of mock-inoculated CD172a+ cells cultured on plastic or on top 889 
of EC.  890 
We also tested if the addition of exogenous TNF-α to CD172a+ cells at the time of 891 
virus inoculation affected EHV-1 replication. The expression of gB in CD172a+ cells 892 
cultured on plastic was compared in the absence or presence of 10 ng/ml recombinant 893 
equine TNF-α at 12 h post-inoculation (hpi). We found that the number of cells 894 
positive for gB among IEP-positive cells was significantly higher (p < 0.001) when 895 
stimulated with equine recombinant TNF-α (Fig. 5B). Moreover, we demonstrated 896 
that the addition of neutralizing TNF-α antibody to co-cultures of CD172a+ cells 897 
adherent to EC generated a trend, although not statistically significant, towards a 898 
decrease in the percentage of gB-positive cells (Fig. 5C). Taken together, these results 899 
indicate that TNF-α is an important soluble mediator enhancing EHV-1 replication in 900 
CD172a+ cells upon adhesion to EC. 901 
  902 
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Figure 5: Effect of TNF-α in the enhancement of EHV-1 replication in CD172a+ cells upon adhesion to 930 
EC. (A) Concentration of TNF-α (pg/ml) in supernatants of CD172a+ cells mock-inoculated or 931 
inoculated with EHV-1 03P37 or 97P70 strains (MOI 1), cultured on plastic or on the top of 932 
immortalized EC for 12 h. (B) Expression of EHV-1 gB protein in CD172a+ cells adherent to plastic 933 
and cultured in LM supplemented or not with 10 ng/ml of equine recombinant TNF-α (+TNF-α) for 12 934 
h. (C) Expression of EHV-1 gB protein in CD172a+ cells adherent to EC and cultured for 12 h in LM 935 
supplemented or not with 10 ng/ml of TNF-α neutralizing antibody (+ Anti-TNF-α).  Data represent 936 
means + SD of three independent experiments and ns = not significant, * = P<0.05, ** = P< 0.001 937 
and *** = P< 0.0001 (by two-way ANOVA test). 938 
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6. Transfer of cytoplasmic EHV-1 material from infected CD172a+ cells to 940 
uninfected adjacent EC  941 
 942 
To investigate whether CD172a+ cells transmit EHV-1 to EC, we analyzed the 943 
intracellular distribution dynamics of IEP and gB proteins in EHV-1 inoculated 944 
CD172a+ cells after 12 h co-culture with immortalized EC monolayers in the presence 945 
of neutralizing antibodies (Fig. 6). We found that IEP was expressed in nuclear 946 
replicative compartments and in the cytoplasm of infected CD172a+ cells adherent to 947 
EC. The gB protein was only expressed in the cytoplasm of these cells and no gB 948 
expression was detected at the plasma membrane of CD172a+ cells after 12 h co- 949 
culture with EC. However, when immunostaining was performed with a biotinylated 950 
horse polyclonal antibody that recognizes EHV-1 late proteins, some signal could be 951 
detected at the plasma membrane of 2 and 0.6% of CD172a+ cells adherent to EC 952 
monolayers and inoculated with EHV-1 03P37 and 97P70, respectively (Fig. 6A). 953 
With both EHV-1 strains, a cytoplasmic IEP positive ‘bridge’ was formed from an 954 
infected CD172a+ cell to an adjacent EC (Fig. 6B). Some cytoplasmic IEP staining 955 
was also observed in the adjacent EC. The late protein gB expressed a weak signal 956 
colocalized with IEP in some regions of both cytoplasmic bridge and cytoplasm of the 957 
EC. Eighteen and 27% of IEP/gB (03P37 and 97P70) positive CD172a+ cells showed 958 
cytoplasmic transfer of EHV-1 material to adjacent EC. However, IEP/gB-positive 959 
plaques could not be observed in EC, also at later time points post-inoculation, 960 
indicating that spread of infection from CD172a+ cells to EC did not automatically 961 
lead to productive infection in EC. 962 
To address whether the enhanced EHV-1 replication in CD172a+ cells upon adhesion 963 
to EC led to a productive infection, we determined the percentage of CD172a+ cells 964 
that produced and transmitted infectious EHV-1 to neighbouring endothelial cells by 965 
co-cultivation assay. After 5 days co-culture of inoculated CD172a+ cells with EC 966 
monolayers, we showed that 0.1% and 0.05% of CD172a+ cells inoculated with EHV- 967 
1 03P37 and 97P70 strains, respectively, transmitted the infection to EC. Taken 968 
together, these results provide evidence for direct cytoplasmic transfer of EHV-1 969 
material from late infected CD172a+ cells to adjacent EC, which typically lead to a 970 
non-productive infection in these cells.  971 
 972 
 973 
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Figure 6: Transfer of cytoplasmic EHV-1 material from EHV-1-infected CD172a+ cell to uninfected 1001 
EC. Cells were inoculated with EHV-1 03P37 and 97P70 strains (MOI 1) and co-cultured with 1002 
immortalized EC for 12 h the presence of neutralizing EHV-1 antibodies. (A) Expression of EHV-1 late 1003 
proteins at the plasma membrane of infected CD172a+ cells adherent to immortalized EC monolayers. 1004 
Cells were fixed with PFA 1% without permeabilization and stained with a biotinylated horse 1005 
polyclonal antibody directed against EHV-1 late proteins (green). (B) EHV-1 immediate-early protein 1006 
(IEP) (green) and gB protein (red) were detected by indirect immunofluorescence. Arrows display 1007 
cytoplasmic transfer of IEP (full arrow) and gB protein (dotted arrow), from late stage infected 1008 
CD172a+ cell to one adjacent EC (arrowhead). Nuclei were counterstained with Hoechst (blue). All 1009 
confocal images represent merged Z-stacks. Scale bar, 10 µm.  1010 
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Discussion 1012 
 1013 
Monocytic cells are assumed to fulfill key role in EHV-1 spread from the blood to 1014 
target organs, but the precise interactions between monocytic cells and EC have not 1015 
been unraveled. In the present study, we demonstrated that EHV-1 infection increased 1016 
adhesion of CD172a+ monocytic cells to EC in vitro. Significantly more EHV-1- 1017 
inoculated CD172a+ cells adhered to EC than to mock-inoculated cells. UV-treatment 1018 
of EHV-1 did not affect the EHV-1-triggered adhesion process, indicating that the 1019 
binding of EHV-1 to CD172a+ cells was sufficient to induce their adhesion to EC. We 1020 
hypothesized that viral binding induces cellular signaling pathways that trigger 1021 
functional changes in CD172a+ cells, which subsequently promote their adhesion to 1022 
EC. By the use of an in vitro flow system, Smith et al. (2001) suggested that 1023 
activation of adhesion molecules present on both leukocytes and EC surfaces is a 1024 
prerequisite for the transfer of EHV-1 from leukocytes to the endothelium. However, 1025 
the authors did not characterize in detail which adhesion molecules were activated on 1026 
the endothelium or examine the exact nature of the adhesion molecules present on the 1027 
cell surface of the carrier cells. Monocytes constitutively express a selection of 1028 
adhesion molecules, including selectins and integrins (Huang et al., 1995; Luscinskas 1029 
et al., 1994). Here, we showed that blocking α4β1 (VLA-4), αLβ2 (LFA-1), and αVβ3 1030 
integrins on EHV-1-inoculated CD172a+ cells significantly reduced adhesion to levels 1031 
comparable to mock-inoculated cells. These results indicated that integrins mediated 1032 
the adhesion of CD172a+ cells to EC. However, adhesion was not completely 1033 
inhibited by the addition of blocking antibodies, suggesting that other adhesion 1034 
molecules may be involved in this process. Besides integrins, L-selectins are 1035 
expressed on myeloid cells and have been shown to play an important role in the 1036 
initial interaction or tethering of monocytes with the endothelium (Giuffre et al., 1037 
1997; Vestweber & Blanks, 1999). Unfortunately, there is no antibody available 1038 
against L-selectin that cross-reacts specifically with equine monocytes to allow 1039 
further experiments. Moreover, although we demonstrated that EHV-1 infection 1040 
induces integrin dependent adhesion of CD172a+ cells to endothelial cells, at this 1041 
stage, it is not clear whether EHV-1 infection induces activation or increased 1042 
expression of specific integrins. Indeed, the antibodies used in this study do not 1043 
discriminate between inactive or activated forms of the integrins and it was 1044 
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technically impossible to assess any potential up-regulation of integrin expression on 1045 
EHV-1 inoculated cells compared to mock, due to a low percentage of infected 1046 
CD172a+ cells detected. 1047 
Next, we addressed the mechanism by which EHV-1 infection induces adhesion of 1048 
CD172a+ cells to EC in the absence of viral gene expression. We demonstrated that 1049 
EHV-1 infection induces CD172a+ cell adhesion in a PI(3)K and ERK/MAPK- 1050 
dependent processes at a very early stage of infection. The specific MEK/ERK 1051 
inhibitor U0126 and the PI(3)K inhibitor LY294002 were able to efficiently decrease 1052 
CD172a+ cell adhesion to EC in a dose-dependent manner. Together, these data show 1053 
that integrin engagement and the activation of integrin-mediated signaling pathways 1054 
are essential in the induction of EHV-1-infected CD172a+ adhesion to EC. Several 1055 
herpesviruses, such as pseudorabies virus (PRV), herpes simplex virus 1 (HSV-1), 1056 
human herpesvirus 8 (HHV-8) and human cytomegalovirus (HCMV) have been 1057 
reported to activate integrin-mediated ERK-MAPK and/or PI(3)K signaling pathways 1058 
through the interactions of viral glycoproteins with putative receptors present at the 1059 
plasma membrane of host cells (Naranatt et al., 2003; Nogalski et al., 2011; Reeves et 1060 
al., 2012; Setas Pontes et al., 2015; Zheng et al., 2014). To date, the EHV-1 envelope 1061 
glycoprotein D (gD) has been shown to interact with αV integrins present on PBMC 1062 
and to be critical for viral entry via endocytosis (Van de Walle et al., 2008). Here we 1063 
hypothesized that EHV-1 gD interacts with αV integrins on CD172a+ cells and 1064 
subsequently activates integrin-mediated signaling pathways (PI(3)K and 1065 
ERK/MAPK) (Fig.7.A). We believe that this activation may induce specific 1066 
functional changes in CD172a+ cells, including the activation of integrins, which in 1067 
turn may facilitate their adhesion to specific endothelial adhesion molecules (Carlos et 1068 
al., 1991) (Fig.7.B). This latter hypothesis is supported by the study of Chang et al. 1069 
(2012) which demonstrated that PKC-dependent ERK activation contributes to 1070 
monocyte adhesion and by studies of Smith et al. (2007 and 2004), demonstrating that 1071 
PI(3)K activity is essential for HCMV-mediated induction of monocyte motility and 1072 
firm adhesion to EC. However, further studies are still needed to decipher the precise 1073 
mechanism of regulation of integrins by EHV-1 in CD172a+ cells and to directly 1074 
address the potential relationship between integrin activation and cellular signal 1075 
transduction pathways in cell adhesion. 1076 
In addition, we showed that EHV-1 replication was enhanced in CD172a+ cells upon 1077 
adhesion to EC. The percentages of IEP- and gB-positive CD172a+ cells were higher 1078 
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in cells adherent to EC than in cells adherent to plastic. These findings corroborate in 1079 
vitro studies on HIV, demonstrating that contacts with EC enhanced HIV-1 1080 
replication in infected monocytes and macrophages (Fan et al., 1994; Gilles et al., 1081 
1995). Interestingly, we demonstrated that the percentage of IEP-positive CD172a+ 1082 
cells significantly increased from 2 to 12 hpa for EHV-1 03P37 strain while it only 1083 
increased at 12 hpa for EHV-1 (97P70). Moreover, we observed a higher increase in 1084 
gB protein expression in IEP-positive cells inoculated with EHV-1 97P70 strain and 1085 
co-cultured for 12 h with EC monolayers, compared to cells inoculated with EHV-1 1086 
03P37. Taken together, the authors believe that these results are due to differences in 1087 
the replication kinetics of EHV-1 in target monocytic cells between the two strains. 1088 
This hypothesis is based on a previous study from Laval et al. (2015) demonstrating 1089 
that EHV-1 (97P70) replication was restricted and delayed in CD172a+ cells adherent 1090 
to plastic and ongoing in vitro studies on the replication kinetics of EHV-1 (03P37) in 1091 
monocytic cells, indicating strikingly different outcomes (unpublished data). We think 1092 
that the adhesion of EHV-1 inoculated CD172a+ cells to EC speeds up the viral 1093 
replication machinery in CD172a+ cells inoculated with EHV-1 97P70 strain, but to a 1094 
lesser extent in CD172a+ cells inoculated with EHV-1 03P37 strain.  1095 
In addition, we showed that TNF-α was produced via direct interaction between 1096 
CD172a+ cells and EC and that TNF-α triggered the enhanced EHV-1 replication 1097 
observed in CD172a+ cells. This is in agreement with previous studies on HCMV and 1098 
HIV infections, which demonstrated that the production of TNF-α induces cellular 1099 
changes in monocytic cells, resulting in increased viral gene expression (Poli et al., 1100 
1990; Soderberg-Naucler et al., 1997). TNF-α secreted by EC was also found to be 1101 
associated with increased HIV expression in monocytic cells (Borghi et al., 2000). 1102 
From our findings, we hypothesize that TNF-α is indirectly influencing IEP 1103 
expression in CD172a+ cells by inducing differentiation of CD172a+ monocytic cells 1104 
into EHV-1-permissive macrophages. TNF-α may induce the production of cellular 1105 
factors important for EHV-1 replication in CD172a+ cells. However, further studies 1106 
are still needed to determine the specific role played by TNF-α in the pathogenesis of 1107 
EHV-1 infection. 1108 
We also demonstrated that the percentage of gB-positive CD172a+ cells adherent to 1109 
EC was reduced following treatment with TNF-α neutralizing antibody. We 1110 
considered that other cytokines besides TNF-α might also play a role in the enhanced 1111 
EHV-1 expression observed in CD172a+ /EC co-cultures, as both monocytic cells and 1112 
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EC are known to secrete a variety of inflammatory cytokines which are important in 1113 
the regulation of viral replication. However, we failed to detect substantial amounts of 1114 
IL-1β and IFN-α produced upon co-culture of mock- or EHV-1-inoculated CD172a+ 1115 
cells with ECs (data not shown). Taken together, our results indicate that the 1116 
enhanced EHV-1 replication observed in CD172a+ cells is a complex process 1117 
involving both cell contacts and the production of soluble factors, with major 1118 
implications for EHV-1 spread to EC (Fig.7.C). Interestingly, EHV-1 neurovirulent 1119 
and non-neurovirulent strains both enhanced EHV-1 replication in CD172a+ cells 1120 
upon adhesion to EC. These findings suggest that additional factors account for the 1121 
difference in pathogenesis of EHV-1 in vivo. 1122 
Finally, we demonstrated that approximately 20% of late infected CD172a+ cells were 1123 
able to transfer cytoplasmic EHV-1 material to uninfected, adjacent EC in the 1124 
presence of neutralizing antibodies (Fig.7.D). Our data are in line with the findings of 1125 
Digel et al. (2006), showing direct transfer of HCMV cytoplasmic material from 1126 
infected to neighboring uninfected cells. Although speculative at this point, we 1127 
hypothesize that EHV-1 spreads from CD172a+ cells to EC through ‘microfusion’ 1128 
events, as described for other herpesviruses (Gerna et al., 2000; Van de Walle et al., 1129 
2003). This strategy would allow the virus to spread from CD172a+ cells to the 1130 
endothelium of target organs in the presence of neutralizing antibodies. In our 1131 
experiments, transfer of EHV-1 from late infected CD172a+ cells to EC 1132 
predominantly resulted in a non-productive infection in EC. These data suggest that: 1133 
(1) only a minority of infected CD172a+ cells can efficiently transfer EHV-1 to EC 1134 
and initiate an infection, (2) EHV-1 infection of EC does not automatically result in 1135 
viral spread to the surrounding tissues. 1136 
Previous in vivo studies showed that EHV-1 infection of endothelial cells of the 1137 
pregnant uterus or CNS resulted in damages of the microvasculature of target organs 1138 
due to the initiation of an inflammatory cascade, vasculitis and microthrombosis 1139 
(Edington et al., 1986; Patel et al., 1982; Smith et al., 1992). EHV-1 infection of 1140 
endothelial cells also induced extravasation of mononuclear cells, resulting in 1141 
perivascular cuffing and local hemorrhages (Stierstorfer et al., 2002). According to 1142 
this, we believe that the adhesion and transfer of EHV-1 from CD172a+ monocytic 1143 
cells to endothelial cells may contribute to clinical thrombosis in horses with EHV-1 1144 
infection. The use of specific anti-adhesive molecules may represent a valuable 1145 
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therapeutic tool to reduce adhesion of infected CD172a+ cells and subsequent transfer 1146 
of EHV-1 to EC of target organs. 1147 
In conclusion, our data suggest that EHV-1 uses specific cellular signaling pathways 1148 
to trigger cellular changes in CD172a+ cells, which result in increased adhesion to EC. 1149 
The interaction between EHV-1-infected CD172a+ cells and EC enhances EHV-1 1150 
replication in CD172a+ cells through cell-to-cell contacts and secretion of soluble 1151 
factors, which subsequently facilitates viral transfer to EC.  1152 
 1153 
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Viruses have evolved under pressure of their host’s immune system over millions of 
years. During this co-evolution, viruses developed various strategies to subvert the 
host’s antiviral responses to ensure their own replication and survival. These 
strategies are as diverse as the viruses themselves. While small RNA viruses mainly 
rely on antigenic variability to avoid host’s immune responses, large DNA viruses 
such as herpesviruses have evolved complex immune evasive strategies to increase 
fitness. The hallmark of a herpesvirus infection is the capacity to establish lifelong 
latent infections in an immunocompetent host, generally without causing severe 
symptoms. The lifelong persistence of herpesviruses reflects the delicate balance 
these viruses establish with the host’s immune system. It is generally not in the 
evolutionary interest of herpesviruses to kill or impair their host, as latent viruses 
require a host that stays alive and is healthy enough to interact with others. In 
addition, the persistence of herpesviruses is facilitated by a wide range of host innate 
and adaptive immune evasion mechanisms that the reactivated virus exploits to stay as 
long as possible in its host. Thus, it is not surprising that current vaccines and antiviral 
therapies against herpesvirus infections often are not fully protective. 
 
Among animal herpesvirus members, equine herpesvirus type 1 (EHV-1) is one of the 
major pathogens affecting horses worldwide. The virus is responsible for respiratory 
disorders, abortion, neonatal foal death and myeloencephalopathy (EHM) (Allen & 
Bryans, 1986; Patel & Heldens, 2005). The interest in EHV-1 has increased during the 
last decade by frequent outbreaks of abortions and/or neurological disorders causing 
serious economic losses to the horse industry every year. It has been reported that the 
incidence of EHM during outbreaks can range from 10 to more than 30% and the 
incidence of abortion during outbreaks can exceed 50% (Goehring et al., 2006; Lunn 
et al., 2009). With a total global equine population estimated at 58 million, with 6 
million in Europe, mortality rates of around 40% during EHM outbreaks raise 
concerns in the equine industry worldwide (Allen et al., 2004; Lunn et al., 2009). 
Despite many years of research, no fully protective vaccines against EHV-1 or 
efficient antiviral drugs have been developed. Current vaccines (inactivated and live-
attenuated) do not provide full protection against EHV-1 associated diseases. These 
vaccines fail to completely prevent virus shedding and cell-associated viremia, and 
subsequently, fail to protect against severe EHV-1 symptoms. Indeed, EHV-1 can still 
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spread via a cell-associated viremia in vaccinated animals, indicating that EHV-1 is 
able to manipulate the host’s immune system (O’Neill et al., 1999; Kydd et al., 2006). 
In addition, no efficacious antiviral treatment is available for EHV-1 infections and 
treatment is mainly limited to supportive therapy. It is clear that a radical paradigm 
shift in the design of control strategies against EHV-1 infection and herpesvirus 
infections in general is needed. This requires a breakthrough in the knowledge on the 
pathogenesis of these viruses and their immune evasion mechanisms. It is for this 
reason that our research group looked for new leads in the interactions between EHV-
1 and its host cells. 
 
Previous in vivo and ex vivo studies of the pathogenesis of EHV-1 demonstrated that 
EHV-1 misuses single immune cells from the URT to breach the BM into the 
connective tissues. These carrier immune cells were mainly identified as CD172a+ 
monocytic cells (Gryspeerdt et al., 2010; Vandekerckhove et al., 2010). Interestingly, 
it was found that the expression of particular late proteins in EHV-1-infected carrier 
monocytic cells was hampered at early stages of infection (Gryspeerdt et al., 2012; 
van der Meulen et al., 2000). These results suggested that an early block in the 
replication cycle of EHV-1 may protect infected monocytic cells from efficient 
recognition by the immune system and hence may allow these carrier cells to reach 
target organs. Monocytic cells are known to play crucial roles in the innate and 
adaptive immune responses during viral infections. In addition, monocytic cells are 
very motile cells and can migrate from the blood into specific tissues during 
homeostasis, inflammatory or immune responses (Shi & Pamer, 2011). Thus, it is not 
surprising that EHV-1 hijacks monocytic cells and uses them as immune-privileged 
vehicles for viral dissemination within the horse. Until now, the precise mechanism(s) 
by which EHV-1 modulates its replication within CD172a+ monocytic cells and how 
the virus is transmitted to target organs in the presence of neutralizing antibodies are 
still unknown and thus, this comprised the main focus of this study. 
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EHV-1 replication in CD172a+ monocytic cells: the Trojan Horse model 
 
In the first part of this thesis (Chapter 3), we examined in vitro the replication kinetics 
of two neurovirulent and three non-neurovirulent EHV-1 strains in target CD172a+ 
monocytic cells and compared them with those in the RK-13 control cell line. We 
demonstrated that the replication of both EHV-1 strains was highly restricted in 
CD172a+ cells compared to RK-13 cells. However, we found that the spatio-temporal 
distribution dynamics of EHV-1 proteins within susceptible CD172a+ cells differ 
between the two strains. While the replication kinetics of the neurovirulent EHV-1 
strain were comparable between susceptible CD172a+ and RK-13 cells, the non-
neurovirulent EHV-1 strain delayed its replication in CD172a+ cells at a very early 
time of infection. In addition, we observed that both neurovirulent and non-
neurovirulent EHV-1 infections were mainly non-productive in susceptible CD172a+ 
cells. Finally, we found that histone deacetylases (HDACs) regulate the silencing of 
gene expression of a non-neurovirulent EHV-1 strain in CD172a+ cells whereas they 
did not appear to influence the replication of a neurovirulent EHV-1 strain in these 
cells.  
 
Chromatin remodeling by HDACs plays a key role in the regulation of viral gene 
expression during herpesvirus infections (Guise et al., 2013). Thus, it is not surprising 
that EHV-1 has developed epigenetic strategies to regulate its own replication through 
HDACs within target CD172a+ cells. HDACs are known to condense chromatin 
structure by deacetylation of lysine residues on histone tails, resulting in repression of 
cellular and/or viral transcription (Sarkar et al., 2006). HDACs perform their 
repressive functions as components of several multi-protein co-repressor complexes, 
such as the co-repressor of RE1 silencing transcription factor (CoRest) (You et al., 
2001). These are then targeted to specific genomic regions by interactions with DNA 
binding factors, such as transcription factors. However, herpesviruses, such as HSV-1, 
have developed various strategies to block HDAC repressor activity. Upon 
dissociation of HDAC-1 or -2 from the CoREST/REST/HDAC repressor complex by 
HSV-1 ICP0, HSV-1 Ser/Thr US3 kinases are then able to indirectly phosphorylate 
these HDACs, thus rendering them inactive (Gu et al., 2005; Gu & Roizman, 2007; 
Walters et al., 2010). Phosphorylation of HDACs results in increased levels of histone 
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acetylation and activation of viral gene expression in cells. From our observations, we 
postulate that the neurovirulent EHV-1 strain acts similarly to HSV-1, and blocks the 
repressor activity of HDAC at promoter sites, thus enhancing its replication in 
CD172a+ cells. In contrast, the non-neurovirulent EHV-1 strain appears to have 
adapted during evolution to misuse HDACs instead of blocking their activity. 
Silencing gene expression by HDACs might be a strategy for the virus to slow down 
its replication in CD172a+ cells, effectively allowing non-neurovirulent EHV-1 to 
behave as a ‘stealth virus’, persisting in CD172a+ cells and functionally hiding itself 
from the immune system longer compared to neurovirulent EHV-1.  
Interestingly, HDACs have also been reported to limit CMV infection in vitro. It was 
shown that the relatively high levels of HDACs in monocytes and T2 cells were 
correlated with non-permissiveness for HCMV (Murphy et al., 2002). Following 
treatment with HDAC inhibitors, non-permissive cells were rendered transiently 
permissive for HCMV, suggesting that HDACs played a role in the repression of viral 
replication. It was proposed that the chromatin structure around the IE promoter 
changes with cellular differentiation and thus may play a role in controlling HCMV 
latency and reactivation. Thus, we hypothesize that, in vivo, acute EHV-1 infection 
promotes activation of blood monocytes that subsequently migrate into different 
tissues (pregnant uterus and/or CNS) and differentiate into permissive macrophages. 
We speculate that this differentiation may decrease HDAC activity and increase 
histone acetylase levels at EHV-1 promoter sites, thus directly enhancing viral 
replication in macrophages. 
 
Moreover, we suggest that differences in the genome sequences of neurovirulent and 
non-neurovirulent EHV-1, in addition to the single nucleotide polymorphism in the 
viral DNA polymerase, might be responsible for the differential control of HDAC 
activity in CD172a+ cells at very early time of infection in vitro and thus may 
contribute to their differing pathogeneses in vivo. We proposed that mutations in the 
coding sequences of some regulatory proteins of non-neurovirulent EHV-1 strain 
might alter their capacity to bind to and subsequently phosphorylate HDAC and/or 
HDAC-containing complexes at viral promoters in CD172a+ cells. This may result in 
increased levels of HDACs and repression of EHV-1 gene expression, and thus may 
indirectly delay viral replication in CD172a+ cells. However, the fact that both EHV-1 
strains can still cause a viremia in vaccinated horses indicates that manipulation of 
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HDACs is only one part of EHV-1’s strategy to bypass detection by the immune 
system. Overall, these results are giving new insights in how EHV-1 modulates its 
replication within CD172a+ monocytic cells and uses them as a ‘Trojan horse’ in 
order to evade immune surveillance and disseminate within the horse. 
 
HDAC inhibitors: the Achilles heel of the Trojan horse? 
 
In this context, the use of antiviral compounds that specifically inhibit the activity of 
HDACs may be an interesting strategy to modulate EHV-1 infections. Over the past 
decade, HDAC inhibitors have been mainly used as potent anti-proliferative agents in 
cancer therapies. Research has led to the development of HDAC inhibitors that 
modify the acetylation state of a large number of cellular proteins involved in 
oncogenic processes, resulting in antitumor effects (Atadja, 2011). In addition, HDAC 
inhibitors have been used as antiviral agents against HIV and EBV infections. For 
instance, valproic acid, a carboxylate HDAC inhibitor, has been combined with highly 
active anti-retroviral therapy (HAART) and used as an adjuvant therapy in clinical 
trials to purge latent reservoirs of HIV-1 in resting CD4+ T-cells (Demonte et al., 
2004; Matalon et al., 2011). This enabled detection of HIV particles and their 
subsequent elimination by HAART. Similarly, HDAC inhibitors such as sodium 
butyrate and valproic acid have been used to activate EBV lytic-phase gene 
expression in cultured cells and mouse models (Ghosh et al., 2012; Shin et al., 2015). 
In addition, a pre-clinical trial with the HDAC inhibitor arginine butyrate combined 
with ganciclovir gave promising results in the treatment of EBV-lymphoma patients 
(Perrine et al., 2007). 
 
Based on these studies, we propose that the use of specific HDAC inhibitors in 
combination with antiherpes viral drugs and vaccination could be an interesting 
approach to treat and prevent EHV-1-induced disease in horses infected with EHV-1 
non-neurovirulent strains. Specific HDAC inhibitors could be used to relieve the 
temporary block of non-neurovirulent EHV-1 gene expression and speed up the 
replication machinery in nasal and blood CD172a+ cells of infected horses. Then, 
treatment with antiherpes viral drugs could inhibit viral replication in these cells at the 
level of the URT and blood circulation and prevent viremia and/or subsequent viral 
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spread to the endothelial cells of target organs. The use of antiherpes viral drugs 
should still be taken with caution since no adequate antivirals against EHV-1 are 
currently available on the market. To maximize the chance of preventing EHV-1-
induced severe symptoms, horses should also be vaccinated before treatment with 
HDAC inhibitors to ensure that they build up a strong immune response to clear the 
virus while forcing viral replication in CD172a+ cells. As cellular immunity mediated 
by CTLs is crucial in the protection against EHV-1 infection, the use of live-
attenuated vaccines is preferred. So far, the current live-attenuated vaccines available 
in Europe can only reduce and not prevent viral shedding and clinical signs (Rosas et 
al., 2006). Thus, a better strategy of vaccination at the URT should be developed to 
prevent viremia. An adequate live-attenuated vaccine should be designed to raise a 
local immunity at the level of the URT. This may allow EHV-1 infected nasal 
monocytic cells to become visible by the immune system and be eliminated by CTL 
before they cross the BM and reach the connective tissues and the blood circulation. 
This new vaccine should be both administered intranasally and intramuscularly to 
completely prevent viremia. For safety reasons, this EHV-1 vaccine strain should be 
able to replicate in the epithelial cells of the URT but no longer infect monocytic 
cells.  
HDAC inhibitors may be of lesser use in horses showing EHV-1 induced neurological 
disorders, as we demonstrated that the replication of a neurovirulent strain was not 
tightly regulated by HDACs. Based on our hypothesis that neurovirulent EHV-1 
strains are rapidly visible to the immune system in CD172a+ cells compared to non-
neurovirulent EHV-1 strains, we speculate that the intranasal administration of a live-
attenuated vaccine will induce a local humoral and cellular immunity in the horse and 
clear the virus at the URT, thus preventing cell-associated viremia, as described 
above. Still, future studies should include more neurovirulent versus non-
neurovirulent strains to see whether this difference in HDAC regulation may be 
generalized or not. 
 
The use of HDAC inhibitors as therapeutic tools to combat EHV-1 infections should 
still be carefully considered. As HDACs are involved in various cellular processes, 
including cell-cycle regulation, cell proliferation and differentiation, it is crucial to 
use highly selective and potent HDAC inhibitors to activate EHV-1 replication in 
CD172a+ cells in order not to impair essential cellular functions. Future studies should 
Chapter 6: General discussion      193 
____________________________________________________________________ 
 
   
  
determine which individual HDAC(s) are the most critical for inhibition and which 
cellular and viral transcription factors are involved in association of the EHV-1 
promoter with hypoacetylated histones and mediate silencing of the non-neurovirulent 
EHV-1 genome within CD172a+ cells. Results should be compared between the two 
pathotypes. The efficacy of HDAC inhibitors should be tested both in vitro and in 
vivo. Clinical studies should determine the best route of administration, the 
therapeutic index of HDAC inhibitors and their adverse effects in horses. HDAC 
inhibitor-based therapy might also be considered as an interesting strategy to purge 
latent EHV-1 reservoirs in aviremic horses. 
 
In addition to their function as an inhibitor of HDAC activity, short-chain fatty acids 
like (sodium) butyrate have been shown to play a role in the diet of the horse. Pasture 
forage is fermented by the equine colonic microbiota to short-chain fatty acids, 
including acetate, propionate and butyrate. Short-chain fatty acids provide a major 
source of energy for the horse and contribute up to 60-70% of its energy requirements 
upon absorption from the caecum and colon (Argenzio & Hintz, 1972; Argenzio et 
al., 1974). Among short-chain fatty acids, butyrate has potent effects on a variety of 
colonic functions and plays a key role in the maintenance of the health of colonic 
tissue (Bugaut & Bentejac, 1993; Cuff et al., 2005; Hamer et al., 2008; Treem et al., 
1994). Butyrate is also involved in various cellular processes, including cell 
differentiation, cell-cycle arrest and apoptosis, and exerts its action in a concentration-
dependent manner (Fung et al., 2011; Li, 2011; Orchel et al., 2005). A study from Li 
et al. (2008) showed that butyrate induces several changes in the expression of genes 
associated with regulatory pathways that are critical to cell growth, immune response 
and signal transduction. In addition, it was proposed that natural stimuli, such as stress 
and weaning might directly affect the intracellular concentration of butyrate, and thus 
influence its availability to modulate gene expression (Li & Elsasser, 2005). 
According to this, we postulate that nutritional environment and physiological factors 
(stress, pregnancy…) may influence the concentration of butyrate in the horse, which 
in turn may modulate cellular and viral gene expression, thus controlling EHV-1 
infection in vivo. Future studies should examine the epigenetic effects of physiologic 
concentrations of butyrate in the control of EHV-1 infection in horses. 
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Entry of EHV-1 into CD172a+ cells: Boarding the Trojan horse 
 
The next step of this thesis was to investigate the molecular mechanisms underlying 
the "restricted" infection of EHV-1 in CD172a+ cells. Virus attachment and entry are 
some of the most critical stages during virus infection and play an important role in 
cell tropism and pathogenesis of virus infections. However, little is known about the 
regulation of CD172a+ cell tropism and susceptibility to EHV-1 infection. In Chapter 
4, we characterized the entry of EHV-1 into CD172a+ monocytic cells. Using dio-
labeled EHV-1 particles, we demonstrated that EHV-1 binds to a limited number of 
CD172a+ cells compared to RK-13 cells, suggesting the presence of a specific subset 
of CD172a+ monocytic cells that could differently support EHV-1 replication and 
contribute to the pathogenesis of EHV-1. In this study, we used the mouse 
monoclonal anti-CD172a antibody to identify cells of myeloid origin, but we could 
not differentiate between specific subsets, such as granulocytes, DCs, monocytes and 
macrophages. This task was mainly hampered by the lack of specific myeloid markers 
commercially available that cross-react with equine cells (Ibrahim et al., 2007). In 
humans and other mammal species, blood monocytes can be divided in two distinct 
subsets: CD14+ CD16- cells, which are often called “classic monocytes” and CD14+ 
CD16+ monocytes, suggested to resemble mature tissue macrophages (Passlick et al., 
1989). Interestingly, CD16+ cells constitute a small percentage of the total monocyte 
population and they are characterized as being more pro-inflammatory and having a 
more prominent role in infections. Previous in vivo and in vitro studies have shown 
that CD16+ monocytes are more permissive to productive HIV-1 infection than the 
majority of blood monocytes, and that this relative permissiveness is due to enhanced 
viral entry (Ellery et al., 2007). A study from Williams et al. (2005) also demonstrated 
that the CD14+CD16+ cells were consistently positive for SIV DNA, suggesting that 
these cells may function as Trojan horses, which carry the virus into the brain. In the 
future, it will be interesting to further identify the specific subset of CD172a+ cells 
susceptible to EHV-1 infection in vitro and check whether CD14+CD16+ cells are 
similarly involved. 
The ability of EHV-1 to bind to a limited set of CD172a+ cells also suggests the 
presence of specific receptor(s) at the surface of these cells. Previous studies have 
already shown that EHV-1 utilizes a cell surface receptor that is distinct from any of 
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the known alphaherpesvirus entry receptors (Frampton et al., 2005). The Major 
Histocompatibility Complex Class I (MHC I) has been identified as a functional entry 
receptor for gD in equine dermal and equine brain microvascular endothelial cells 
(Kurtz et al., 2010; Sasaki et al., 2011). However, a study from Azab et al. (2012) 
demonstrated that MHC I antibodies did not efficiently block EHV-1 entry into 
PBMC, suggesting the presence of different receptors in equine leukocytes. Hence, 
we investigated the nature of the receptor(s) involved in the binding of EHV-1 to 
CD172a+ monocytic cells. We found that enzymatic removal of heparan sulfate did 
not affect EHV-1 infection, while removal of sialic acids from the cell surface by 
treatment with neuraminidase had a very strong effect in inhibiting EHV-1 infection 
of CD172a+ cells. These results showed that sialic acid residues on these cells and not 
heparan sulfate are involved in EHV-1 infection. Thus, we propose that EHV-1's 
narrow cellular tropism in vitro may be in part due to its interactions with specific 
sialic acid containing cell-surface receptor(s) on CD172a+ cells.  
 
Sialic acid-binding viruses include important human pathogens, such as adenovirus, 
influenza virus and rotavirus (Arnberg et al., 2002; Isa et al., 2006; Matrosovich et 
al., 2015). So far, influenza virus is the best-studied example of sialic acid 
involvement in viral entry. Influenza virus uses hemagglutinin (HA) as an attachment 
receptor to bind to sialic acids on the cell surface (Wu & Air, 2004). The type of 
linkage between terminal sialic acids and the second sugar is one of the major 
determinants of influenza virus tropism and host specificity (Imai & Kawaoka, 2012). 
Human influenza viruses preferentially bind to sialic acid attached to galactose by an 
α2,6 linkage while avian and equine influenza viruses bind to α2,3 galactose-linked 
sialic acids (Connor et al., 1994; Matrosovich et al., 2000). To date, sialic acid-
containing lipids and polymers have been developed as entry blockers of influenza 
virus into cells (Guo et al., 2002; Matrosovich & Klenk, 2003). As alternatives to 
sialic acids, HA binding peptides have also been considered promising candidates as 
novel antiviral drugs (Matsubara et al., 2010). Similarly, the use of antivirals that 
specifically act as entry blockers of EHV-1 into target CD172a+ cells may be an 
interesting approach to prevent EHV-1 infection. However, further studies are still 
needed to determine which sialylated glycans are present on CD172a+ cells and which 
are involved in EHV-1 binding and entry. In addition, EHV-1 glycoprotein(s) that 
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may serve as viral glycan-binding proteins should be identified. Recently, it has been 
demonstrated that EHV-1 gC has hemagglutination activity against equine red blood 
cells (Andoh et al., 2015). This suggests a potential role of gC as a viral lectin, 
involved in the binding of sialic acids residues on CD172a+ cells. EHV-1 gC may also 
be an interesting candidate in the design of sialic acid binding peptides that block 
EHV-1 binding to CD172a+ cells.  
 
In this chapter, we also found that blockage of αvβ3 integrins by neutralizing 
antibodies significantly reduced EHV-1 entry at a post-binding step. We hypothesized 
that αvβ3 integrin is not used as a cellular receptor, involved in attachment of EHV-1 
to cells, but rather as a co-receptor used to mediate post-binding entry of EHV-1 into 
CD172a+ cells. The sequential engagement of distinct receptors and co-receptors may 
allow the timing of key events in EHV-1 entry into CD172a+ cells. Interestingly, 
several studies have indicated that αvβ3 integrin serves as a co-receptor for various 
herpesviruses, including HSV and HCMV (Gianni & Campadelli-Fiume, 2012; Wang 
et al., 2005). For instance, it has been shown that αvβ3 integrin acts as a co-receptor 
routing HSV to a pathway dependent on lipid rafts, dynamin-2 and acidic endosomes 
(Gianni et al., 2010). For EHV-1, it has been demonstrated that the interaction 
between αvβ3 integrin present on PBMC and the arginine, serine, and aspartic acid 
(RSD) motif present in gD triggers EHV-1 entry via endocytosis potentially by 
inducing conformational changes of the receptor and initiating signaling cascades 
(Van de Walle et al., 2008). EHV-1 may use αvβ3 integrin to route its entry via 
endocytosis into CD172a+ cells in order to shorten its exposure at the cell surface. The 
restricted expression of αvβ3 integrin on CD172a+ cells may also be an important 
determinant of EHV-1 tropism. Thus, αvβ3 integrin could be a viable target for 
antiviral therapies to prevent EHV-1 infection and in particular cell-associated 
viremia by interrupting the entry process of EHV-1 into susceptible CD172a+ cells.  
 
Finally, we characterized the mode of entry of EHV-1 into CD172a+ cells by the use 
of pharmacological inhibitors and co-localization assays. We demonstrated that EHV-
1 enters CD172a+ cells via an endocytic mechanism that requires cholesterol, tyrosine 
kinase activity, actin polymerization, dynamin activity and endosomal acidification. It 
is not surprising that EHV-1 enters target CD172a+ cells by endocytosis as this 
mechanism offers several advantages over entry by fusion. First of all, endocytosis 
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allows the virus to bypass obstacles associated with cytoplasmic crowding and the 
network of microfilaments (Sodeik, 2000). Secondly, a drop in pH within endocytic 
vesicles may allow viruses to sense their location in the cell and trigger the 
membrane/fusion penetration reactions that deliver the viral genetic material to the 
cytoplasm (Marsh & Helenius, 1989). Thirdly, viruses that are endocytosed avoid 
leaving evidence of their presence exposed at the plasma membrane and thus, this 
may delay their detection by the immune system. Many viruses including HSV-1 and 
HIV are capable to enter cells via fusion but often prefer to use endocytic pathways 
for productive entry (Daecke et al., 2005; Miyauchi et al., 2009; Nicola et al., 2003). 
Here, we propose that EHV-1 may enter CD172a+ cells by phagocytosis. 
Phagocytosis is mainly used by professional phagocytes, such as monocytes and 
macrophages to interfere with microbial invasion and to remove dead cells 
(Flannagan et al., 2012). In addition, studies reported that some human herpesviruses, 
including HSV-1 and CMV use phagocytosis-like uptake to gain entry into cells 
(Clement et al., 2006; Tiwari & Shukla, 2012). Thus, we propose that EHV-1 exploits 
phagocytosis to promote its entry within CD172a+ monocytic cells. The formation of 
protrusions may facilitate uptake of EHV-1 into the cell and may protect the virus 
from neutralizing antibodies. Future studies are still needed to further examine the 
phagocytic uptake of EHV-1 into CD172a+ cells. A better understanding of the 
interactions between EHV-1 and membrane protrusions on CD172a+ cells may 
provide new insights in the development of therapeutics against EHV-1 infection in 
particular by preventing virus uptake.  
 
In conclusion, a hypothetical model of EHV-1 entry into CD172a+ cells is provided in 
Figure 1. We postulate that EHV-1 initially binds to CD172a+ cells via an interaction 
between EHV-1 gC and sialic acid containing cell-surface receptor(s) present on 
CD172a+ cells (A). This interaction may initiate intracellular signaling cascades that 
activate αvβ3 integrin on the cell surface of CD172a+ cells and thus facilitate the 
second interaction of EHV-1 via gD with its αvβ3 integrin co-receptor (B). This second 
interaction may in turn activate integrin-mediated signaling pathways, which trigger 
rearrangements of the actin cytoskeleton in the cell, including the polymerization of 
actin underneath the contact zone, facilitating the formation of membrane protrusions 
at the surface of CD172a+ cells (C). This leads to the engulfment of EHV-1 particles 
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and clustering of αvβ3 integrins in phagosomes and transport within the cytoplasm (D). 
Here, we want to point out that the mechanism of EHV-1 binding and entry into 
CD172a+ cells was similar between EHV-1 non-neurovirulent and neurovirulent 
strains and thus may not account for differences in the neuropathogenic vs abortigenic 
potential of EHV-1 in vivo. However, we think that the development of antivirals that 
block several steps of EHV-1 entry into target CD172a+ cells could efficiently prevent 
cell-associated viremia and both EHV-1 induced abortion and neurological disorders 
in horses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Hypothetical model of EHV-1 entry into a CD172a+ cell. (A) Initial attachment of EHV-1 
may occur via binding of gC to a sialic acid containing cell-surface receptor and initiates intracellular 
signaling cascades that activate αvβ3 integrin on the cell surface of CD172a+ cells. (B) This may 
facilitate the second interaction of EHV-1 via gD with αvβ3 integrin co-receptor, which in turn activates 
cellular integrin-mediated signaling pathways. (C) This activation may induce rearrangements of the 
actin meshwork underneath the contact zone, clustering of αvβ3 integrins and the formation of 
membrane protrusions that facilitate uptake of EHV-1 into the cell. (D) EHV-1 is transported through 
the cytoplasm in phagosomes. 
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Transmission of EHV-1 from CD172a+ monocytic cells to endothelial cells (EC): 
unloading the Trojan horse 
 
EHV-1-induced abortion and neurological disease are direct results of viral spread 
from infected leukocytes to the EC lining the blood vessels of the pregnant uterus and 
CNS, and their subsequent infection. In order to initiate a replication in the EC of 
these target organs, EHV-1-infected CD172a+ cells must employ specific strategies to 
adhere and subsequently transmit EHV-1 to the EC in the presence of neutralizing 
antibodies. Some studies highlighted the importance of cell-to-cell contacts between 
PBMC and EC in the transmission of EHV-1 and the involvement of adhesion 
molecules present on the cell surface of both cell types (Goehring et al., 2011; Smith 
et al., 2001). However, at the start of this thesis, it was still unclear how exactly 
CD172a+ cells adhere and transmit EHV-1 to EC.  
 
In Chapter 5, we demonstrated that EHV-1 infection significantly increased adhesion 
of CD172a+ cells to EC. Antibody experiments showed that α4β1, αLβ2 and αvβ3 
integrins partially mediated the adhesion of EHV-1 infected CD172a+ cells to EC. We 
found that the activation of integrin-mediated signaling pathways, including PI(3)K 
and ERK/MAPK were also essential for this adhesion process. Based on these results, 
we proposed that the interaction of EHV-1 via gD with αvβ3 integrin on the surface of 
a CD172a+ cell activates the intracellular integrin-mediated PI(3)K and ERK/MAPK 
signaling pathways which in turn up-regulate α4β1, αLβ2 and αvβ3 integrin expression 
on the surface of the infected CD172a+ cell. Thus, activated integrins can interact with 
some of their respective EC ligands and mediate CD172a+ cell adhesion to EC. The 
interaction of EHV-1 gD with αvβ3 integrin is likely to direct events that modulate 
both viral entry and cellular adhesion. As integrin activation is a complex and 
dynamic process, it is still unclear whether viral binding to αvβ3 integrin activates 
distinct and/or overlapping integrin-mediated signaling pathways that mediate these 
events. Integrins, including αvβ3 integrins, are well known to play various roles in cell 
adhesion, migration, angiogenesis and immune responses (Hynes, 2002; Weis & 
Cheresh, 2011). Therefore, it is not surprising that EHV-1 utilizes αvβ3 integrins as co-
receptors to enter into target CD172a+ cells and as cellular receptors to facilitate viral 
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transmission. This suggests a very important role of αvβ3 integrin in the pathogenesis 
of EHV-1.  
Binding of herpesviruses to integrins is known to activate specific cellular pathways 
that play a key role in the manipulation of biological functions of monocytes. For 
instance, it has been shown that integrin engagement and the subsequent activation of 
PI(3)K signaling pathway in HCMV-infected monocytes results in the production of 
pro-inflammatory mediators that drive newly infected monocytes from the blood 
circulation to host tissues and facilitate their adhesion to EC (Smith et al., 2004). 
Similarly, we think that EHV-1 infection of CD172a+ cells may result in cellular 
activation, the induction of cellular motility, migration and secretion of inflammatory 
cytokines and chemokines. Although speculative at this stage, it is interesting to think 
that EHV-1 might use an inflammatory response to induce the migration and adhesion 
of infected CD172a+ cells to EC and the recruitment of additional monocytic cells that 
may serve as target for viral infection in the tissue. This could participate to the 
inflammatory cascade associated with EHV-1 infection of EC of the CNS and 
pregnant uterus, thus contributing to the development of EHV-1-induced disease.  
 
In Chapter 5, we also found that EHV-1 replication was enhanced in CD172a+ cells 
upon adhesion to EC and correlated with the production of TNF-α. Based on this 
finding, we postulate that EHV-1 is able to manipulate the biology of infected 
CD172a+ monocytic cells by inducing their differentiation into macrophages and 
promoting their adhesion to EC. While short-lived monocytes that are less permissive 
to EHV-1 infection are used as a ‘Trojan horse’ to evade immune surveillance and 
disseminate via the blood circulation within the host, it appears that EHV-1 prefers to 
use long-lived permissive macrophages to spread to EC of target organs. As TNF-α is 
known to be primarily produced by macrophages and EC and to be central for the 
control of viral replication (Borghi et al., 2000; Kodukula et al., 1999; Paludan & 
Mogensen, 2001; Pavic et al., 1993), it is likely that the production of TNF-α by both 
cell types may enhance EHV-1 replication in differentiated CD172a+ cells. Although 
we could only detect noticeable amounts of TNF-α in CD172a+-EC co-cultures, we 
believe that the secretion of other inflammatory cytokines and chemokines might be 
crucial in the regulation of EHV-1 replication in CD172a+ cells both in vitro and in 
vivo.  
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Following enhancement of EHV-1 replication in CD172a+ cells, we observed transfer 
of viral material from infected CD172a+ cells to neighbouring EC. We suggest that 
EHV-1 spreads from infected CD172a+ cells to neighbour EC through cell-cell 
fusions. Transmission of virus from monocytes to endothelial cells via similar 
‘microfusion events’ has already been described for other herpesviruses, such as 
HCMV and PRV (Digel et al., 2006; Van de Walle et al., 2003). For instance, it has 
been shown that the adhesion and subsequent fusion of immune-masked porcine 
monocytes to EC result in efficient spread of PRV to EC. The fusion process was 
found to be virus-mediated since the presence of PRV gH was found indispensable for 
the fusion to occur. For EHV-1, a recent study from Spiesschaert et al. (2015) 
demonstrated that gB mediated EHV-1 transfer from PBMC to EC. Interestingly, they 
also demonstrated striking differences between EHV-1 and EHV-4-infected PBMC in 
their capacity to adhere and transfer the virus to EC, which might help to explain their 
differing pathogeneses in vivo. Like other herpesviruses, EHV-1 appears to use cell-
to-cell contacts as an immune evasive mechanism to spread from infected CD172a+ 
cells to EC of target organs in the presence of neutralizing antibodies. However, one 
additional possible strategy might be that EHV-1-infected CD172a+ cells migrate 
through the endothelium of the pregnant uterus by diapedesis. Indeed, transendothelial 
migration of monocytes has been shown to be of particular interest in studies of the 
pathogenesis of HIV and HCMV infection (Bentz et al., 2006; Westhorpe et al., 
2009). In the future, it will be interesting to examine the potential of EHV-1-infected 
CD172a+ cells to migrate through EC. This could be achieved by performing a 
transendothelial migration assay with the use of transwell chambers. The permeability 
of EC upon adhesion of EHV-1-infected CD172a+ cells should also be examined. 
Although EHV-1 is able to spread from CD172a+ cells to EC, this transfer mainly 
resulted in a non-productive infection. We think that not all infected leukocytes will 
transfer the virus to endothelial cells, not every transfer will lead to effective spread to 
neighboring endothelial cells and not every successful infection of endothelial cells 
will cause infection of surrounding tissues. Previous in vivo studies showed that EHV-
1 infection of endothelial cells of the pregnant uterus or CNS resulted in damages of 
the microvasculature of target organs due to the initiation of an inflammatory cascade, 
vasculitis and microthrombosis (Edington et al., 1986; Patel et al., 1982; Smith et al., 
1992). Moreover, it has been reported that EHV-1 infection of endothelial cells 
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induced extravasation of mononuclear cells, resulting in perivascular cuffing and local 
hemorrhages (Stierstorfer et al., 2002). Thus, we suggest that the adhesion and 
transfer of EHV-1 from CD172a+ monocytic cells to endothelial cells may contribute 
to clinical thrombosis in horses with EHV-1 infection. Therefore, the use of anti-
adhesive therapies might be an interesting approach to prevent virus passing from 
infected CD172a+ cells to EC and thus interfere with EHV-1 pathogenesis. So far, 
anti-adhesive therapy in clinical trials has been widely studied for treatment of 
inflammatory disorders such as inflammatory bowel disease and Crohn’s disease 
(CD) (van Assche, et al., 2002). For instance, natalizumab, a humanized monoclonal 
antibody against human α4 integrin has been approved for the treatment of patients 
with CD (van Assche, et al., 2005). However, before using anti-adhesive therapies for 
treatment of EHV-1 infections, future studies are still needed to characterize the 
specific adhesion molecules present on both CD172a+ cells and EC that are involved 
in the multistep process of leukocyte recruitment to EC, a task hampered at the time 
of this thesis by the lack of antibodies that cross-react with equine cells. 
 
In conclusion, the work in this thesis provides new insights in the interaction between 
EHV-1 and CD172a+ monocytic cells. Increasing evidence supports the concept that 
EHV-1 hijacks immune cells and uses them as a ‘Trojan horse’ to disseminate within 
the horse and evade immune surveillance (Figure 2). As this mechanism may be 
fundamental for the development of EHV-1-induced diseases in vaccinated horses, 
halting or uncovering the 'Trojan horse' may be of a particular interest in the 
development of new therapeutics against EHV-1 infections. 
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Figure 2: Hypothetical ‘Trojan horse’ model of EHV-1 dissemination in infected horses. (1) EHV-1 first replicates in the epithelial cells of the URT. Then, EHV-1 enters a 
small population of CD172a+ monocytic cells and uses these cells to cross the BM and reach the connective tissues. EHV-1 silences its replication within CD172a+ cells to 
avoid detection by the immune system while reaching the bloodstream and draining lymph nodes (2). Via the blood circulation, EHV-1 is transported undetected within 
CD172a+ cells to target organs such as the CNS (3) or pregnant uterus (4). There, EHV-1-infected CD172a+ cells adhere to EC lining the blood vessels of these organs. The 
adhesion process activates EHV-1 replication within CD172a+ cells and facilitates EHV-1 transfer to EC and their subsequent infection. 
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Chapter 7. 
Summary-Samenvatting 
 
  
   
  
Summary 
 
Equine herpesvirus type 1 (EHV-1) is one of the major pathogens affecting horses 
worldwide. After primary replication in the upper respiratory tract (URT), the virus 
spreads via a cell-associated viremia to the pregnant uterus and/or the central nervous 
system. Replication in the endothelial cells lining the blood vessels of these organs 
can lead to abortion or neurological disease. Current vaccines do not provide full 
protection against EHV-1-induced diseases. Indeed, EHV-1 can still spread via a cell-
associated viremia in vaccinated animals, thus avoiding the host’s immune response. 
Equine CD172a+ monocytic cells have been shown to be one of the main target cells 
of EHV-1 in the URT and in the blood and were proposed to serve as a ‘Trojan horse’ 
to facilitate the dissemination of EHV-1 to target organs. Therefore, the general aim 
of this thesis was to investigate in detail in vitro how EHV-1 hijacks specific 
CD172a+ monocytic cells and modulates its replication in order to disseminate within 
the host. 
 
In Chapter 1, an overview of the current knowledge of EHV-1 was given with 
emphasis on the pathogenesis of EHV-1 and the known EHV-1 immune evasive 
strategies. 
 
In Chapter 2, the aims of this thesis were formulated. 
 
In Chapter 3, the replication kinetics of EHV-1 non-neurovirulent (Chapter 3.A) and 
neurovirulent (Chapter 3.B) strains in equine CD172a+ monocytic cells were 
examined and compared with replication kinetics in rabbit kidney epithelial cells 
(RK-13) control cell line. The number of cells supporting replication for both EHV-1 
strains was highly restricted among CD172a+ cells (4-8%) compared to RK-13 cells 
(100%). However, the spatio-temporal distribution dynamics of EHV-1 proteins 
within the limited population of susceptible CD172a+ cells differed between the two 
strains. While the replication kinetics of neurovirulent EHV-1 were comparable 
between susceptible CD172a+ and RK-13 cells, non-neurovirulent EHV-1 delayed its 
replication in CD172a+ cells at a very early time of infection. In addition, both 
neurovirulent and non-neurovirulent EHV-1 infections were mainly non-productive in 
  
susceptible CD172a+ cells. Finally, it was shown that histone deacetylases (HDACs) 
regulated the silencing of non-neurovirulent EHV-1 gene expression in CD172a+ cells 
whereas it did not influence the replication of neurovirulent EHV-1 in these cells.  
In Chapter 4, the binding and entry of EHV-1 into CD172a+ monocytic cells was 
examined in order to get better insights in the regulation of CD172a+ cell tropism and 
susceptibility to EHV-1 infection. By the use of Dio-labeled EHV-1 particles, it was 
shown that EHV-1 only bound to 15-20% of CD172a+ cells compared to 70% of RK-
13 control cells, suggesting the presence of specific receptor(s) at the surface of the 
cells. Enzymatic removal of heparan sulfate did not affect EHV-1 infection while 
removal of sialic acids from the cell’s surface by treatment with neuraminidase 
significantly inhibited EHV-1 infection of CD172a+ cells, indicating that sialic acid 
residues on these cells and not heparan sulfate were essential for EHV-1 infection. 
Moreover, it was found that αvβ3 integrins were involved in the post-binding stage of 
CD172a+ cell infection. Finally, the mode of entry of EHV-1 into CD172a+ cells was 
characterized by the use of pharmacological inhibitors and co-localization assays. It 
was concluded that EHV-1 entered CD172a+ cells via an endocytic mechanism that 
requires cholesterol, tyrosine kinase activity, actin, dynamin activity and endosomal 
acidification, pointing towards a phagocytic mechanism.  
 
Given the importance of the interactions between monocytic cells and endothelial 
cells (EC) in the pathogenesis of EHV-1, Chapter 5 focused on the ability of EHV-1 
inoculated CD172a+ cells to adhere and subsequently transmit EHV-1 infection to 
equine venous EC. It was shown that EHV-1 infection significantly increased 
adhesion of CD172a+ monocytic cells to EC in vitro. Antibody experiments showed 
that α4β1, αLβ2 and αvβ3 integrins partially mediated the adhesion of EHV-1 infected 
CD172a+ cells to EC.  In addition, it was demonstrated that the activation of integrin-
mediated signaling pathways, including PI(3)K and ERK/MAPK were also essential 
for this adhesion process. EHV-1 replication was enhanced in CD172a+ cells upon 
adhesion to EC and correlated with the production of TNF-α. In the presence of 
neutralizing antibodies, it was observed that approximately 20% of infected CD172a+ 
cells transferred cytoplasmic material to uninfected EC, resulting mainly in a non-
productive infection.  
 
   
  
In Chapter 6, a general conclusion on the research data generated in this thesis was 
formulated in which the new insights in the interaction between EHV-1 and CD172a+ 
cells were summarized. 
 
 The main conclusions drawn in this thesis are: 
 
Ø When entering into CD172a+ cells, EHV-1 modulates its replication, 
essentially hijacking the cells and using them as a ‘Trojan horse’. This 
mechanism allows the virus to pass through the blood circulation, evading 
immune surveillance and reaching the targets organs. The differential control 
of HDACs in CD172a+ cells may potentially contribute to the differences in 
pathogenesis between neurovirulent and non-neurovirulent EHV-1 in vivo. 
 
Ø The attachment and entry processes of EHV-1 into CD172a+ cells play 
determining roles in the narrow cell tropism and pathogenesis of EHV-1. 
 
 
Ø EHV-1 uses cell-to-cell contacts as an immune evasive mechanism to spread 
from infected CD172a+ cells to EC in vitro. The adhesion and transfer of 
EHV-1 from CD172a+ monocytic cells to EC may possibly contribute to 
clinical thrombosis in horses with EHV-1 infection. 
  
Samenvatting 
 
Equine herpesvirus type 1 (EHV-1) is wereldwijd één van de belangrijkste 
pathogenen bij paarden. Na primaire vermeerdering in de bovenste luchtwegen 
verspreidt het virus zich via een cel-geassocieerde viremie naar de drachtige uterus 
en/of het centraal zenuwstelsel. Vermeerdering in de endotheelcellen in de bloedvaten 
ter hoogte van deze organen kan leiden tot abortus of neurologische ziekte. De 
bestaande vaccins bieden geen volledige bescherming tegen ziektes veroorzaakt door 
EHV-1. EHV-1 is namelijk in staat om zich te verspreiden via een cel-geassocieerde 
viremie in gevaccineerde dieren, waarbij het de immuunrespons van de gastheer 
ontwijkt. CD172a+ monocytaire cellen van paarden zijn gekend als één van de 
belangrijkste doelwitten van EHV-1 in de bovenste luchtwegen en in het bloed, en 
zouden door EHV-1 gebruikt worden als “Trojaans paard” om uit te zaaien naar 
doelwitorganen. Op basis daarvan werd de algemene doelstelling van deze thesis: het 
uitvoeren van een gedetailleerd onderzoek naar de manier waarop EHV-1 specifieke 
CD172a+ monocytaire cellen kaapt en hoe het virus zijn vermeerdering aanpast zodat 
het zich kan verspreiden in de gastheer. 
 
In hoofdstuk 1 werd een overzicht gegeven van de huidige kennis omtrent EHV-1, 
met nadruk op de pathogenese en de gekende immuun-ontwijkende strategieën. 
 
In hoofdstuk 2 werden de doelstellingen van deze thesis geformuleerd. 
 
In hoofdstuk 3 werden de vermeerderingskinetieken van niet-neurovirulente 
(hoofdstuk 3.A) en neurovirulente (hoofdstuk 3.B) EHV-1 stammen in CD172a+ 
monocytaire cellen vergeleken met de vermeerderingskinetiek in konijnennier 
epitheelcellen (RK-13), een controle cellijn. Voor beide EHV-1 stammen was het 
aantal CD172a+ monocytaire cellen dat vermeerdering toeliet sterk beperkt (4-8%) in 
vergelijking tot RK-13 cellen (100%). Anderzijds verschilde de tijdruimtelijke 
verdeling van de EHV-1 eiwitten binnen de populatie gevoelige CD172a+ cellen voor 
de 2 virusstammen. Terwijl de vermeerderingskinetiek van neurovirulente EHV-1 in 
gevoelige CD172a+ en RK-13 cellen vergelijkbaar was, zagen we dat de 
vermeerdering van niet-neurovirulente EHV-1 vertraagd was vanaf een zeer vroege 
   
  
fase in de infectie. Bovendien waren infecties met neurovirulente en niet-
neurovirulente virusstammen in gevoelige CD172a+ monocytaire cellen hoofdzakelijk 
niet-productief. Tenslotte werd aangetoond dat histone deacetylases (HDACs) de 
onderdrukking van niet-neurovirulente EHV-1 genexpressie regelden in CD172a+ 
cellen, doch niet de vermeerdering van neurovirulente EHV-1 in deze cellen.  
 
In hoofdstuk 4 werden de binding en toegang van EHV-1 in CD172a+ monocytaire 
cellen onderzocht om zo een beter inzicht te verwerven in de regulatie van CD172a+ 
celtropisme en gevoeligheid voor EHV-1 infectie. Door gebruik te maken van Dio- 
gemerkte EHV-1 partikels kon worden aangetoond dat binding enkel optrad bij 15 à 
20% van de CD172a+ cellen, in vergelijking tot 70% bij de RK-13 controle cellen, 
wat erop wijst dat specifieke receptoren aanwezig zijn op de cellen. Enzymatische 
verwijdering van heparaansulfaat had geen effect op de EHV-1 infectie, maar 
verwijderen van siaalzuren van het celoppervlak met neuraminidase gaf wel een 
significante inhibitie van de EHV-1 infectie in CD172a+ cellen, wat erop wees dat 
siaalzuren en niet heparaansulfaat essentieel zijn voor infecties met EHV-1. Verder 
werd vastgesteld dat αvβ3 integrines betrokken waren in het stadium na binding tijdens 
EHV-1 infectie in CD172a+ cellen. Tenslotte werd de wijze van binnenkomst van 
EHV-1 in CD172a+ cellen gekarakteriseerd door het gebruik van farmacologische 
inhibitoren en co-lokalisatie testen. Het besluit was dat EHV-1 CD172a+ cellen 
binnenkwam via een endocytose mechanisme waarvoor cholesterol, tyrosine kinase 
activiteit, actine, dynamine activiteit en endosomale verzuring nodig waren, wat in de 
richting wijst van een fagocytose mechanisme. 
 
Gezien het belang van de interacties tussen monocytaire en endotheliale cellen (EC) 
in de pathogenese van EHV-1, werd in hoofdstuk 5 gefocust op het vermogen van 
EHV-1 geïnoculeerde CD172a+ cellen om zich aan te hechten en vervolgens het virus 
over te dragen aan equine veneuze EC. Er werd aangetoond dat EHV-1 infectie leidde 
tot significant meer aanhechting van CD172a+ monocytaire cellen aan EC in vitro. 
Antistofexperimenten toonden aan dat α4β1, αLβ2 en αvβ3 integrines gedeeltelijk de 
aanhechting van EHV-1 geïnfecteerde CD172a+ cellen aan EC medieerden. Ook werd 
aangetoond dat de activering van integrine-gemedieerde signaalroutes, waaronder 
PI(3)K and ERK/MAPK, essentieel waren voor dit aanhechtingsproces. 
 
  
EHV-1 vermeerdering was toegenomen in CD172a+ cellen na adhesie aan EC en 
gecorreleerd met de productie van TNF-α.  
Bij ongeveer 20% van de geïnfecteerde CD172a+ cellen werd, in de aanwezigheid van 
neutralizerende antistoffen, waargenomen dat cytoplasmatisch materiaal 
overgedragen werd naar ongeïnfecteerde EC, wat aanleiding gaf tot overwegend niet-
productieve infectie. 
 
In hoofdstuk 6 werd op basis van de bekomen gegevens in deze thesis een algemene 
conclusie geformuleerd waarin de nieuwe inzichten in de interactie tussen EHV-1 en 
CD172a+ cellen werden opgesomd: 
 
De belangrijkste conclusies van deze thesis zijn: 
 
Ø Bij het intreden in CD172a+ cellen moduleert EHV-1 zijn vermeerdering, 
waarbij de cel in wezen gekidnapt wordt en als een “Trojaans paard” gebruikt 
wordt. Dit mechanisme stelt het virus in staat om door de bloedcirculatie te 
passeren, waarbij het de immuunbewaking ontwijkt en de doelwitorganen kan 
bereiken. De verschillen in de controle over HDACs in CD172a+ cellen liggen 
mogelijk mee aan de basis van de verschillen in de pathogenese tussen 
neurovirulente en niet-neurovirulente EHV-1 stammen in vivo. 
 
Ø De aanhechtings- en intredeprocessen van EHV-1 in CD172a+ cellen spelen 
een determinerende rol in het nauwe celtropisme en de pathogenese van dit 
virus. 
 
Ø EHV-1 gebruikt celcontacten als een immuunsysteem ontwijkend mechanisme 
zodat het zich kan verspreiden van geïnfecteerde CD172a+ cellen naar EC in 
doelwitorganen. De aanhechting en overdracht van EHV-1 van CD172a+ 
monocytaire cellen naar EC kan mogelijks bijdragen tot klinische trombose in 
paarden met EHV-1 infecties.  
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